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Abstract. 
 
In this thesis, the novel synthesis of tetra- and triazolo-analogues of the pyrrolobenzodiazepines, 
pyrrolobenzothiadiazepines, benzodiazepines and benzothiadiazepines are described. These 
compounds are of great interest as synthetic targets due to their potential medical properties. The key 
processes are the intramolecular 1,3-dipolar cycloaddition between the azide and the nitrile present 
in compound (1), the azide and the alkyne present in compound (2) the azide and the alkene present 
in compound (3), to form the novel final compounds of type (4). The synthesis of these precursors 
from readily available starting materials is discussed. 
 
N
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N N
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N3
NX
N
N3
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X = CO, SO2
Z = N, CH, CH2
R1 = H, OMe, 
R2 = H, OH.
N3
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R1
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1
2 34
 
 
The intramolecular 1,3-dipolar cycloaddition of the alkene with the azide (3) afforded the triazoline 
(4, Z = CH2) which upon nitrogen extrusion formed either the methyl imine (5) or an aziridine (6) as 
shown in the Scheme on the next page. Reactions of other alkenes, more highly substituted than 
compound (3) are also described. 
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This thesis will also describe a general route to triazolobenzodiazepines and 
triazolobenzothiadiazepines (7, X = CO, SO2; Z = CH). The reactions of the corresponding nitriles 
(7, X = CO, SO2; Z = N) will also be described, as with other approaches to the 
pyrrolobenzodiazepines. 
 
N3
NX
R
H
Z
X = CO, SO2
Z = N, CH
R = iPr, Me, Bn, tryptophan
7
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PBD Pyrrolobenzodiazepine δ Chemical shift (unit in NMR) 
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1 Introduction 
1.1 Benzodiazepines. 
 
The benzodiazepine nucleus is a well studied pharmocophoric scaffold that has emerged as a core 
structural fragment of various muscle relaxant, antistaminic, anxiolytic and anticonvulsant agents.1-6 
The most well studied examples are the 1,4-benzodiazep-2-ones (1) and the 1,4-benzodiazep-2,5-
ones (2) but less is known about 1,4-benzodiazep-5-ones (3), which, as will been seen later, form the 
heterocyclic core of our target molecules. 
 
N
N
Cl
OMe
6, Valium
N
N
N
O Me
CO2Et
F
N
H
N
O
N
Cl
N
H
N
H
N
H
NH NH NH
O
O
O
O
1 2 3
4, Flumazenil 5, Clobenzepam
 
Figure 1-1 
 
Nonetheless, 1,4-benzodiazepin-5-one nucleus has proved to be a major synthon for the development 
of new drugs,7,8 such as the antidepressant Flumazenil (4), antistaminic Clobenzepam (5)2,3,8 and the 
anxiety drug Valium (6).5,9 
 
The major developments in the synthesis of 1,4-benzodiazepin-5-one (3) are modified Strecker-type 
reaction,1 Ugi four component condensation,2,10 the Schmidt rearrangements,3,11-14 aryne 
nucleophilic substitution,3,15 hetero Diels-Alder4 and 1,3 dipolar cycloaddition.8 
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Due to the fact that this thesis will focus on tri- and tetracyclic systems, approaches to the simple 
bicyclic systems will not be reviewed further. This introduction will look at the synthesis of tricyclic 
pyrrolo-benzodiazepines and -thiadiazepine analogues, tricyclic systems of relevance and also 
tetracyclic systems which have a benzodiazepine/thiadiazepine core.  
 
1.2 Pyrrolobenzodiazepines. 
 
Pyrrolobenzodiazepines (PBDs) are a family of DNA interacting antitumour-antibiotics known as 
the “anthramycins”. They were first discovered in 1965 when Lei mgruber and co-workers isolated 
anthramycin from Streptomyces refuineus.16,17 Other compounds were later isolated from other 
various Streptomyces species18-28 and some well known examples are anthramycin (7),17,22,23,29-33 
mazethramycin (8),32 porothramycin (9),34 sibiromycin (10),22,23,30,32 tomaymycin(11),20-23,30,32,33,35 
prothracarin (12),36 sibanomycin (13) (DC-102),34,37 neothramycins A (14a) and B (14b),20,23,32,38 
DC-81 (15),20-22,24,29-33 chicamycin A (16)20,32,33,39 and abbeymycin (17)34-36 as shown in the Figure1-
2. 
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Figure 1-2 
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The DNA-interactive ability and consequential biological effects are a result of the covalent bond 
formation between the N10 and C11 (carbinolamine/imine) moiety in the central B ring of the PBD 
structure, as shown in the Figure 1.3 below,34,40 and N2 of the guanine residue in the minor groove of 
DNA.16,23,24,26,29-32,35,41-43 The molecules have a right handed twist provided by the S configuration at 
C11a in compound (18) and it is of note that this feature allows this structure to follow the curvature 
of the minor groove of the DNA double helix,16,19,20,44-47an essential factor in the biological activity 
of these compounds. 
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Figure 1-3 
 
The main synthetic approaches to the PBD structure involve either ring closure between an amino 
group and a thioacetal (Section 1.2.1), protected-NH ring closures (Section 1.2.2), cyclisation 
between an azide and aldehyde (Section 1.2.3) and cyclisations involving nitro reductions (Section 
1.2.4). Typical examples of each method will be detailed below. This section will limit itself to 
methods developed post 1994 as before this time Thurston and Bose have reviewed34 this area. Only 
ring formation processes will be considered, and side chain manipulations and the synthesis of so 
called “conjugates” by side chain manipulation will not be considered. 
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1.2.1 Amino-thioacetal ring closure. 
 
One approach for the synthesis of analogues of the PBD pharmacophore involves the formation of 
the N10-C11 bond formation by B ring closure between a thioacetal and an amine moiety. This 
process appeared in Thurston’s original review, but has now been extended to include access to 
“conjugate” systems (examples of conjugate systems are shown in scheme 2-1 compounds 26-
30)19,23-25,27,29-31,33,35,37,48 
 
One of the key intermediates in the synthesis of conjugated analogues of the PBD pharmacophore 
are the carboxylic acids (19).30 Coupling, in the presence of triethylamine, of (S)-(+)-pyrrolidine 
methyl ester hydrochloride with the activated acid of compound (19) afforded compound (20) which 
was reduced with DIBAL-H to the corresponding aldehyde (21), and protected with the 
diethylthioacetal group by using TMSCl-EtSH to give the key intermediate (22), as shown in 
Scheme 1-1.  
 
O
MeO CO2H
Br NO2 O
MeO
Br
N
NO2
O
CO2Me
O
MeO
Br
N
NO2
O
CHO
O
MeO
Br
N
NO2
O
CH(SEt)2
(i) (ii)
(iii)
n n
n n
19 20
21 22
 
 
Scheme 1-1 (i) SOCl2, L-pyrrolidine methyl ester hydrochloride, Et3N, H2O, 0C, 3 hrs, 80% (ii) 
DIBAL-H, DCM, -78C, 45mins, 65% (iii) EtSH-TMSCl, CHCl3, rt, 18 hrs, 82%. 
 
The formation of the conjugate systems was achieved by the linking of the R groups (26-30) (which 
are shown in the Scheme 1-2) to the intermediate compound (22) to afford the linked compounds 
(23) (also shown in the Scheme 1-2). These were reduced to afford the amino-diethylthioacetal 
Chapter 1        Introduction 
  
5 
 
precursors (24), which in turn were cyclised by the deprotection of the diethylthioacetal to form the 
conjugate systems (25) of the DC-81 structure.  
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N
N
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N
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N
H
N
O
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Y
X
N
X
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Scheme 1-2 (i) 26-30, K2CO3, acetone or DMF, reflux, 24-48hrs (ii) SnCl2.2H2O, MeOH, reflux, 24-
48hrs (iii) HgCl2/CaCO3, MeCN:H2O (4:1), 8-12 hrs. 
 
Similar diethylthiocetal approaches to the PBD nucleus have also been reported,23,24,29,31-33,37,49-53 
including other conjugates and also PBD dimers20,54-57 which are useful DNA cross linking agents. 
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1.2.2 Ring closure involving N-protected amines.  
 
N10 protected PBDs have been shown to be unable to interact with DNA and are therefore devoid of 
cytoactivity58 (biological activity with in the cytoplasm of the cell). However, these molecules can 
sometimes act as prodrugs in that enzymatic removal of the protecting group will form the active 
N10-C11 imine bond, carbinolamine or methyl forms which may then interact with the DNA 
strand.46 In this section of the introduction the synthesis of one such analogue by this approach is 
illustrative and will be detailed, drawing on a paper by Berry and Howard.46  
 
The first stage in the synthesis was to produce the C-ring acetal (35), which was synthesised in four 
steps from the commericially available N-carbobenzyloxy-L-proline methyl ester (31), as shown in 
scheme 1-3. Amine (35) was joined with 4, 5-dimethoxy-2-nitrobenzoic acid (36) by the standard 
coupling procedure employing an equimolar amount of 2-(1H-benzotriazole-1-yl)-1, 1, 3, 3-tetra-
methyluronium tetrafluoroborate (TBTU) and diisopropylethylamine (DIPEA) in DMF to afford 
(37) in 51% yield. The subsequent reduction of the nitro moiety utilising 10% palladium on carbon 
with hydrogen afforded the aniline (38). 
 
MeO
MeO N
NH2
O
OMe
MeO
MeO
MeO N
NO2
O
OMe
MeO
MeO
MeO OH
NO2
O
HN
MeO OMe
N
MeO OMe
CbzN
H O
CbzN
HO
CbzN
CO2Me
Cbz (i) (ii) (iii) (iv)
(v) (vi)
31 32 33 34 35
36 37 38
35
 
Scheme 1-3 (i) LiBH4, THF, 0ºC (ii) SO3·pyridine, Et3N, DMSO/DCM (4:5), -10ºC (iii) SOCl2, 
HC(OMe)3, MeOH, 60ºC (iv) Raney-Ni, EtOH or H2, 10% Pd/C, EtOH (v) TBTU, DIPEA, DMF 
(vi) H2, 10% Pd/C, EtOH 
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43a, X = O
43b, X =
(i)
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O O
S
X
X
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OH
S
X
X
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44b, X =39a, X = O39b, X =
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42
 
 Scheme 1-4 (i) 43a-b, triphosgene, pyridine, DCM, 0ºC (ii) 44a, pyridine, DCM, 0ºC (iii) 
(MeCN)2PdCl2, acetone (iv) 44b, pyridine, DCM, 0ºC (v) 40, m-CPBA, DCM, 0ºC (vi) 41, DBU, 
benzene, 5ºC. 
 
At this stage in the synthesis, an attempt to protect the amine as either the sulfone (39a) or the 
sulfide (39b) carbamate, using the corresponding chloroformates (44a,b), which were prepared 
freshly (as seen in the box in the Scheme 1-4) from 2-(phenylsulfonyl)ethanol (43a) or 2-
(phenylthio)ethanol (43b) and triphosgene. However, on attempting to synthesise the Ptec-protected 
PBD (39b) from (38) utilising this strategy, intramolecular cyclisation to the PBD sulfide (40) 
occured, and therefore (39b) could not be isolated. This is likely to be due to the HCl liberated 
during the protection reaction causing premature hydrolysis of the acetal leading to the ring closure. 
Interestingly, this was not the case for the sulfone Psec intermediate (39a), which could be isolated. 
Acetal deprotection by treatment with trans-bis(acetonitrile)palladium(II) chloride in acetone 
afforded the cyclised compound (41). The sulfone (41) was also obtained in 87% yield by the 
oxidation of the sulfide (40) with m-CPBA (3-chloroperoxybenzoic acid) in DCM. The deprotection 
of (41) with DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) in benzene yielded the PBD pharmacophore 
(42) in 77% yield. This approach is quite general, and similar approaches using Troc and Boc 
protected amines48,59-61 have also appeared, as well as PNZ58 and Alloc.62-65 
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1.2.3 Azide based cyclisations. 
 
Due to the incorporation of the azide group into many of the molecules used later in this thesis, these 
routes are particularly relevant. Staudinger/aza-Wittig methodology66-71 and azide reduction routes 
have been exploited in the synthesis of many PBDs. In this subsection a brief overview will be 
described.  
 
One analogue was described by O’Neil36 who produced fluoropyrrolo analogues (as shown in the 
Scheme 1-5). Thus, reduction of the fluoro substituted prolines (45)72 with DIBAL-H followed by 
deprotection with 4M HCl in 1,4-dioxane afforded the cis-4-fluoro- (46a), trans-4-fluoro- (46b), and 
4,4’-difluoroprolinol (46c) hydrochlorides in good yields. The coupling of 2-azidobenzoyl chloride 
with (46a-c) afforded the compounds (47a-c) which upon oxidation with Dess-Martin periodinane 
furnished the PBD precursors (48a-c). Staudinger/aza-Wittig cyclisation with DPPE in THF gave the 
fluoro-substituted PBDs, (49a-c) in 71, 80, 62% yields, respectively. 
 
(iii) (iv)
N
R2
CO2Me
Boc
R1
45a-c
N
H
R2 R1
OHHCl N3
N
OH
O R2
R1
N3
N
O
O R2
R1
48a-c
N
N
O R2
R1
49a-c
(i) (ii)
47a-c46a-c
a, R1 = F, R2 = H; b, R1 = H, R2 = F; c, R1 = F, R2 = F
 
Scheme 1-5 (i) DIBAL-H, THF, -78C to r.t., o.n., then 4M HCl in 1,4-dioxane, o.n. (ii) 2-
azidobenzoyl chloride, Et3N, DCM, -78C to r.t., o.n. (iii) Dess-Martin periodinane, DCM, r.t., o.n. 
(iv) DPPE, THF, 2hrs. 
 
Kamal et al,39 have utilised solid phase synthesis for the synthesis of hydroxyl derivatives of the 
PBDs (see Scheme 1-6). The synthesis started from the Wang trichloroacetamidate resin (51) which 
was prepared by the Hanessian protocol and then coupled with Fmoc-protected 4-hydroxyproline-
methyl ester (52). The product (53) was deprotected (54) and coupled with 2-azidobenzoic acid in 
the presence of DCC and DMAP to afford the amide (55). The reduction of the ester moiety to the 
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aldehyde (56) was achieved by treatment with DIBAL-H at -78C. The Staudinger/aza-Wittig 
cyclisation process on compound (56) and the subsequent cleavage of the Wang resin gave the final 
compounds of type (58). 
 
OH Cl3CCN O
NH
CCl3 N
OH
Fmoc
MeO2C
N
O
Fmoc
MeO2C
HN
O
MeO2C
N
N
O
OH
R H
N
N
O
O
R H
N
N3
O
O
CHO
N
N3
O
O
CO2Me (v)
(vi) (vii)
(i) (ii)
(iii) (iv)
R
R
50 51 52
53 54 55
56 57 58
 
Scheme 1-6 (i) DBU, DCM (ii) BF3OEt2 or CF3SO3H, DCM (iii) 20% piperidine/DMF (iv) 2-
azidobenzoic acid, DCC, DMAP, DCM, 0C (v) DIBAL-H, DCM, -78C, 2 hrs (vi) PPh3, toluene 
(vii) TFA/DCM (1:3).  
 
An example of a reductive cyclisation was studied by Kamal et al,73 (shown in Scheme 1-7) in which 
they used HI in the ring closure to bring about reduction of the aromatic azide (60) to the aromatic 
amine which underwent intramolecular cyclisation with the aldehyde to yield the PBD 
pharmacophore (61) in 70-75% yields.  
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CHO
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O
R
R1N
CO2Me
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O
R
R1
R
R1 N
N
O
H
(i) (ii)
6159 60
 
Scheme 1-7 (i) DIBAL-H, DCM, -78C, 45mins, 80-85% (ii) HI, r.t., 70-75%. 
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Azides can also give the pyrrolobenzodiazepines via other reductive cyclisations27,39,73-77 and many 
such methods have been studied in the Kamal group.24,30,31,33,37,42,43,56,78 Thus, for example, the use of 
Al/NiCl2.6H2O or Al/NH4Cl have been reported to give efficient and effective routes to PBDs via 
azide reduction and cyclisation (as shown in Scheme 1-8). A very simple azide reduction involved 
employing FeSO4.7H2O/NH3 as the reducing system79 as shown in the Scheme 1-8. Compound (64) 
was produced in yields of 68-72%.  
 
N
N3
O
CO2Me
R2
R
R1 N
N3
O
CHO
R2
R
R1 N
N
O
HR
R1
R2
a) R = R1 = R2= H, b) R = OH, R1 = OMe, R2 = H, 
c) R = R2 = H, R1 = CH3 d) R = R1 = H, R2 = OH
62 63 64
(i) (ii)
 
Scheme 1-8 (i) DIBAL-H, DCM, -78C, 45 min, 72%-75% (ii) FeSO4.7H2O/NH3, DCM, 4 hrs, r.t. 
1.2.4 Nitro based reductive cyclisations. 
 
The formation of the N10-C11 imine bond can also be achieved from reductive cyclisations 
involving the nitro group, and this constitutes the last of the methods commonly used for PBD 
synthesis that will be presented in this thesis.  
  
As an example, Kamal and Reddy80 have synthesised compound (69), and the thione derivative (71), 
as shown in the Scheme 1-9. The synthesis started from the coupling of proline (66) with the 
activated 3,4,5-substituted-2-nitrobenzoic acid (65) to give the coupled product (67). Esterification 
followed by reduction with DIBAL-H yielded the (2S)-N-(2-nitrobenzoyl)-pyrrolidine-2-
carboxaldehydes (68). Intramolecular cyclisation in the presence of iron and a mixture of acetic 
acid/THF as solvent yielded the DC-81 analogue (69) in 65-75% yields. The synthesis of the thione 
derivative from compound (68) was achieved by treatment with Lawesson’s reagent to yield 
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compound (70), which underwent intramolecular cyclisation in the presence of iron, acetic acid/THF 
to afford the thione derivatives (71). 
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NO2
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(v)
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c) R1 = H, R2 = OH, R3 = OMe
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65
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Scheme 1-9 (i) SOCl2, benzene, r.t., 3-4 hrs (ii) 66, Et3N, THF, 0ºC, 1 hr (iii) H+, MeOH, reflux, 2-
3hrs (iv) DIBAL-H, DCM, -78ºC, 45 mins (v) Fe, AcOH, THF, r.t., 3-6 hrs (vi) Lawesson’s reagent, 
toluene, 80ºC, 2-3 hrs. 
 
It is notable that earlier studies by Thurston81 led to the discovery that the balance of AcOH:THF 
was important in order to prevent the over reduction of the newly formed imine bond of compound 
(73) which would yield the undesired secondary amine (74) as shown in Figure 1-4: 
 
N
CHO
NO2
O
N
N
O
N
CH2
H
N
O
Reductive
Cylcisation
Over
reduction
72 73 74
 
Figure 1-4 
 
Rojas-Rousseau et al,82 have reported the synthesis of an analogue (85) of porothramycin (see 
Scheme 1-10) which utilises Raney-Ni nitro reduction. The first step was the formation of (5S)-5-
(ethoxy-ethoxymethyl)pyrrolidin-2-one (75) as per literature methods.83 After deprotonation, this 
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compound was treated with 2-nitrobenzoyl chloride yielding the imide (76) in 95% yield. The 
unstable α-hydroxy-2-nitrobenzamides (77) were generated by reduction with DIBAL-H at -78C in 
toluene, and were quantitatively converted to the more stable α-methoxy-2-nitrobenzamides (78). 
The primary alcohol was reprotected with an acetyl group to afford compound (79) and the methoxy 
group was eliminated to form the enamide (80) in high yield by heating in toluene in the presence of 
quinolinium camphorsulfonate [QCS] as a catalyst. The enamide (80) was converted into a highly 
versatile unsaturated aldehyde (81) moiety quantitatively via a Vilsmeier-Haack reaction.  
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Scheme 1-10 (i) NaH, KI, 2-nitrobenzoyl chloride (95%) (ii) DIBAL-H, Toluene (80%) (iii) MeOH, 
TsOH (100%) (iv) Ac2O, Py (98%) (v) 15 mol% QCS, Toluene (94%) (vi) POCl3, DMF (100%) (vii) 
CH2[P(O)(OMe)2]2, nBuLi (87%) (viii) Ba(OH)2, then CO2 (86%) (ix) DMSO, COCl2, iPr2NEt 
(99%) (x) Raney-Ni, then MeOH, TFA. 
 
Treatment of the aldehyde (81) with tetramethyl-methylenediphosphonate in the presence of one 
equivalent of nBuLi at 0C provided compound (82) as a single diastereoisomer in 87% yield. 
Chapter 1        Introduction 
  
13 
 
Saponification of the acetate (82) with barium hydroxide afforded to the primary alcohol (83), which 
upon Swern oxidation with iPr2NEt as base led to the aldehyde (84) in almost quantitative yields 
(99%). Reductive cyclisation employing Raney-Ni followed by treatment with methanol and small 
amounts of TFA afforded the porothramycin analogue (85). 
 
Langois et al,84 reported a similar approach to a different analogue in which the A ring contains a 
methylenedioxy group (see below for Scheme 1-11). This was coupled with the (5S)-5-(ethoxy-
ethoxymethyl) pyrrolidin-2-one (75), and proceeded to the nitro acetylated aldehyde (87) in much 
the same manner as described above. The aldehyde (87) was condensed with the lithiated anion of 
diethyl-[2-(dimethylamino)-2-oxoethyl]phosphonate to provide the derivative (88).  
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Scheme 1-11 (i) NaH-KI, THF, r.t. (86%) (ii) DIBAL-H, toluene -78C (97%) (iii) MeOH, H+ 
(94%) (iv) Ac2O-Py (100%) (v) QCS, toluene, reflux, (89%) (vi) DMF, POCl3, DCM (84%) (vii) 
nBuLi, (EtO)2-P(O)CH2CONMe2 (viii) Ba(OH)2, dioxane, r.t. (99% for two steps) (ix) DMSO, 
(COCl)2, iPr2NEt (99%) (x) Raney-Ni then MeOH, H+ (68%). 
 
The acyl protection of the primary alcohol was removed by alkaline hydrolysis to afford (89), 
followed by oxidation under Swern conditions using Hünig’s base yielded the PBD precursor (90) 
without any racemisation. Reduction of the aromatic nitro moiety with Raney-Ni gave rise to the 
PBD imine, which was not purified at this stage but was converted to the crystalline carbinolamine 
methyl ether (91) by weak acid-MeOH treatment.  
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1.3 Pyrrolobenzothiadiazepines. 
 
Whilst the biological aspects and synthesis of 1,4-benzodiazepine and pyrrolobenzodiazepine 
pharmocophores have been well studied, the pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide 
(95) nucleus has attracted less interest.85 Pyrrolo[1,2-b][1,2,5]benzothiadiazepines are pyrrolo[2,1,-
c][1,4]benzodiazepines possessing a sulfonyl moiety at position 5 in the 7-membered 1,4-diazepine 
ring, and have gained interest as analogues of the benzodiazepines due to their possible activity 
against leukaemia,86,87 and as non-nucleoside reverse transcriptase inhibitors,67,88-90 with some 
activity against HIV.86,87,89,91-93 
 
For these reasons, pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) (92-95, shown in Figure 1-5) 
have been synthesised. A brief overview of the methods used to make them follows.  
 
S N
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O O
R
S N
N
O
O O
R
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R2 S N
N
O
O O
H
S N
N
O O
92 93 94 95
 
Figure 1-5 
 
The synthesis of the analogues (92-94), shown in the Scheme 1-12, was achieved by coupling of 
sulfonyl chloride (96) with the fully saturated (97a) or unsaturated pyrrolo ester (97b) derivatives, 
followed by the reduction with iron and acetic acid to give the corresponding amino ester (99). 
 
Intramolecular cyclisation occured by heating in the presence of 2-hydroxypyridine as a bifunctional 
catalyst (a catalyst which contains two functional groups, i.e. the basic lone pair on the nitrogen and 
the acidic proton on the hydroxyl group) to afford the analogues (92a, unsaturated pyrrole ring), 
(93a-b, unsaturated pyrrole ring), (94, fully saturated pyrrole ring) (the R groups are shown in table 
1-1).89 
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Table 1-1 
Compound R1 R2 
92a H H 
93a Cl H 
93b H Cl 
94a H H 
 
NO2
S
Cl
O O S N
CO2Et
NO2
O
O
HN
EtO2C
R2
R1 S N
CO2Et
NH2
O
O
R2
R1 S N
N
H O
O O
R2
R1(i) (ii) (iii)
92a, 93a-b, 94
96
97a-b 98 99
 
 
Scheme 1-12 (i) tBuOK, 18-crown-6 (ii) Fe, acetic acid (iii) 2-hydroxypyridine  
 
The cyclopropyl analogue (92b-c) was obtained by the intramolecular cyclisation of the 1-(2-
fluorobenzene-1-sulfonyl)-1H-pyrrole-2-(N-cyclopropyl)carboxyamide (103) in the presence of 
sodium hydride and cuprous iodide. The amide derivative (103) was synthesised by treatment of the 
carboxylic acid in the presence of the amine, EDC and DMAP, whereby the acid in turn was 
synthesised via the coupling of the 2-fluorobenzene-1-sulfonyl chloride (100) with the unsaturated 
pyrrolo ester (97b) in the presence of 18-crown-6 and potassium tert-butoxide followed by the 
alkaline hydrolysis of the ester.89(as shown in Scheme 1-13) 
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CONHR
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(iii)(ii) (iv)(i)
92 b,c
100 101 102 103
 
Scheme 1-13 (i) tBuOK, 18-crown-6 (ii) KOH (iii) R-NH2, EDC, DMAP (iv) NaH, CuI. R= 
cyclopropyl or benzyl 
 
The synthesis of compound (95) was carried out by Silvestri et al,94 by two different routes. The first 
of these was the coupling of pyrrole-2-carboxaldehyde (105) to 2-nitrobenzenesulfonyl chloride 
(104) in the presence of tBuOK and 18-crown-6 as a condensing agent followed by the 
intramolecular cyclisation via reduction of the nitro group of compound (106) to the amine with iron 
and acetic acid. The second route employed treatment with acetic-formic anhydride to compound 
(107) to afford 1-(2-foramidobenzenesufonyl)pyrrole (108) which was cyclised with phosphorus 
oxychloride via a Bischler-Napieralski reaction as seen in the Scheme 1-14. 
 
95
S N
NO2
O O
S N
NHCHO
O O
S N
N
O O
CHO
S N
NH2
O O
S Cl
NO2
O O
HN
OHC (i)
(ii)
(iii) (iv)
96 105 106
107 108
 
Scheme 1-14 (i) tBuOK, 18-crown-6 (ii) Fe, acetic acid (iii) Formic acid, acetic anhydride 
(iv) POCl3 
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1.4 Tetracyclic PBDs and PBTDs. 
 
One of the aims of this work was to make tetracyclic analogues of the pyrrolobenzodiazepines.69,96 
The specific targets that were intended were those formed by intramolecular azide 1,3-cycloadditions 
as shown in the Figure 1-6: 
N3
NX
W
N
NX
N N
W
W = CH2, CH, CN109 110
 
Figure 1-6 
 
There were two reasons for this, firstly, the possibility that (110) (W = CH2) would collapse to an 
imine or aziridine, both of interest in potential DNA interaction processes and, secondly, to produce 
analogues of tetracyclic PBDs such as the CNS active bretazenil (111, structure shown in Figure 1-
7). For this reason a brief review of the approaches to tetracyclic PBDs follows.  
 
N
N
N
Br
O
O tBu
H
O
111, bretazenil
 
Figure 1-7 
 
The main workers in this area are Silvestri et al, and the table below and next three Schemes show 
their approaches to compounds of general structure (112)89,94 and (113)97 (as shown in Figure 1-8 
and substituent groups in table 1-2). 
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Figure 1-8 
 
Table 1-2 
Compound X Y R 
112a CH N H 
112b  CH CH H 
113a CO - CH2Ph 
113b CH2 - CH2Ph 
113c CH2 - H 
113d CH2 - CH3 
 
The formation of imidazo[5,1-d]pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (112b, Y = X = 
CH) was acheived by two different synthetic routes,94 as shown in Scheme 1-15. The first of these 
was the direct route from compound (95) using tosylmethyl isocyanide (TosMIC) and nBuLi 
resulting in cycloaddition across the azomethine double bond. The second route was a two step 
synthesis starting from compound (114), and treatment with triethyl orthoformate to form the 
tetracyclic system which was oxidised with MnO2 to form compound (112b). 
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Scheme 1-15 (i) CH(OEt)3 (triethyl orthoformate) (ii) MnO2 (iii) TosMIC, nBuLi. 
 
The synthesis of the aptazepine analogue (113d) started from the synthesis of the readily available 
compound (115, as shown in Scheme 1-16)86 which underwent thermal cyclisation in toluene to 
afford the tetracyclic PBTD dioxopiperazinyl derivative (113a). Reduction using a mixture of 
lithium aluminium hydride and sulfuric acid gave pyrazinopyrrolo[1,2-b][1,2,5]benzothiadiazepine 
(113b) a further example of a tetracyclic PBTD. Compound (113b) was debenzylated using 
hydrogen in the presence of 10% palladium on charcoal as the catalyst to yield (113c) which was 
reductively methylated with formaldehyde in the presence of hydrogen to give the methyl derivative 
(113d) in 70% yield.97 
 
113a 113b 113c 113d
S N
N
O O
OEt
OO
HN
S N
N
O O
NO
O
S N
N
O O
N
S N
N
O O
N
H
S N
N
O O
N
Me
(i) (ii)
(iii)
(iv)
115
(v)
 
Scheme 1-16 (i) Toluene, heat (ii) LiAlH4 (iii) H2SO4 (iv) H2, Pd/C (v) (CH2O)n, H2, Pd/C 
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The PBTD (116),86,90 easily obtained from the substituted pyrrole (107), was hydrolysed with 
potassium hydroxide, after which TFA-induced ring closure afforded the azetidino 
pyrrolobenzothiadiazepine (118, as shown in Scheme 1-17). 
 
S N
NH2
O O
107
S N
H
N
O O
O
OEt
S N
H
N
O O
O
OH
(iii)
S N
N
O O
O
(i) (ii)
116 117 118
 
Scheme 1-17 (i) (EtO)2CHCH2CO2Et, acetic acid/H2O (ii) KOH (iii) Trifluoroacetic acid 
 
The reaction of the substituted pyrrole (107, as shown in Scheme 1-18) with ethyl glyoxylate 
dimethoxy-acetal followed by bromoacetyl-bromide gave the PBTD (120). Treatment of compound 
(120) with an equimolar amount of aqueous methylamine in the presence of triethylamine in a sealed 
tube furnished a mixture of the lactam derivative (121) and the aptazepine derivative (122). Excess 
treatment of the methylamine under the same conditions yielded the compound (123). 
S N
NH2
O O
107
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O O
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O O
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O O
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CONHCH3
CONHCH3
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Scheme 1-18 (i) ethyl glyoxylate dimethoxyacetal, TsOH, absolute EtOH, reflux, o.n. (ii) 
BrCOCH2Br, NaHCO3 
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Broggini et al,98,99 have published two routes to bretazenil analogues both of which started from the 
(S)-N-Boc protected proline derivative (124, as shown in Scheme 1-19), which was reduced in the 
presence of DIBAL-H and subjected to Wittig olefination to afford compound (125). Deprotection 
gave the intermediate (126). Coupling to the substituted 2-nitrobenzoyl chloride (127) afforded the 
8-substituted 2-nitro derivatives, (128), which after reductive treatment with iron and acetic acid 
afforded the compounds (129). Diazotisation with sodium nitrite and hydrochloric acid followed by 
treatment with sodium azide gave compound (130), whilst coupling with methyl-2-
chloroacetoacetate afforded the hydrazonyl derivative (132). Subsequent treatment of the azido 
derivative (130) by heating in carbon tetrachloride, or heating the hydrazonyl derivatives (133) with 
triethylamine and toluene yielded the [1,2,3]triazolo[1,5-a]pyrrolobenzodiazepine and pyrazolo[1,5-
a]pyrrolobenzodiazepine derivatives (131) and (134), respectively, via 1,3-dipolar intramolecular 
cyclisation. 
N
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CO2Me
H
N
Boc
H
N
NO2
O
H
N
NH2
O
H
N
N3
O
H
N
N
O
NN
H
H
(viii)
(ix)
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(iii) (iv)
(v) (vi) (vii)
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H
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O
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N
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O
N
H
H
CO2Me
N
N
O
H
N
CO2Me
X
X X X X
X X X
124 125 126 127
128 129 130 131
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Scheme 1-19 (i) DIBAL-H, dry toluene, N2 atmosphere, -60C (ii) Ph3PMe+I-, tBuOK, dry THF, N2 
atmosphere, 0C (iii) TFA, N2 atmosphere, 1hr (iv) K2CO3, dry toluene, reflux, 4hrs (v) Fe, AcOH, 
EtOH, reflux, 2hr  (vi) NaNO2, HCl, Et2O, 0C, 30 mins then NaN3, r.t., 40min (vii) CCl4, reflux, 
5hrs (viii) NaNO2/H+ then MeCOCHClCO2Me (ix) Et3N, toluene, reflux. 
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1.5 Other Tricyclic 1,4-Benzodiazepines. 
 
In this thesis (see discussion) some of the target molecules were the “a” fused tricyclic 
benzodiazepine analogues represented by the general structure (135), shown below. A review of the 
published syntheses of such systems now follows. Examples of compounds in this class include 
Alprazolam (136), Estazolam (137) and Flumazenil (4), as shown in Figure 1-9. Alprazolam and 
Estazolam are common anxiolytic agents,100,101 Flumazenil100 is a cognitition enhancer and all are 
common anxiolytic agents and all have found both clinical and commercial success. 
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N
N
N
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N
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136, Alprazolam 137, Estazolam
N
N
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4, Flumazenil
Me
CO2Et
F
135
 
Figure 1-9 
 
1,3-Dipolar cycloadditions of nitriles, alkenes and alkynes with azides will form the main part of this 
section (1.5.1) as they will become important later in this thesis. Also discussed are the Ugi four 
component reaction (1.5.2), the imidazolo formation approach (1.5.3) and the Harvey reaction 
(1.5.4) which are all important as they contain the triazole or tetrazole annulated ring on the “a” face. 
Finally, an approach to azetidinobenzodiazepines will be detailed (1.5.5), as this system will be of 
some importance later on in this thesis. 
1.5.1 The 1,3-dipolar cycloaddition of azides with nitriles, alkynes and alkenes. 
 
Broggini et al,102 have explored the cyclisation of the dipolarophilic nitrile moiety with a dipolar 
azide (see reaction Scheme 1-20).  
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Scheme 1-20 (i) NaNO2, HCl then NaN3 (ii) Toluene, reflux (iii) 95% formic acid 
 
Starting from 2-aminocarbonylanilines (136), treatment with sodium azide gave the 2-substituted 
aryl azides (137), which could not be isolated in analytically pure form due to side cyclisation 
products. The intramolecular cyclisations of the crude compound (137), containing various R and X 
groups (shown in the table 1-3) were carried out by heating to reflux in dry toluene to afford 
compound (138).  
Table 1-3 
Entry X R Time 
(hrs) 
Products and yields 
138 141 142 
137a H H 33 75 - - 
137b Cl H 77 95 - - 
137c H Me 64 30 - - 
137d H Ph 15 57 - - 
137e H 4-Me-C6H6 16 56 - - 
137f H 4-Me-C6H6 15 47 - - 
137g H 4-Me-C6H6 16 65 - - 
140 - - 480 - 5 6 
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The parent 4,5,7-unsubstituted product (142) was also seen as a valuable target and hence the 
starting material 2-amino-N-cyanomethylbenzamide (139) was converted to the corresponding azide 
derivative (140) as before. Unfortunately the yield of this reaction was low due to the formation of 
the undesired 3-cyanomethylbenzotriazin-4-one (141) (20% after purification). The 1,3-dipolar 
cycloaddition between the nitrile and the azide of compound (140) proved to be troublesome since a 
very long reaction time was required and extensive decomposition occurred at high temperatures. In 
addition compound (140) lost molecular nitrogen, generating the corresponding nitrene which 
resulted in the re-formation of compound (139). Due to this, compound (142) was best synthesised in 
37% yield by benzyl group cleavage of compound (138a) with 95% formic acid.  
 
The intramolecular cycloaddition between an alkene and an azide can result in the formation of a 
triazolidine (143) which can spontaneously lose molecular nitrogen to form either an aziridine (144) 
or a methylimine (145) as shown in the Figure 1-10.9,103  
 
N
N
N
N N
Me
143 144 145
 
              Figure 1-10 
 
Broggini et al,103 investigated these processes by the synthesis of compounds (146a-d) (see Schemes 
1-21). The unsubstituted compounds (146a-b) were not fully characterised due to their ability at 
room temperature to undergo intramolecular cycloaddition to give a crude mixture of 
diastereoisomeric 1,2,3-triazolo[1,5-a][1,4]benzodiazepinones (147a-b) and (148a-b) on reaction 
work-up. Complete conversion into these compounds was accomplished by stirring a 0.02M ethereal 
solution of the crude azides at room temperature to give the yields shown in the table. Further 
treatment of the triazole derivatives (147a-b) and (148a-b) in toluene at reflux gave the 
corresponding diastereoisomeric aziridines (149a-b) and (150a-b) or the methyl imines (151a-b) via 
the extrusion of nitrogen from the triazole ring. 
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Table 1-4 
Compound Time 
(hrs) 
Products and yields (%) 
147 148 149 150 
146a 0.75a 61 28 - - 
146b 0.5a 57 18 - - 
146c 7.5b - - 58 33 
146d 6.5b - - 47 31 
Intramolecular cycloadditions of N-alkenoyl aryl azides (146) 
a
 in dry Et2O, r.t. 
b in refluxing toluene 
 
In contrast, the phenyl-substituted azides (146c-d) (shown in the Scheme 1-22)103 were more stable 
and were obtained as crystalline solids. The intramolecular cycloaddition was accomplished by 
heating at reflux in toluene and 1% triethylamine giving the diastereoisomeric aziridino-[2,1-
(ii)
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R
Me
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151a, b
151a, b
(ii)
a: R = Ph; b: R = CO2CH2Ph
 
Scheme 1-21 (i) Et2O, r.t. (ii) toluene, reflux 
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c][1,4]benzodiazepinones (149c-d) and (150c-d) via the intermediate triazoles with thermal 
expulsion of molecular nitrogen in the yields shown in the table 1-5. 
 
 
Table 1-5 
Compound Time 
(hrs) 
Products and yields (%) 
149a 149b 150a 150b 151a 151b 
147a 1 43 - - - 44 - 
147b 1 - 48 - - 44 - 
148a 6 - - 30 - - 42 
148b 8 - - - 53 - 43 
 
When the same reaction was carried out in a study by Molteni et al,104 the homochiral azides (146a-
f) when heated in toluene with 2% TsOH gave pure imines (153a-f) with high yields (92-98%) after 
recrystallisation from diisopropyl ether. It is noteworthy that the homochiral azides (146a-f) were 
stable at room temperature and did not undergo room temperature intramolecular cyclisation to the 
intermediate (152a-f). 
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 Scheme 1-22 (i) toluene reflux 
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Scheme 1-23 (i) TsOH (2% mol), toluene, reflux (ii) –N2 
 
A list of the different R and R1 groups in compound (153) are listed in the table 1-6: 
 
Table 1-6 
Entry a b c d e f 
R CO2Bn CO2Bn CO2Bn Ph Ph Ph 
R1 H Me Ph H Me Ph 
 
The loss of molecular nitrogen from intermediate (152) to form product (153) can occur via two 
different routes.104 
152
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Me
O
R1
N
N
R
Me
O
R1
N
N
R
Me
O
R1
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H
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N
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H+
- H+
(-N2) 153H
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Figure 1-11 
 
The first route requires prototropic migration on compound (154) after the loss of nitrogen from 
compound (152) to give compound (153). Alternatively, ring closure gives the aziridino[2,1-
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c][1,4]benzodiazepinones (155), which in the presence of a catalystic amount of TsOH yielded 
product (153) through the mechanism shown in Figure 1-11. 
 
Broggini and Baccalli et al,9 have also utilised intramolecular cycloaddition between an alkene and 
azide to yield imines directly as shown in the Scheme 1-24. Reduction of the readily available 
compound (158) afforded compound (159). The diazotisation of (159) followed by treatment with 
sodium azide led to the derivatives (160) which could be isolated before intramolecular cyclisation 
between the alkene and the azide. The conversion of (160) to (162) via the intermediate triazoline 
(161) was achieved by heating to reflux in toluene, which proceeded in good yields (54-72%).  
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Scheme 1-24 (i) Fe, EtOH, AcOH, (ii) NaNO2, HCl then NaN3 (iii) toluene, reflux. X : a = H, b = 
Cl, c = F 
 
A further example of the formation of a seven membered ring utilised a different type of 
intramolecular 1,3-dipolar cycloaddition between an alkene and a nitrilimine in the intermediate 
compound (167) to make diastereoisomers of pyrazolo[1,5-a][1,4] benzodiazepine-4-ones (168) and 
(169) (the yields are shown in the table 1-7) which were isolated via column chromatography as pure 
diastereoisomeric cycloadducts.105 The nitrilimine precursor (166) was easily constructed from 
precursor (163) as shown Scheme 1-25. 
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Scheme 1-25 (i) K2CO3, toluene, reflux (ii) Fe, EtOH, 20% AcOH (iii) NaNO2, HCl then 
MeCOCHClCO2Me (iv) Ag2CO3, dioxane or Et3N, dioxane. R= a: H, b: Me, c: Ph 
 
Table 1-7 
Entry Compound Base (Eq.) Time (hrs) Products and Yields (%) 
    168 169 
a 166a Ag2CO3 (2) 52 75 21 
b 166b Ag2CO3 (2) 140 61 33 
c 166c Ag2CO3 (2) 140 69 27 
d 166a Et3N (5) 24 52 20 
 
The final example in this section involves a 1,3-dipolar cycloaddition between an azide and an 
alkyne. The synthesis of these two functional groups involved the reaction of 5-substituted isatoic 
anhydrides (170) with methylpropargylamine as shown in the reaction Scheme 1-26.100 
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Scheme 1-26 (i) N-Methylpropargylamine (ii) NaNO2, HCl (iii) NaN3, X = H, Cl, F, NO2, NH2 
 
The reaction was carried out in boiling dioxane in the case of (170) (where X = H) and for the less 
reactive substrates (where X ≠ H) in boiling DMF to give the anthranilamides (171) in moderate 
yields (44-54%). These compounds were all treated with sodium nitrite and acid to form the 
diazonium salts (172) followed by sodium azide to form the azides (173). As before the azides could 
not be isolated as they underwent in situ 1,3-dipolar cycloaddition with the terminal alkyne to yield 
the [1,2,3]triazolo[1,5-a][1,4]benzodiazepin-5-one derivatives (174) in 41-55%. 
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1.5.2 Reactions involving multi-component Ugi processes. 
 
Another route to provide the terminal alkyne and the azide that allow access to 
triazolobenzodiazepines has been achieved by Akritopoulou-Zanze et al,106 who utilized the Ugi 
multi-component reaction with components containing a terminal alkyne and an azide. The synthesis 
is shown in the Scheme 1-27, and a variety of seven membered rings fused with the triazoles have 
been successfully synthesised using coupling partners containing the azide functionality on the 
carboxylic acid (route 1) or aldehyde inputs (route 2 and 3) and the acetylenic functionality on the 
amine (routes 1 and 2) or carboxylic acid (route 3). 
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Scheme 1-27 (i) MeOH, 24-48 hours, r.t. (ii) benzene, reflux, 4-18hrs. 
(R groups are shown in table 1-8) 
 
The Ugi reactions proceeded smoothly to provide the intermediates in moderate to high yields as 
shown in the table 1-8. Heating these intermediates to reflux in benzene afforded the cyclised 
products in excellent yields, via intramolecular alkyne-azide cycloaddition (IAAC).  
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Table 1-8 
Aldehyde H
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H
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H
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Ugi Yield (%) 81 71 51 33 50 
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H
N
N
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IAAC Yield 
(%) 
96 97 96 97 86 
 
The four pot Ugi condensation reaction has proven to be a simple and effective route through to 
other 1,4-benzodiazepin-5-ones. Thus, Tempest et al,10 have successfully synthesised the compounds 
(181-182) in the Figure 1-12.  
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Figure 1-12 
 
A four pot condensation in which a variety of substituents could be added in the final multi-
component Ugi-type step (shown in Scheme 1-28) started from the commercially available 
aminocarboxylate (183) which was treated with 2,5-dimethoxytetrahydrofuran in acetic acid to form 
the 1H-pyrrol-1-yl derivative (184). The aldehyde moiety of compound (185) was introduced using 
POCl3 in DMF in good yields (64-77%) and the precursor (186) was synthesised by hydrolysis of the 
ester with sodium hydroxide solution to provide the carboxylic acid and the aldehyde moieties (two 
of the four parts of the Ugi four pot condensation reaction). The final part of the synthesis introduced 
the other two components, the isocyanate and the amide (shown in the table 1-9), to provide the 
analogues (187a-b) in 75-85% yield.107 
Cl
OH
O
N
O
N
N
O
HN
O
R
R1Cl
OMe
O
N
O
Cl
OMe
O
N
Cl
OMe
O
NH2
HH
(i) (ii)
(iii) (iv) Cl
183 184
185 186 187a, b
 
 Scheme 1-28 (i) 2,5-dimethoxytetrahydrofuran, AcOH, 4hrs (ii) DMF, POCl3 (iii) 1% aq. NaOH, 
40C, 8hrs (iv) R-NC, R1-NH2, MeOH, 40C, 4-18hrs. (See table 1-9 for R groups and yields) 
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Table 1-9 
Entry Amine Isonitrile Yield (%) 
R 
Me
NH2
 
NC
 
75 
R1 
NH2
 
NC
 
85 
 
1.5.3 Imidazolo ring formation: imidazolobenzodiazepines. 
 
Flumazenil (structure 4 shown in the Scheme 1-29) blocks the central effects of the classical 
benzodiazepines and has been used in the treatment of benzodiazepine overdosing and sedation as 
well as being evaluated for the improvement of cognitive function in Alzhiemer’s patients.108  
 
The synthesis (shown in the Scheme 1-29)108 starts from the iminochloride (189) which was 
prepared by the dropwise addition of a slight excess of POCl3 to a hot toluene solution of the amine 
(188) in the presence of N,N-dimethyl-p-toluidine. The treatment of the iminochloride (189) with 2 
eq of the lithiated (195) at -35C gave rise to a mixture of the uncyclised intermediate (192a) and 
Flumazenil (4) (approx 20:1) on aqueous work up. A non-aqueous workup procedure allowed the 
isolation of the intermediate (192a), isomerisation to compound (192b), and intramolecular 
cyclisation and elimination of dimethylamine to produce Flumazenil (4) in isolated yields of upto 
98%. 
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4, Flumazenil192b
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(v)
(vi)
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N
O
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F
CO2Et
Me
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H
N
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N
F
CN
Me
Me2N
Me2N
N
H
N
O
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F
N
Me
NMe2
N
H
N
O
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F
N
Me
NMe2
N
N
MeO
Cl
N
H
N
MeO
O
NH2
CN
N
CN
NMe2
N
EtO2C
NMe2
NH2
CO2Et
.HCl
Ph
Ph
(i)
(ii)
(iii)
(iv)
(ii)
(iii)
N
N
MeO
N
N
H
N
MeO
MeO2C
CO2Me
(vii)
(viii)188
189
190
191
192a
193a 194
195
196
 
 
Scheme 1-29 (i) POCl3, N,N-dimethyl-p-toluidine toluene, 100C, 2hrs, 86% (ii) LHMDS, THF, -
30C, 2hrs, N,N-dimethyl-p-toluidine (iii) AcOH, reflux (iv) DMF-DMA, Et3N, DCM, r.t., 1hr (v) 
BnzCl (vi) DMF-DEA, reflux, 5 hrs (vii) Me2NH, EtOH, 30mins (viii) CH2(CO2Me)2, LHMDS, 
THF, -30C, 16hrs. 
 
This method was further exploited in the synthesis of compound (194) by the treatment of the 
iminochloride (189) with the amidine (196) as the building block to give the intermediates (193a and 
b) as a 1:1 mixture. The isomer (193a) was converted to the more stable isomer (193b) which could 
then be heated in the presence of acetic acid to give, in quantitative yields, the nitrile derivative 
(194).  
 
The synthesis of imidazo[1,5-a][1,4] benzodiazepines has been explored by Gu et al,109 by 
employing the reactions as shown in the Scheme 1-30. The synthesis started from commercially 
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available isatoic anhydride (197a) or 5-chloroisatoic anhydride (197b) which was heated in the 
presence of N-methylglycine in dimethyl sulfoxide to afford the the corresponding di-lactams (198a-
b). Deprotonation with sodium hydride in THF and DMF, followed by the treatment with 
diethylphosphorochloridate, formed the intermediate enol-phosphates (not shown). These were 
subsequently reacted with a solution of ethyl or tert-butylisocyanoacetate and sodium hydride in 
DMF to afford compounds (199a-d). Further side chain manipulation of (199a-b) yielded examples 
(200a-h). 
 
N
N
O Me
N O
OR
XN
H
N
O
O
Me
198a X = H
198b X = Cl
XO
H
N O
O
X
197a X = H
197b X = Cl
199a X = H, R = Et
199b X = Cl, R = Et
199c X = H, R = iBu
199d X = Cl, R = iBu
N
N
O Me
N O
OR1
X
200a X = H, R = Me
200b-h X = Cl, R1 = Me, Pr, 
iPr, CH(Et)2,CH2tBu, (CH2)2tBu
(i) (ii)
(iii)
(iv)
(v) (vi)
 
Scheme 1-30 (i) N-Methylglycine, DMSO, 140C (ii) NaH, THF, DMF, (EtO)2POCl (iii) NaH, DMF, 
CNCH2CO2R (iv) 10% KOH in MeOH, H2O, HCl (v) SOCl2, toluene (vi) R1OH. 
 
1.5.4 The Harvey approach. 
 
This synthesis (shown in Scheme 1-31) started with methyl 2-azidobenzoate and its thermal 
cycloaddition to (3-chloro-acetonylidene)triphenylphosphorane via a Harvey approach which is 
visualised as a 1,3-dipolar cycloaddition of the azide group to the C=C bond of the resonance 
phosphorane structure with spontaneous elimination of the stable phosphine oxide to give the 
intermediate compound (201). The treatment of compound (201) with ammonia, benzylamine or p-
toludine gave the 1,2,3-triazolo[1,5-a][1,4]benzodiazepine derivatives (202) in the yields shown in 
the table 1-10.101 
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Table 1-10 
Reaction conditions Product Yield (%) 
NH3, CH3CN, 80C, 12hrs, NOTE 
Et3N was not needed 
N
N
O
H
N N
 
87 
BnNH2, Et3N, toluene, reflux, 5 days 
N
N
O
Bn
N N
 
80 
p-toluidine, Et3N, toluene, 140C, 14 
days 
N
N
O
Tol-p
N N
 
52 
  
1.5.5 Thioacetal-amine ring closure to form an azetidinobenzodiazepine. 
 
Bose and Srinivas110 have replaced the C ring pyrrole of the PBD structure with an azetidine ring, to 
produce an azetidino[2,1-c][1,4]benzodiazepine ring system (ABD). This synthetic approach, shown 
in the Scheme 1-32, involved the initial preparation of the 4-benzyloxy-5-methoxy-benzoic acid of 
the A ring fragment. This fragment was converted into the corresponding acid chloride under the 
(i) (ii)
CO2Me
N3
Ph3P
O
Cl
CO2Me
N
N
N
Cl
N
N
O
R
N N
201 202
 
Scheme 1-31 (i) toluene, reflux (ii) see table 1-10. 
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usual conditions and coupled to (S)-azetidine-2-carboxylic acid in the presence of triethylamine, to 
afford the corresponding amide (203) which was used without purification and converted to the 
methyl ester by treatment with thionyl chloride and methanol. Formation of the aldehyde (206) was 
achieved with lithium borohydride to afford the alcohol in 78% yield, followed by subsequent 
oxidation. The aldehyde (206) proved to be unstable, so was converted to the diethyl thioacetal (207) 
which was further reduced with tin(II)chloride dihydrate to afford the uncyclised intermediate 
precursor (208). The deprotection of the diethyl thioacetal, using HgCl/CaCO3 led to the B-ring 
closure to afford the carbinolamine (209), which upon debenzylation yielded the azetidine ring 
system (210).  
 
 
N
N
O
MeO
BnO
H
H
OH
N
N
O
MeO
HO
H
H
OH
N
NH2
O
MeO
BnO CH(SEt)2
N
NO2
O
MeO
BnO CH(SEt)2
N
NO2
O
MeO
BnO CHO
N
NO2
O
MeO
BnO CH2OH
N
NO2
O
MeO
BnO CO2Me
N
NO2
O
MeO
BnO CO2H (i) (ii)
(iii) (iv) (v)
(vi) (vii)
203 204 205
206 207 208
209 210
 
 
Scheme 1-32 (i) SOCl2, MeOH (ii) LiBH4, THF, 0C, r.t. (iii) IBX, DMSO, r.t., 30mins (iv) EtSH, 
TMSCl, r.t., 12hrs (v) SnCl2.2H2O, MeOH. reflux, 40mins (vi) HgCl, CaCO3, MeCN:H2O (4:1), 
2.5hrs (vii) 10% Pd/C, cyclohexadiene, EtOH, 45 mins. 
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1.6 Tricyclic Benzothiadiazepines. 
 
In this the final part of the introduction the synthesis of tricyclic derivatives of the 1,2,5-
benzothiadiazepines will be discussed. These structures have attracted interest as novel inhibitors of 
human immunodeficiency virus type 1 (HIV-1),88,111 and examples are shown in the Figure 1-13:  
 
N
NS
O O Me
O
N
NS
O O
Cl
R
O
N
NS
O O
211 212 213
 
Figure 1-13 
 
Di Santo et al,111 have synthesised analogues of compound (211), shown in the Figure 1-13. Hence, 
the reaction of 2-nitrobenzensulfonamide with tert-butoxycarbonic anhydride in the presence of 
DMAP afforded the protected 2-nitrobenzenesulfonamide (215). Reduction in the presence of iron 
and hot acetic acid at 60C gave compound (216), which was further treated with 2,5-
dimethoxytetrahydrofuran in hot acetic acid to undergo the Clauson-Kaas reaction to form the 
pyrrole ring system of compound (217). The formation of the pyrrole ring system occurred easily 
and was accompanied by deprotection of the amide moiety with formation of the required pyrrole 
sulfonamide (218). Also, isolated as a side product of the reaction was the tricyclic 
pyrrolobenzothiazepinone (219), due to acid catalysed intramolecular cyclisation of the intermediate 
(217), with elimination of tert-butylalcohol. Further transformation of 2-(1H-pyrrol-1-yl) 
benzenesulfonamide (218) to (219) was accomplished by treatment with triphosgene. The final stage 
was the alkylation of compound (219) with iodoethane to yield the analogue (211) in 72% (as shown 
in the Scheme 1-33). 
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Scheme 1-33 (i) (Boc)2O, DMAP (ii) Fe, AcOH (iii) 2,5-dimethoxytetrahydrofuran, AcOH 
(iv) triphosgene (v) C2H5I, K2CO3. 
 
The second route started from the 2-nitrobenzenesulfonamide derivative (220) which was Boc-
protected and reduced, as carried out for the first route. The Clauson-Kaas reaction yielded the N-
ethyl-2-pyrrolo system (223), which was treated with triphosgene to give the analogue (211) in 62% 
yield (as shown in the Scheme 1-33). 
 
Disanto et al,111 also synthesised the analogue (213a) (shown in the Scheme 1-34) by the treatment 
of 2-(1H-pyrrol-1-yl)benzenesulfonamide (224) with paraformaldehyde in refluxing ethanol. 
Intramolecular cyclisation with formic acid as a reagent did not yield the compound (213b) and so 
the treatment of (224) in the presence of triethyl orthoformate to yield (225), and subsequent 
intramolecular cyclisation was used to access compound (213b).  
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Scheme 1-34 (i) (CH2O)n, EtOH (ii) Formic acid (iii) H+, HC(OEt)3 (iv) H+ 
 
The 3-chloro-pyrrolo[2,1-d]1,2,5]benzothiadiazep-7(6H)-one 5,5-dioxide derivatives (shown in the 
Scheme 1-35) were synthesised starting from 5-chloro-2-nitrobenzenesulfonyl chloride (226) which 
was successfully coupled to secondary amines. The N-protection of the sulfonamide was achieved 
with (Boc)2O in the presence of 4-dimethylaminopyridine (DMAP) to afford N-tert-butoxycarbonyl-
5-chloro-2-nitrobenzenesulfonamide derivatives (228). Reduction with iron in hot acetic acid to 
afford (229) followed by treatment with dimethoxytetrahydrofuran in acetic acid at reflux via the 
Clauson-Kaas method yielded the 5-chloro-(1H-pyrrol-1-yl)benzenesulfonamides (230). Finally, the 
cyclised compounds (212a-b) were obtained by treatment with triphosgene.88 
 
212a,b
NO2
S
Cl
O O
NO2
S
N
O O
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NO2
S
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Cl Cl Cl
NH2
S
N
O O
Boc
R
Cl
N
S
N
O O
R
H
Cl S N
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O O R
O
R
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(iv) (v)
226 227 228
229 230
 
Scheme 1-35 (i) R-NH2 (ii) (Boc)2O, DMAP (iii) Fe, AcOH (iv) 2,5-dimethoxytetrahydrofuran, 
AcOH (v) triphosgene R = H, Et. 
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2 Discussion: Synthesis of the tetrazolopyrrolobenzodiazepines and 
tetrazolopyrrolobenzothiadiazepines. 
 
In this research project the aim, summarised in Figure 2-1, is to synthesise tetra- and triazolo-
analogues of the pyrrolobenzodiazepines, pyrrolobenzothiadiazepines, benzodiazepines and 
benzothiadiazepines. As discussed in the introduction, these compounds are of great interest as 
synthetic targets due to their potential medical properties. In the first part of the discussion, the 
synthesis of triazolo/tetrazolo pyrrolobenzodiazepines and pyrrolobenzothiadiazepines will be 
discussed (Sections 2.1 & 2.2), followed by the synthesis of other triazolo/tetrazolo benzodiazepines 
(Section 3), alkene cycloaddition (Section 4), and the further developments towards benzodiazepine 
analogues (Sections 5 & 6). 
233
234
235
236
237
238
239
240
N
NX
N N
Z
Y
X
N3
NX
N
Boc
H
O
N
Boc
NH2O
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N
N3
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242, CH, 243 CH2
R1 = H, OMe, 
R2 = H, OH.
OHX= CO, SO2
231, Y = NH2
232, Y = N3
N3
NXR1
R2
R1
R2
R1
R2
R1
R2
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R2
R2
R1
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R1
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Figure 2-1 
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2.1 Synthesis of Tetrazolopyrrolobenzodiazepines and Tetrazolopyrrolobenzo-
thiadiazepines. 
2.1.1 Synthesis of 2-azidobenzoic and sulfonic acids (232). 
 
231a, X = CO
231b, X = SO2
232a, X = CO
232b, X = SO2
X
NH2
OH
1. NaNO2, H2SO4 
or HCl, 0°C
2. NaN3, 0°C
X
N3
OH
 
Scheme 2-1 
 
The chemistry shown in Scheme 2-1 relies upon the use of 2–azidobenzoic acid (232a, X = CO) and 
2-azidobenzenesulfonic acid (232b, X = SO2) as starting materials. The synthesis69 of both the azido 
products started from the commercially available corresponding anilines [(231 X = CO, SO2) 
Aldrich]. Straightforward diazonium formation followed by the displacement of nitrogen by the 
nucleophilic azide anion gave the products, and probably proceeds via the mechanism shown in 
Figure 2-2 to give the azides in high yields, 95%.  
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Figure 2-2 
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The 1H NMR spectrum (500 MHz) was consistent with the structure of 2-azidobenzoic acid (232a, X 
= CO) which showed four aromatic protons with a 1,2-substitution pattern i.e. two doublets at 7.20 
ppm, 7.67 ppm and two pseudo triplets at 7.15 and 7.49 ppm, respectively. The appearance of a 
sharp peak at max 2124 cm-1 in the IR spectrum is consistent with an azide group being present, 
which along with the correct mass of 186.0 [M+Na]+ supports the structural assignment.  
 
The structural assignment of the 2-azidobenzenesulfonic acid (232b, X = SO2) was consistent with 
the 1,2-substitution pattern present in the aromatic region of the 1H NMR (400 MHz) spectrum with 
triplets at 7.15 ppm, 7.45 ppm and the doublets being at 7.28 and 7.70 ppm. The IR spectrum of the 
product showed the diagnostic azide absorption peak at max 2122 cm-1 and confirmed the formation 
of the product. 
2.1.2 Coupling of the acid chlorides with prolinamide. 
 
234a, X = CO
234b, X = SO2
X
N3
OH
X
N3
N
C
N
-H2O
X
N3
N
OH2N
2. L-prolinamide, K2CO3, r.t.
1. (COCl)2, DMF,  or 
SOCl2, 
232a, X = CO
232b, X = SO2
233a, X = CO
233b, X = SO2
 
Scheme 2-2 
 
With the azide group in place, the next step was the coupling of the corresponding acid chloride to 
prolinamide with a view to subsequent dehydration to put in place the nitrile group. The carboxylic 
acid was refluxed in SOCl2 to give the acid chloride which was coupled up with the prolinamide in a 
mixed phase reaction pot containing K2CO3 as the base. The N-aryl prolinamide (233a, X = CO) was 
not isolated from the mixture but instead underwent in situ dehydration to give the nitrile (234a, X = 
CO) as a mixture of rotamers in 33% yield. This may have been due to an excess of the acid chloride 
in solution which initiated the dehydration as shown in the Figure 2-3. 
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Figure 2-3 
 
The structure of (234a) was confirmed by the 1H (400 MHz) NMR spectrum which showed loss of 
the amide protons. The aliphatic CH2 protons of the pyrrolidine ring structure were found at 2.01-
2.10 (1H), 2.11-2.25 (1H), 2.27-2.41 (1H), 3.27-3.34 (1H), 3.37-3.45 (1H), 3.72-3.83 (1H) ppm with 
the single CH in the ring at 4.92 ppm. The aromatic protons were located downfield at 7.23 (2H), 
7.34 and 7.48 ppm. The 13C Dept-135 (100 MHz) NMR spectrum showed doubling up of the three 
proline CH2 signals and the CH showing that the product was a mixture of rotamers. The presence of 
a quaternary carbon at 117.4/117.6 ppm showed the presence of the (C≡N), further proof of which 
came from the IR spectrum with a max 2241 cm-1 (C≡N)  and a correct mass at 259.1304 [M+NH4]+ 
in the high resolution mass spectrum. 
 
The 2-azidobenzenesulfonic acid (232b, X = SO2) was converted into the acid chloride by heating at 
reflux as a suspension in 2M (COCl)2 in DCM and DMF. Coupling the acid chloride to prolinamide 
in a mixed phase process with K2CO3 as the base was successful. This time the isolated product was 
the amide (233b, X = SO2) in 62% yield, the structure of which was confirmed by the 1H (400 MHz) 
NMR spectrum which gave two broad singlets at 5.72 and 6.90 ppm in addition to the expected 
pyrrolidine and aromatic protons. The 13C (100 MHz) NMR spectra showed a quaternary carbon at 
174.2 ppm which confirmed the presence of the (CONH2). The IR spectrumgave a peak at max 
3250- 3700 cm-1 for the N-H stretches and a carbonyl amide stretch at max 1670 cm-1 which along 
with the correct accurate mass of 313.1077 for [M+NH4]+ gave further evidence for the structural 
assignment. 
 
The amide (233b, X = SO2) was dehydrated by treatment with tosyl chloride and pyridine112 at reflux 
under nitrogen to yield the nitrile (234b, X = SO2) in 37% yield. The structure was confirmed by the 
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1H (400 MHz) NMR spectrum which showed the disappearance of the two broad amide NH2 singlets 
and the 13C NMR (100 MHz) which showed a new quaternary carbon at 118.3 ppm and the loss of 
the amide carbonyl at 174 ppm. The IR spectrum with a new peak at max 2305 cm-1 (C≡N) and the 
loss of the amide carbonyl and N-H peaks, along with the confirmation of the mass of 295.0972 for 
the measured ion [M+NH4]+ in the mass spectrum gave further evidence for the structural 
assignment. The mechanism of the dehydration is similar to that in the Figure 2-3 with tosyl chloride 
in place of the acid chloride.  
 
2.1.3 An alternative synthesis of the azido nitrile (234). 
 
235a, X = CO
235b, X = SO2
234a, X = CO
234b, X = SO2
N3
NX
N
N3
NX
OH
NH3 , I2,
 
 
Scheme 2-3 
 
An alternative route to the nitrile (234) was to utilise the prolinol derived alcohol (235), the 
synthesis113 of which is described later in section 2.2.2.1, and to treat it with a mixture of 
concentrated ammonia and water (7:3) and freshly ground iodine, and heating to reflux. The process 
was inconsistent and always gave lower yields than the dehydration route. The proposed mechanism 
is shown in Figure 2-4.113 
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Figure 2-4 
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2.1.4 Synthesis of tetrazolopyrrolobenzodiazepine & tetrazolopyrrolobenzothiadiazepine. 
 
234a, X = CO
234b, X = SO2
241a, X = CO
241b, X = SO2
Toluene, X
N3
N
C
N
N
NX
N N
N
 
Scheme 2-4 
 
The next stage utilises a Huisgen 1,3-dipolar cycloaddition between the nitrile and the azide to make 
a tetrazolo ring101,114-116 as shown in Figure 2-5. 
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R1 R1
N
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N
N
N
 
Figure 2-5 
 
Successful cyclisation proceeded by heating to reflux in toluene for both examples. The PBD (241a, 
X = CO) reacting in 40 % yield in 6 hours and the PBTD (241b, X = SO2) reacting in quantitative 
yield in 72 hours. The lack of the azide and nitrile peaks in the IR spectrum at max ~2100 cm-1 and 
2305 cm-1 implies that these groups were not present. 
 
The 1H (400 MHz) NMR spectrum for the PBD (241a), showed the six upfield aliphatic protons 
between 2.16-3.91 ppm and the single CH in the pyrrolidine ring system at 4.83 ppm. The four 
aromatic protons were downfield at 7.64, 7.76, 7.94 and 8.18 ppm giving a pattern of dt, dt, dd and 
dd consistent with a 1,2-disubstituted benzene ring system. The 13C (100 MHz) NMR spectra showed 
the presence of the three CH2 and the CH of the pyrrolidine ring system downfield and the four CH 
of the benzene ring along with three quaternary carbons and the imine bond quaternary carbon at 
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154.5 ppm. Further evidence was given by the correct measured mass of 242.1034 for the ion 
[M+H]+. 
 
Evidence for the formation of the PBTD (241b, X = SO2) was given by the 1H (500 MHz) NMR 
which showed the six aliphatic CH2 protons between 1.80-3.64 ppm and the single CH at 5.59 ppm 
showing the pyrrolidine ring is still intact. The four aromatic protons at 7.65, 7.83, 8.12, 8.16 with 
the multiplicity of dt, dt, dd, dd, showed the 1,2-substitution pattern of the benzene ring. The 13C-
Dept (100 MHz) NMR spectrum showed the three CH2 and the CH upfield for the aliphatic ring 
system and the presence of four aromatic CH signals. The 3 quaternary carbons appeared in the 13C 
(100 MHz) spectrum, the key one being the imine bond at 155.4 ppm, a feature that is consistent 
with the assigned structure. The measured mass of 278.0707 for the ion [M+H]+ is further proof of 
the structural assignment. 
2.2 Synthesis of the triazolopyrrolobenzodiazepine and triazolopyrrolobenzo-
thiadiazepine (242). 
 
Access to the triazolo systems required the synthesis of the azido alkyne system shown in Figure 2.1. 
Two routes to the azido alkyne precursors were explored, one of which involved conversion of 
prolinol into the alkyne and then coupling (discussed in section 2.2.1), whilst the other involved 
coupling up to prolinol and then producing the alkyne (discussed in section 2.2.2). 
2.2.1 Synthesis via alkyne formation then coupling (the Corey Fuchs route). 
 
The key here was to convert a proline derivative (238) into the alkyne (244), couple up the alkyne to 
the relevant acid chloride and then investigate the intramolecular 1,3-dipolar cycloaddition as shown 
in the Scheme 2-5. 
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The Corey-Fuchs method converted the commercially available N-Boc protected prolinal (238) to 
the terminal dibromo alkene (243) using the ylide shown in Figure 2-6. This ylide was synthesised 
by Wolkoff’s method117 using triphenylphosphine and carbon tetrabromide118 to form a stable 
intermediate which was used as crude in the next step. The dibromo Boc-protected proline derivative 
(243) gave fully consistent spectroscopic data. 
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Figure 2-6 
2.2.1.1  Conversion of the dibromo prolinal derivative (243) into the alkyne (245) and subsequent 
coupling to the acid chlorides (246). 
 
The Scheme 2-6 shows the sequence of the reactions that were carried out in the synthesis of the 
desired compounds (242, X = CO, SO2).  
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Scheme 2-6 
 
Thus, the dibromo species (243) was converted into the terminal alkyne (244) by treatment with 
potassium tert-butoxide in dry THF.119 The alkyne (244) was isolated after treatment of the 
intermediate potassium salt with aqueous acid according to the mechanism outlined in Figure 2-7: 
 
Br
Br H
R
KOC(CH3)3
Br R K R H R
H2O
H+
 
Figure 2-7 
 
The alkyne (244, in Scheme 2-6) was found to be air sensitive119 so had to be used directly in the 
next step in which the Boc group was removed by treatment with TFA.120 The crude, deprotected, 
proline-derived alkyne (245) was coupled to either 2-azidobenzoyl chloride (246a, X = CO) or 2-
azidobenzenesufonyl chloride (246b, X = SO2) in the presence of base to give, after intramolecular 
1,3-dipolar cycloaddition, the triazolo-PBD (242a, X = CO) and triazolo-PBTD (242b, X = SO2) in 
low overall yields (3% and 14% from the commercially available prolinal, respectively). Due to the 
low overall yields and extremely difficult nature of this route it was not explored any further, 
particularly in light of the ease of the highly successful nature of the route described in the next 
section. 
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2.2.2 Synthesis via coupling then alkyne formation. 
2.2.2.1 Prolinol coupling reaction. 
 
232a, X = CO
232b, X = SO2
X
N3
OH
X
N3
N
OH
1. (COCl)2, DMF, 
or SOCl2, 
2. L-prolinamide, 
K2CO3,  r.t.
235a, X = CO
235b, X = SO2
 
Scheme 2-7 
 
This route started with the coupling of L-prolinol to the corresponding acid chlorides (as shown in 
Scheme 2-7).69 The L-isomer was chosen in order to produce analogues with the same 
stereochemistry as the natural products discussed in the introduction. In both cases the acids (232, X 
= CO, SO2) were converted to the acid chlorides and coupled up to prolinol in an aqueous solution of 
potassium carbonate giving the alcohol (235, X = CO, SO2) in good to excellent yields (63% for X = 
CO, and 96% for X = SO2). 
 
Evidence for the successful coupling (235a, X = CO) was given by 1H NMR (400 MHz) spectrum 
which showed the seven protons on the pyrrolidine ring at 1.60-1.84 (3H), 2.04-2.14 (1H), 3.15-3.26 
(2H) and 3.66 ppm (1H). The two protons of the alkanol chain where located at 3.75-3.78 (1H) and 
4.28-4.31 ppm (1H) and the alcohol hydrogen appeared as a broad singlet at 4.67 ppm. The four 
aromatic protons where found at 7.10-7.15 (2H), 7.24 (1H) and 7.37 ppm (1H). The 13C-Dept 135 
(100 MHz) NMR spectrum showed the four CH2 for the pyrrolidine ring system at 24.5, 28.6, 49.6 
and the alkyl chain at 66.5 ppm. The four aromatic carbons were present at 118.5, 125.3, 127.8 and 
130.7 ppm. The 13C (100 MHz) NMR spectra showed the three quaternary carbons at 129.3, 136.0 
and 169.0 ppm, the latter being the carbonyl. The IR spectrum contained the expected azide peak, 
plus a broad peak between max 3000-3500 cm-1 for O-H stretching, and the measured mass of 
269.1008 for the ion [M+Na]+ gives further evidence for the structure. 
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Confirmation of the second successful coupling (235b, X = SO2) was given by the 1H (400 MHz) 
NMR spectrum with the pyrrolidine ring CH2 system protons being downfield at 1.67-1.78 (1H), 
1.79-1.99 (3H), 3.38 (1H), 3.49-3.56 (1H) and the CH of the pyrrolidine ring being at 4.02-4.08 ppm 
(1H). The alkyl chain protons were found at 3.62 (1H) and 3.70 ppm. The 13C-Dept 135 (100 MHz) 
NMR spectrum showed the four CH2 signals, three for the ring system and one for the alkanol chain. 
The single CH of the pyrrolidine ring system was downfield and the four aromatic carbons upfield. 
The two quaternary carbons were clear in the 13C (100 MHz) NMR spectrum and were found at 
129.0 and 138.2 ppm. The IR spectrum showed a broad peak at max 3172-3693 cm-1 and gave 
further strong evidence for the proposed structure, together with consistent mass spectral data. 
2.2.2.2 Oxidation of the alcohols (235). 
 
235a, X = CO
235b, X = SO2
(COCl)2, DMSO,X
N3
N
OH
X
N3
N
HO
236a, X = CO
236b, X = SO2
Et3N, -78oC
 
Scheme 2-8 
 
Oxidation of the alkyl alcohol (235, X = CO, SO2) to the aldehyde (236, X = CO, SO2) was the next 
step. The first method for the attempted oxidation used pyridinium chlorochromate (PCC).69 
Unfortunately, after several attempted oxidations the yield was still low (<15%), even using freshly 
prepared PCC. The next conditions tried were those of the Swern oxidation121 which uses COCl2 and 
DMSO, for which the mechanism is shown in Figure 2-8.122 
Chapter 2  Discussion Part I 
53 
 
 
Me
S
Me
O
Cl
Cl
O
O
Me
S
Me
O
Cl
O
Cl
Me
S
Me
Cl
O R
-HCl
S
O
R
Me
H2
C
Base
S
O
R
Me CH2
H R H
O
Me
S
Me
H
H
..
..
 
Figure 2-8
 
 
This proved to be successful giving yields of 73% and 72% for (236, X = CO and SO2), respectively. 
The carbonyl compound (236a, X = CO) gave a mixture of rotamers shown by the appearance of the 
aldehyde CH as two singlets at 9.22 and 9.62 ppm in the 1H (400 MHz) NMR spectrum. Further 
proof was given by the disappearance of both the alkanol chain protons and the broad singlet of the 
CH2OH. The 13C-Dept 135 (100 MHz) NMR spectrum showed doubling up of the three CH2 units, a 
CH downfield, four aromatic CHs, together with the distinctive CHO signals at 198.0 and 199.3 
ppm. The 13C (100 MHz) NMR spectrum showed 3 quaternary carbons. The disappearance of the 
broad peak max ~3000-3500 cm-1 in the IR spectrum showed the O-H stretching was not present 
which, along with the presence of a new peak at 1732 cm-1 for the CHO stretch, gave further 
evidence for the formation of the aldehyde. The measured mass of 245.1032 for the ion [M+H]+ 
showed the correct mass for the molecule.  
 
The 1H (400 MHz) NMR spectrum for the sulfonyl analogue (236b, X = SO2) showed the formation 
of the product with the disappearance of the alkanol chain signals and the appearance of the 
aldehyde signal downfield at 9.72 ppm. Further evidence came from the 13C-Dept 135 (100 MHz) 
NMR spectrum with the appearance of the distinctive aldehyde signal upfield at 200.5 ppm. The 
disappearance of the broad OH stretch in the IR spectrum max 3000-3500 cm-1 and the appearance of 
a carbonyl stretch at 1730 cm-1 gave further evidence for the aldehyde. 
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2.2.2.3 Conversion of the aldehydes (236) into alkynes (237) and subsequent triazole formation 
(242). 
Bestmann Ohira,
X
N3
N
O
N
NX
N N
X
N3
N
236a, X = CO
236b, X = SO2
237a, X = CO
237b, X = SO2
242a, X = CO
242b, X = SO2
K2CO3, MeOH, r.t.
 
Scheme 2-9 
 
The next step in the synthesis was to convert the aldehyde moiety of compound (236) into the 
terminal alkyne (237). This was proceeded by using the Bestmann-Ohira reagent which was 
synthesied123 in a two step synthesis procedure. The azidation of tosyl chloride formed tosyl azide in 
situ which was reacted with dimethyl (2-oxopropyl)phosphonate to give the Bestmann Ohira reagent. 
All spectroscopic data agreed with the literature.123 
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SO2N3
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Scheme 2-10 
 
With the reagent in hand, the aldehydes were converted to the alkynes by reaction in a basic solution 
of K2CO3 in MeOH. The proposed mechanism124 for the formation of the alkyne moiety is shown in 
Figure 2-9. 
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In both cases, the alkyne product (237, X = CO, SO2) was not isolated, as the alkyne and the azide 
moiety underwent a 1,3-dipolar cycloaddition to form the desired triazole product (242, X = CO, 
SO2). The formation of the triazolopyrrolobenzodiazepine (242a, X = CO) occurred in 83% yield. 
The 1H NMR (400 MHz) spectrum showed a singlet downfield at 7.57 ppm, which showed that the 
product had an extra aromatic proton, over that which was expected for the alkyne. The aliphatic 
protons of the pyrrolidine ring where found upfield at 2.03-3.78 ppm and the CH of the pyrrolidine 
ring at 4.70 ppm. The four aromatic protons of the benzene ring were found downfield at 7.49, 7.62, 
7.92, 8.04 ppm in the 1,2-substitution pattern of dt, dt, dd, and dd. The 13C-Dept 135 (100 MHz) 
NMR spectrum showed the presence of five CH signals downfield for the benzene and triazole 
carbons as well as three CH2 signals and a single CH for the pyrrolidine ring system upfield. Further 
proof of the cyclisation came from the IR spectrum which showed no peak for the azide at max ~ 
2100 cm-1 and no peaks for the alkyne. The correct accurate mass of 241.1083 for the ion [M+H]+ in 
the mass spectrum supported the structural assignment. It is noteworthy that this process allowed the 
formation of the triazolo- PBD directly from the aldehyde, a nice example of a domino style “click” 
reaction (a series of intramolecular reactions which proceed through highly reactive intermediates, of 
which one is the click reaction between the alkyne and the azide). The structure of the final product 
was confirmed by a single crystal X-ray diffraction (see Figure 2-10), which showed clearly the 
tetracyclic ring system.  
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Figure 2-10 
 
The structure of the triazolopyrrolobenzothiadiazepine (242b, X = SO2) was assigned on the basis of 
the 1H NMR (400 MHz) spectra which showed a singlet downfield at 7.79 ppm for the new aromatic 
proton in the triazole ring moiety. The pyrrolidine ring CH2 protons were upfield between 1.63-3.68 
and the single CH of the pyrrolidine ring was at 5.19 ppm. The four aromatic protons of the benzene 
ring were found in the usual 1,2-substitution pattern at 7.62 (dt), 7.83 (dt), 8.10 (dd), 8.15 (dd) ppm. 
The appearance of five CH signals downfield in the 13C Dept-135 (100 MHz) at 125.4, 128.7, 129.3, 
134.1, 134.4 ppm confirmed an extra aromatic carbon from the newly formed triazole ring. Further 
evidence for the structure was given by the IR spectrum which showed the lack of the distinctive 
azide absorbance peak at max ~ 2100 cm-1 together with an absence of the alkyne peaks. The 
accurate mass for the measured ion [M+H]+ was consistent at 277.0752. X-Ray crystallographic 
analysis, shown in Figure 2-11, confirmed the structural assignment as the triazolopyrrolo-
N
N
N N
242a
O
 
Chapter 2  Discussion Part I 
57 
 
benzothiadiazepine. Once more this product was formed directly from the aldehyde via an 
intermediate alkyne which could not be isolated but gave instead the 1,2,3-triazole product directly. 
On this occasion the yield of the triazolo-PBTD from the aldehyde was quantitative.  
 
Figure 2-11 
 
 
Due to the success of this Bestmann-Ohira derived methodology, it was decided to investigate the 
synthesis and reactivity of other amino acid derived alkynes (i.e. other than proline). This, together 
with the synthesis and reactivity of the corresponding nitriles is described in the next section.
N
NS
N N
242b
O O
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3 Discussion: Synthesis of Other Tetrazolo- and Triazolo- Benzodiazepines and 
Benzothiadiazepines. 
 
As described above, the success of the Bestmann-Ohira route as a method for making triazolo PBDs 
and PBTDs prompted the examination of the suitability of the route for making triazolo 
benzodiazepines and benzothiadiazepines from amino acids other than proline. The same short series 
of amino acids would also be used to make the nitrile precursors for the synthesis of tetrazolo 
benzodiazepines and benzothiadiazepines using the route that was applied above to the successful 
synthesis of tetrazolo PBDs and PBTDs. The proposed routes are outlined in the Figure 3-1. 
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Figure 3-1 
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3.1 Synthesis of Triazolo-benzodiazepines and benzothiadiazepines. 
3.1.1  Triazolo Systems Part 1: Synthesis of the alcohols (247). 
 
1. SOCl2 , or 
(COCl)2, DMF, 
2.255-258,
K2CO3, r.t.
X
OH
N3
X
N
N3
H
OH
R
232a, X = CO
232b, X = SO2
247a, X = CO
247b, X = SO2
 
Scheme 3-1 
 
The acid chlorides were made in the usual way and were coupled to a variety of amino acid alcohol 
derivatives (255-258). The different amino acid alcohols chosen were alaninol (255), phenylalaninol 
(256), valinol (257) and tryptophanol (258). Each example was successful apart from the coupling of 
the acid chloride (246b, X = SO2) with tryptophanol. Each acid chloride was added to a basic 
mixture of K2CO3 in water with the amino acid derivative in an organic phase of DCM. Yields are 
shown in the table 3-1: 
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Table 3-1 
 Amino acid derivative Yield Product 
 
 
232a X = CO
232b X = SO2
X
OH
N3
 
 
 
 a X=CO b X= SO2  
i HO
Me
NH2255
 
38% 81% 
247i
X
N
N3
H
OH
Me
 
ii HO
NH2
Ph
256
 
93% 81% 
247ii
X
N
N3
H
OH
Ph
 
iii HO Me
Me
NH2257
 
88% 55% 
247iii
X
N
N3
H
OH
 
iv 
HO
H
N
NH2
258
 
90% Unsuccessful 
247iv
X
N
N3
H
OH
H
N
 
 
All compounds gave consistent spectroscopic data. The structure of compound (247ai), for example, 
was confirmed by 1H NMR (400 MHz) spectroscopy which showed (3H, d, J 6.8) upfield at 1.22 for 
the methyl and a broad singlet at 3.18 ppm for the alcohol unit. The methyl was coupled to the CH 
signal which appeared at 4.16-4.26 (1H, tq, J 6.8, 3.74), the aromatic protons were downfield at 7.11 
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(1H, d), 7.16 (1H, t), 7.42 (1H, dt), 8.03 (1H, dd), and the N-H was found downfield at 7.55 ppm 
(1H, bd, J 5.8). The 13C (100 MHz) NMR spectrum showed a methyl carbon at 17.1 ppm, a CH at 
48.5 ppm and the CH2 at 67.2 ppm. The four aromatic CH carbons were seen at 118.4, 125.2, 132.2, 
132.5 ppm. The quaternary carbons in the 13C NMR (100 MHz) spectrum were detected at 124.8 and 
137.1 for the quaternary carbons in the benzene ring and for the carbonyl at 165.3 ppm. The 
secondary amide NH was shown at max 3018 cm-1 in the IR spectrum and the broad peak of the O-H 
stretch was present between max 3310-3495 cm-1. The correct mass of 243.0854 for the ion [M+Na]+ 
provided further evidence for the structural assignment.  
3.1.2 Triazolo Synthesis Part 2: Synthesis of the aldehydes (248). 
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(COCl)2, DMSO,
Et3N, -78oC
247a, X = CO
247b, X = SO2
248a, X = CO
248b, X = SO2
 
Scheme 3-2 
With the coupling reactions mostly being successful, attention turned to the oxidation of the alcohols 
to give the aldehyde moiety. In cases (248ai) and (248bi) oxidation by the Swern method121 and 
other methods (Dess-Martin,4,85,95,125 PCC, TPAP44 etc.) did not yield the aldehyde. The 
phenylalaninol (247aii & 247bii) and valinol adducts (247aiii, & 247biii) gave the four expected 
aldehydes in good yield under Swern conditions, whilst the benzoyl (247aiv) tryptophan adduct gave 
the aldehyde in below 10% yield under all conditions of oxidation. All spectroscopic data were fully 
consistent with the assigned structure. For example, with the oxidation to the aldehyde (248aii), the 
1H NMR (400 MHz) spectrum showed the presence of a signal at 9.61 (1H, s) for the aldehyde 
moiety. Along with the absence of the CH2 signal on the primary alcohol chain at 3.60-3.71 ppm, 
this gave strong evidence for the success of the oxidation. The 13C Dept-135 (100 MHz) spectrum 
showed a deshielded CH at 198.6 ppm and the disappearance of an aliphatic CH2. Similarly, infra-
red spectroscopy showed the loss of the alcohol OH and appearance of the aldehyde carbonyl, which 
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together with the correct measured mass of 319.1150 for the [M+Na]+ ion further supported the 
structure. 
The structures of the other examples were confirmed in the same manner with 1H (400 MHz) NMR 
spectroscopy showing the disappearance of the primary alcohol chain and the appearance of the 
deshielded CHO proton downfield above 9 ppm. All of the 13C (100 MHz) NMR spectra showed the 
presence of an extra CHO downfield close to 200 ppm and the disappearance of an aliphatic CH2 
upfield for the primary alcohol alkyl chain. The correct accurate masses were observed by high 
resolution mass spectrometry for all the examples, apart from (248bii), as this was found to be 
extremely unstable and was used directly in the next step, decomposing before accurate mass could 
be obtained. Table 3-2 summaries the yields of the different analogues. 
 
Table 3-2 
 R group Yield Product 
  
a, X=CO b, X= SO2  
i Me
 
0% 0% 
248i
X
N
N3
H
O
Me
 
ii Ph
 
72% 65% 
248ii
X
N
N3
H
O
Ph
 
iii 
Me
Me
 
50% 75% 
248iii
X
N
N3
H
O
 
iv 
H
N
 
<10% N/A 
248iv
X
N
N3
H
O
H
N
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3.1.3 Triazolo Synthesis Part 3: Reaction of the aldehydes (248) with the Bestmann-Ohira reagent. 
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K2CO3, MeOH, r.t. 1,3-dipolar 
cycloaddition
 
Scheme 3-3 
 
With the aldehydes in hand, the next step was to take advantage of the previously utilised Bestmann-
Ohira methodology124,126 to make the terminal alkyne. The evidence for successful reactions came 
from the disappearance of the aldehyde peak around 9 ppm in the 1H (400 MHz) NMR spectra and 
the loss of the deshielded carbon in the 13C (100 MHz) NMR spectra characteristic of the aldehyde 
moiety at over 190 ppm.  
 
For the examples, where [X = CO, R = tryptophan, 250aiii, and X = SO2, R = CH(CH3)2, 250biv] 
the Bestmann-Ohira process proceeded as per the proline systems described previously i.e. the 
alkyne intermediate could not be isolated and the reaction gave the tricyclic system directly in yields 
of 54% and 33%, respectively. Spectroscopic data was consistent with the expected structures. For 
example, [248biii, when X = SO2, R = CH(CH3)2] the 1H (400 MHz) NMR spectrum showed a 
signal at 7.77 (1H, s) for the new aromatic proton of the triazole ring system as well as the four 
aromatic protons at 7.62 (1H, dt), 7.80 (1H, dt), 8.05 (1H, dd) and 8.10 ppm(1H, dd). A signal at 
5.35 ppm (1H, bs), was consistent with the N-H, and the presence of signals at 0.90 (3H, d), 1.04 
(3H, d), 2.18 (1H, dsept) and 4.58 ppm (1H, m) for the CH-isopropyl linkage confirmed the 
assignment. The 13C (100 MHz) NMR spectra showed five aromatic CHs at 125.4, 126.7, 129.2, 
134.2, 134.4 ppm [four for the benzene ring & one for the new triazole ring system], the presence of 
three quaternary carbons at 133.5, 133.9, 135.1 ppm and the presence of signals at 17.7 (Me), 18.9 
(Me), 32.8 (CH), 54.5 ppm (CH) ppm for the CH-isopropyl linkage. Further evidence for the 
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cyclisation was the disappearance of the azide peak in the IR spectrum and the correct mass of 
301.0717 for the ion [M+Na]+ in the high resolution mass spectrum. 
 
The remaining examples in this series (X = CO, R = iPr, X = CO or SO2, R = CH2Ph) did not cyclise 
directly and are discussed in the next section. 
3.1.4 Isolation of alkynes (249) and subsequent cyclisation.  
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250a, X = CO
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Scheme 3-4 
 
As discussed above, three of the alkynes from the Bestmann-Ohira reaction did not undergo in-situ 
1,3-dipolar cyclisation and could be isolated, which was confirmed by IR and NMR spectroscopy. 
For example, for compound (249ai, when X= CO and R= [CH(CH3)2]), there was a sharp peak for 
the azide in the IR spectrum at max 2129 cm-1 and the terminal CH of the alkyne was found in the 1H 
(400 MHz) NMR spectrum at 2.22 ppm (1H, d, J 2.4, HC≡C), and at 72.0 ppm in the 13C (100 MHz) 
NMR spectrum. 
 
The compounds were heated to reflux in CHCl3 and monitored by TLC. In all cases, TLC showed 
the complete disappearance of the starting material after 72 hours and the appearance of a single new 
spot. In all cases spectroscopic analysis confirmed that intramolecular 1,3-dipolar cyclisation had 
occurred with the disappearance of the azide and alkyne groups (shown in the IR spectrum), loss of 
the alkyne HC≡C and the gaining of the new triazole CH (shown in the 1H and 13C NMR spectra). 
For example, compound (250ai, X = CO, R = CH[CH3]2), showed the disappearance of the azide and 
alkyne peaks in the IR spectrum and also the movement of the terminal alkyne proton downfield to 
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7.68 ppm (1H, s) in the 1H (400 MHz) NMR spectrum and the presence of 5 aromatic CH carbons in 
the 13C (100 MHz) NMR spectra at 123.0 (CH) 129.1 (CH), 130.6 (CH), 131.7 (CH), 133.3 ppm 
(CH) [four for the benzene ring system and one for the new triazole ring]. The correct mass of 
265.1064 for the measured ion [M+Na]+ further supports the structural assignment. The yields of the 
different analogues are logged in the table 3-3 
 
Table 3-3 
Starting Material time (hrs) yield (%) Product 
249aii
N
N3
H
O
Ph
 
72hours 99% 
250aii
N
N
N N
H
Ph
O
 
249bii
S
N
N3
HO
Ph
O
 
72 hours 99% 
250bii
N
NS
N N
H
Ph
OO
 
249aiii
N
N3
H Me
Me
O
 
72 hours 98% 
O
250aiii
N
N
N N
H
Me
Me
 
 
For compound (250aii, X = CO, R = CH2Ph) further structural evidence was given by the X-Ray 
crystal structure which is shown in Figure 3-2. 
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Figure 3-2 
 
3.2 Attempted Synthesis of Tetrazolobenzodiazepines and 
Tetrazolobenzothiadiazepines. 
  
The success of the prolinamide based synthesis of the tetrazolo-pyrrolobenzodiazepine and 
benzothiadiazepine, described previously in this thesis, prompted the exploration of the use of some 
other amino acids as precursors for the synthesis of tetrazolobenzodiazepines and 
tetrazolobenzothiadiazepines. Time restrictions meant that the study was limited to valine and 
phenylalanine. 
 
250aii
N
N
N N
HO
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3.2.1  The coupling of the amino acids to the different acid chlorides. 
 
The first step in this process was the coupling up of the amino acid to the corresponding acid 
chloride (246, X= CO, SO2), derived by the treatment of the acids (232) with SOCl2 as shown in 
Scheme 3-5: 
 
X
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N3
X
N
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R
O
1. SOCl2 ,  or 
(COCl)2, DMF, 
2. L-amino acid,
K2CO3, r.t.
251a, R = CH2Ph
251b, R = iPr
232a, X = CO
232b, X = SO2
 
Scheme 3-5 
  
The coupling of the acid (232, X = CO, SO2) via the acid chloride with both valine and 
phenylalanine proceeded with excellent yields (95% and 83%, respectively) but coupling up to the 
sulfonyl chloride failed in both instances, despite repeated attempts. The structures of the products 
were confirmed by 1H NMR spectroscopy. For example, compound (251a, X = CO, R = CH2Ph) 
which showed the presence of the five aromatic phenylalanine protons downfield in the region of 
7.27-7.38 ppm as well as the two benzylic protons upfield at 3.30 (1H, dd, J 14.0, 6.3) and 3.37 (1H, 
dd, J 14.0, 5.6) with the methine resonating at 5.10 (1H, dt, J  6.3, 5.6), which along with the single 
proton for the secondary amide at 8.06 ppm (1H, bd, 6.9) gave strong evidence for the structural 
assignment. The 13C Dept-135 (125MHz) NMR spectrum showed the presence of the CH2 of the 
alkyl chain at 37.1 and the CH at 54.3 ppm. The presence of a total of seven types of aromatic CH 
carbons, four from the di-substituted azido benzene ring and three from the mono-substituted 
benzene ring, together with the five quaternary carbons in the 13C (125MHz) NMR spectra, two of 
which are carbonyls, confirmed the assignment. The correct mass of 333.0944 for the measured ion 
[M+Na]+ in the HRMS provided further evidence.  
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3.2.2 Conversion of the carboxylic acids into amides. 
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H2N
Method A
SOCl2, NH3, N
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251a, R = CH2Ph
251b, R = iPr
252a, R = CH2Ph
252b, R = iPr
 
Scheme 3-6 
 
The next stage in the synthesis was to convert the carboxylic acid (251) into the primary amide 
(252). Unfortunately, the usual coupling method, conversion to the acid chloride and reaction with 
ammonia, was unsuccessful so an activation method utilising (benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium (BOP) was used to give the desired products in 72% and 
91% yields, starting from phenylalanine and valine, respectively.  
 
Proof for the presence of the amide in the phenylalanine derivative (252a) was given by the 1H (400 
MHz) NMR spectrum which showed the presence of two broad singlets at 5.98 ppm (1H, bs) and 
6.61 ppm (1H, bs). The IR spectrum showed the a clear NH stretch, which along with the correct 
measured mass of 332.1110 for the ion [M+Na]+ in the mass spectrum, confirmed that the reaction 
was successful. 
 
The valine analogue (252b) showed similarly consistent data, for example, the amide CONH2 
protons were present in the 1H (400 MHz) NMR spectrum at 5.83 (1H, bs) and 6.67 ppm (1H, bs), 
and the high resolution mass spectrum gave the correct accurate measurement of 284.1111 for the 
ion [M+Na]+. 
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3.2.3 Conversion of the amides into the nitriles. 
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O
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H2N
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Pyridine,
252a, R = CH2Ph
252b, R = iPr
253a, R = CH2Ph
253b, R = iPr
Tosyl chloride, 
 
Scheme 3-7 
 
The penultimate step (the step prior to cyclisation) was the dehydration of the two primary amides 
(252a-b) to the nitriles (253a-b). This was carried out by using tosyl chloride and pyridine112 and 
heating to 60C. Evidence for the successful dehydration in the case of the phenylalanine derivative 
was given in the 1H (400 MHz) NMR spectrum which showed the disappearance of the two broad 
signals for the primary amide of the starting material. The 13C (100 MHz) NMR spectrum showed 
the disappearance of the carbonyl signal down field at 173.3 ppm and the appearance of a new peak 
at 118.2 ppm which is consistent with the loss of C=O unit and the formation of a nitrile. The IR 
spectrum showed the presence of a new peak at max 2089 cm-1 for the nitrile with a further peak at max 2128 cm-1 which showed that the azide was still intact. Along with the disappearance of the 
primary amide NH stretches in the infra red spectrum and the correct accurate mass of 314.1017 for 
the measured ion [M+Na]+, the data all supported the structural assignment for the compound 
(253a). 
 
The valine derived system (253b) showed the same set of diagnostic signals (the loss of the NH2, 
appearance of the nitrile) together with a consistent high resolution mass measurement.  
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3.2.4 Attempted synthesis of tetrazolobenzodiazepines (254). 
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Scheme 3-8 
 
With the nitriles (253) synthesised, the next step was to perform the intramolecular 1,3-dipolar 
cycloaddition. After heating the phenylalanine analogue for 72 hours at reflux in CHCl3, no reaction 
had occurred, so the solvent was replaced with xylene and the mixture heated at reflux for 96 hours 
after which time a new product had formed. 
  
The isolated product was not the expected tetrazole (254) and showed a high resolution mass 
measurement of 266.1270 for the ion [M+H]+, which was consistent with the loss of nitrogen and the 
gain of two protons. The 1H (400 MHz) NMR spectrum showed a signal at 5.58 integrating to two 
protons (broad singlet) and the IR spectrum showed new peaks at max 3357, 3474 cm-1 consistent 
with the formation of an amine. This inferred that the structure of the new product was that of 
compound (259a). The presence of the CHCH2Ph was shown by signals at 3.17 (1H, dd), 3.23 (1H, 
dd) and 5.21-5.24 ppm (1H, m) in the 1H (400 MHz) NMR spectrum, as well as the single amide 
proton at 6.48 (1H, bd) and consistent signals at 6.63 (1H, t), 6.69 (1H, d) and 7.19-7.45 ppm (7H, 
m) for the disubstituted and monosubstitued benzene ring systems. The 13C (100 MHz) NMR spectra 
was also consistent with the assigned structure. The product was obtained in 18% yield. 
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A possible mechanistic pathway, shown in Figure 3-3, can be proposed whereby nitrene (260) 
formation occurs rather than 1,3-dipolar cycloaddition, and is followed by proton abstraction from 
the solvent to give the amine (261), a reduction process that is not uncommon with azides. 
Intramolecular attack of the nitrile by the amine and subsequent proton transfer (262) and 
tautomerism then yields the observed product (259). Alternatively, ring closure of the nitrene (260) 
by intramolecular reaction with the nitrile to compound (263) followed by proton abstraction to 
compound (264) from the solvent could also lead to the observed product. 
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Figure 3-3 
 
The same type of product was formed by heating in xylene at reflux for 36 hours and also after 
shorter periods in the same solvents in the presence of zinc17 and copper116,127-130 catalysts. 
Pleasingly, the isopropyl analogue behaved in the same manner to furnish the corresponding 2-
amino-1,4-benzodiazepine (259b, R = iPr) in 50% yield. 
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Scheme 3-9 
Conclusion. 
 
As discussed in section 2, the synthesis of the proline derived nitriles and alkynes (234 and 237) 
allowed access to the tetrazolo and triazolo PBD and PBTD analogues (241 and 242). With other 
amino acids, the triazolo systems (250) could be accessed, but the tetrazolo systems (254) could not 
be formed, due to the formation of the benzodiazepines (259) instead. The structures of which are 
shown are shown in the Figure 3-4 below. 
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Figure 3-4 
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4 Discussion: Use of Intramolecular Azide to Alkene Cycloadditions to Produce 
PBD Derivatives. 
 
As described in the previous chapters, the intramolecular reactions between an azide group and an 
alkyne or nitrile allows the synthesis of triazolo- and tetrazolobenzodiazepines and 
benzothiadiazepines including some tetracyclic pyrrolobenzodiazepine analogues. In this section the 
intramolecular reaction between alkenes and azides as a route to pyrrolobenzodiazepine analogues 
will be investigated. The Figure 4-1 shows the plan whereby a proline derived alkene is to be 
coupled to ortho-azidobenzoic or sulfonic, acid. The possible outcomes of the reaction are the 
triazoline (243), aziridine (270) or the cyclic imine (271), where the latter two products form via 
nitrogen extrusion reactions.131 Each of the products (270) and (271) (the aziridine and imine) have 
functionality which may interact with nucleophilic residues in DNA. 
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266, R= CO2Et
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N
O
R
N
R
N3
NX
N
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N N
N
NX
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Figure 4-1 
 
The literature details the use of an N-(ethoxycarbonyl) group (R = CO2Et) as a precursor for the 
synthesis132 of the N-unsubstituted proline derived alkene (268).  
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4.1.1 Synthesis of the alkenyl pyrrolidine derivative (266, R = CO2Et). 
 
Step 1: 
 
265 266
N
H
OH
N
OH
CO2Et
1. 4M NaOH, Ethyl 
Chloroformate 0oC
2. 2M HCl
 
Scheme 4-1 
 
The first step of the synthesis was to protect commercially available prolinol (265) with the 
carbethoxy group prior to the oxidation of the primary alcohol (266). This was done by treating the 
prolinol with chloroformate in the presence of aqueous sodium hydroxide. Neutralisation with 2M 
HCl gave the product in 96% yield. Spectroscopic analysis confirmed the inclusion of the carbethoxy 
group. 
 
Step 2: 
 
266 267
N
OH
CO2Et
N
O
CO2Et
(COCl)2, DMSO,
Et3N, -78oC
 
Scheme 4-2 
 
With the successful protection of the amine, the next stage was the oxidation of the alcohol (266) to 
the aldehyde (267). Swern oxidation was used to give the product in 89% yield as a mixture of 
rotamers. 1H (400 MHz) NMR spectroscopy showed two rotameric signals at 9.48 & 9.56 ppm for 
the aldehyde. No broad peak for the OH of the alcohol and also the loss of the signals between 3.59-
3.69 ppm for the CH2 next to the alcohol in the spectrum supported the assignment. The 13C NMR 
(100 MHz) spectrum showed a signal downfield at 200.2/200.3 ppm (rotamers) for the carbon of the 
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aldehyde moiety together with the loss of the primary alcohol CH2. The IR spectrum showed the loss 
of the broad OH stretch and a new peak for the carbonyl stretch of the aldehyde moiety.  
 
Step 3: 
 
267 268
N
O
CO2Et
Ph3P+CH3Br-, nBuLi
N
CO2Et
THF, -78oC
 
Scheme 4-3 
 
With the aldehyde (267) successfully synthesised the next step was to use the Wittig reaction to 
convert the aldehyde moiety into a terminal alkene.  The reaction proceded using nBuLi and 
methyltriphenylphosphonium bromide to make the ylide which reacted with the aldehyde to form the 
alkene (268) as a mixture of air sensitive rotamers in 45% yield. The key evidence for the formation 
of the correct structure was given by the 13C NMR (100 MHz) spectrum which showed signals at 
113.8/138.5 for the new vinylic CH2 and 138.2/138.5 for the CH of the new alkene, as well as the 
loss of the diagnostic aldehyde CH. 
4.1.2 The coupling of the pyrrolidinyl alkene (269) to the acid chlorides (246). 
 
269268
N
CO2Et
N
N3
X Cl N3
NXEt3N, Et2O, r.t.
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246b, X = SO2
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Scheme 4-4 
 
The next step was to couple up the alkene (269) with the acid chlorides (246a-b, X = CO, SO2). The 
deprotection to create the free amine was carried out using potassium hydroxide and hydrazine 
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hydrate in ethylene glycol as described in the literature.132 The acid chloride (246a-b) was coupled to 
the resultant amine in an ethereal solution of triethylamine. This procedure gave the product (240a, 
X = CO) in 32% yield as a mixture of rotamers. The structure of the product was confirmed by the 
1H (400 MHz) NMR spectrum which showed the presence of signals at 4.89 & 5.20 (1H, 2 x d), 4.89 
& 5.20 (1H, 2 x d) and 5.56 & 5.90 (1H, 2 x dd) for the terminal alkene. The 13C (100 MHz) NMR 
spectrum was also fully consistent showing (as a mixture of rotamers) the three pyrrolidine ring CH2 
signals, the terminal alkene CH2 (114.5/114.9), the alkene CH (118.4/118.5) and the pyrrolidine ring 
CH (58.4/61.1 ppm) together with four aromatic CH signals and the carbonyl and two quaternary 
carbons. The IR spectrumgave a sharp peak at max 2128 cm-1 which showed the presence of the 
azide group which is consistent with the uncyclised product. Further proof was given by the correct 
mass of 265.1064 for the measured ion [M+Na]+. 
 
With the successful synthesis of compound (240a, X = CO) achieved, attention was turned to the 
coupling of the sulfonyl derivative (240b, X = SO2). The same method was used to give the correct 
product in 20% yield, which showed fully consistent spectroscopic data for the assigned structure. In 
the 1H (400 MHz) NMR spectrum, for example, signals at 4.37-4.40 (1H, m, CH=CHH), 4.54 (1H, 
dd, CH=CHH) and 5.30-5.37 (1H, m, CH=CH2) showed the presence of the terminal alkene. The 1H 
(400 MHz) NMR spectrum also showed the expected four aromatic signals for the four aromatic 
protons of the benzene ring. The IR spectrum showed the azide at max 2137 cm-1, which, with the 
correct mass of 301.0722 for the measured ion [M+Na]+ further supported the structural assignment. 
 
4.1.3 Cycloaddition of the alkene and the azide. 
 
With the alkene in hand the final step was to study the 1,3-dipolar cycloaddition between the alkene 
and the azide. Both examples (240a-b, X = CO, SO2) were treated by heating to reflux in chloroform 
and monitoring by TLC. The first example in this discussion will be compound (240a, X = CO). 
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After 16 hours this reaction was deemed complete and was concentrated and purified to give an 
inseperable mixture of two compounds, in a ratio of 1:1. Spectroscopic analysis confirmed that the 
starting material was not present as the sharp azide peak was not present in the IR spectrum, and 1H 
(400 MHz) NMR spectroscopy showed that the protons of the alkene were not present. Mass 
spectroscopic analysis showed that the starting material had lost 28 mass units and hence the 
triazoline (243a) intermediate could be discounted. The 1H NMR (400 MHz) spectrum showed the 
presence of a total of eight aromatic protons which is consistent for two aromatic benzene ring 
systems, a feature confirmed in the 13C (100 MHz) NMR spectra which showed eight aromatic CHs 
and four aromatic quaternary carbons together with two carbonyl signals. The methyl imine (270a) 
was inferred from an extra quaternary carbon at 165.5 ppm in the 13C (100 MHz) NMR spectrum 
and a clear methyl signal at 22.4 ppm in the 13C (100 MHz) NMR spectrum, which appeared at 2.27 
ppm (3H, s) in the 1H (400 MHz) NMR spectrum. Evidence for the aziridine (271a) was given by 
the presence of an extra CH2 (seven in total) in the 13C (100 MHz) NMR spectra and the presence of 
the extremely distinctive CH2CH of the aziridine in the 1H (400 MHz) NMR spectrum. 
N3
NX
N
NX
N N
N
NX
Me
N
NX
CHCl3, 
240a, X = CO
240b, X = SO2 243a, X = CO
243b, X = SO2
270a, X = CO
270b, X = SO2
271a, X = CO
271b, X = SO2
-N2
 
Scheme 4-5 
 
In contrast to the amide system (240a, X = CO), the sulfonamide (240b, X = SO2) gave a much 
cleaner reaction yielding only a single product which was identified as the aziridino-
pyrrolobenzothiadiazepine (271b, X = SO2) presumably formed as shown below. Thus, the 13C 
(125MHz) NMR spectra showed the expected four CH2 signals, two aliphatic CHs and the expected 
aromatic carbons (4 CHs and 2 quaternary). Mass spectrometric analysis confirmed the loss of 28 
mass units so the intermediate triazoline (243b, X = SO2) could be discounted. The 1H (500 MHz) 
NMR spectrum showed the aziridine CH2 protons coupled to the aziridine CH which was in turn 
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coupled to the pyrrolidine CH, confirming the connectivity of the aziridinopyrrolo system (271b, X 
= SO2).  
240b
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271b
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O O
N
NS
N N
O O
N
NS
O O
CHCl3,  -N2
 
Scheme 4-6 
 
The mechanism for the nitrogen extrusion to form the aziridine or the cyclic imine is also shown in 
Figure 4-2.  
N
N
N
N
N
N
N
CH2H
N
CH2H
NN
N
CH2H
 
Figure 4-2 
4.1.4 Formation and subsequent cycloaddition of a substituted alkene and the azide. 
 
(Ph3P)=CHCO2Et,
N3
NX
EtO2C
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NX
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236a, X = CO
236b, X = SO2
272a, X = CO
272b, X = SO2
toluene, r.t.
 
Scheme 4-7 
A substituted alkene was synthesised from the aldehydes (236a-b, discussed previously) in order to 
perform further studies of the above cycloaddition between the alkene and the azide. The aldehyde 
(236a, X = CO) was treated with (carbethoxymethyl)triphenylphosphorane in toluene at room 
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temperature to afford the ethylcarbothoxy substituted alkene (272a, X = CO). 1H (400 MHz) NMR 
spectroscopy showed the disappearence of the characteristic deshielded aldehyde peak and also the 
inclusion of signals at 1.29 & 1.31 (3H, t) and 4.13 & 4.21 (2H, q) for the presence of the carbethoxy 
unit (the product exists in rotameric form). The IR spectrum showed that the azide was still intact at max 2130 cm-1 showing the product had not undergone cycloaddition. Further evidence was 
provided by the accurate mass measurement.  
274
N
NX
CO2Et
N
NX
N N
275
272
273
CHCl3, 
N3
NX
EtO2C
N
NX
CO2Et
*
 
Scheme 4-8 
 
The precursor (272a, X = CO) was heated at reflux in CHCl3 for 48 hours before being purified and 
analysed. IR analysis showed the lack of a peak in the region max 2130 cm-1 showing that the azide 
had reacted. The 1H (400 MHz) spectrum showed that the product was a 1:1 mixture of isomers. The 
shifting of the former alkene peaks upfield to 2.77 (1H, d), 3.08 (1H, dd) and 3.37 ppm (1H, dt) 
provided evidence that the aziridine (274a, X = CO, see Scheme 4-8) or triazoline (273a, X = CO) 
had formed. The accurate mass confirmed that the mass of the starting material had decreased by 28 
mass units inferring that the aziridine (274, X = CO) was the product. The formation the cyclic imine 
(275a) could be discounted due to the lack of the extra CH2* group (see Scheme 4-8) in the 13C (100 
MHz) spectrum. 
This method was further examined with the sulfonyl (236b, X=SO2) which was treated under the 
same conditions but this time the intermediate alkene (272b, X = SO2) was not isolated but the azide 
and the alkene underwent in situ cycloaddition to form the aziridine (274b, X = SO2) as a single 
isomer in 17% yield, from the aldehyde (236b) 
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4.2 Attempted Synthesis of Other Aziridinobenzodiazepines. 
 
In view of the formation of the aziridino PBDs and PBTDs detailed above, it was decided to look at 
some other intramolecular azide to alkene cycloadditions that might give access to some other 
aziridino-fused benzodiazepine derivatives. The 4-vinyl-azetidinones (277 & 282) where chosen for 
this study to provide a potential route to azetidinobenzodiazepines as analogues of the potent 
antibiotic pyrrolobenzodiazepines which contain both the -lactam ring and the electrophilic imine 
(or aziridine) of the PBD (or PBTD) which is the feature that provides the PBDs (or PBTDs) with 
their antibiotic activity.133-135 The -lactams are a well known class of antibiotics, so the synthesis of 
azetidinobenzodiazepine fused lactams is of interest. The proposed route to 
azetidinobenzodiazepines is shown in the Figure 4-3 and is discussed in the rest of this section. 
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Figure 4-3 
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4.2.1 Synthesis of the 4-vinyl-azetidinone (277). 
 
287
276
277
Me
N
Me
OClO2S N
Me
OH
Na2SO3, KOH
-78oC
ClO2S-N=C=O,
 
Scheme 4-9 
 
The synthesis started from isoprene (276) which was cooled to -78C in ether before slow addition 
of chlorosulfonylisocyanate (CSI). It was important to keep the reaction at low temperature to 
eliminate possible side reactions which have been noted by Moriconi and Meyer136 who showed that 
reaction at room temperature led to the structure (288a, as shown in Scheme 4-10), the presence of 
which was shown upon workup with p-anisidine to give the structure (288b).  
 
288a, R=Cl
288b, R=NHC6H5-p-Cl
276
Me Me O
NHSO2R
CSI, r.t.
 
Scheme 4-10 
 
To add more complications to the reaction sequence, it was noted that if the -lactam (287) was 
warmed to room temperature the four membered ring would undergo ring opening to form the 6-
membered ring lactam (289), which undergoes further transformations as shown in Figure 4-4. 
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Figure 4-4 
 
In the event, when the reaction was carried out at -78C with an excess of isoprene and allowed to 
reach a temperature no higher than -10C, the desired -lactam (277) was isolated in 44% yield after 
the removal of the N-sulfonyl group in situ. The spectroscopic analysis was consistent with the 
literature data136 for the expected structure. For example, the 13C NMR spectra showed the presence 
of the alkene with the CH at 113.8 ppm and the CH2 at 141.1 ppm which supports the structure of 
the desired -lactam rather than other possible side products. 
4.2.2 Synthesis of the 1-(2-azidobenzoyl)-4-vinyl-azetidin-2-one. 
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Scheme 4-11 
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With the N-unsubstituted -lactam (277) to hand, the next stage was coupling to the corresponding 
acid chloride (246a) using DMAP and Et3N. Coupling up to the acid chloride (246a) gave the 
expected alkene (278), the structure of which was confirmed by the 1H (400 MHz) NMR spectrum 
which showed signals at 5.35 (1H, d, J 10.7), 5.45 (1H, d, J 17.3) and 6.24 ppm (1H, dd, J 10.7, 
17.3) for the alkene. The aromatic ring system was shown to be present due to the signals at 7.22 
(1H, t), 7.23 (1H, d), 7.42 (1H, dd) and 7.52 ppm (1H, dt, ArH). The 13C (100 MHz) NMR spectrum 
showed the presence of the alkene 114.9 (CH2) and 117.5 ppm (CH) plus all other expected signals. 
The presence of the sharp azide peak [at max 2131 cm]-1 in the IR spectrum showed that the azide 
was intact and the product had not undergone a 1,3-dipolar cycloaddition. 
4.2.3 Attempted cyclisation by the reaction of the alkene and azide. 
 
The following potential outcomes were considered with a view to discovering which of the cyclised 
products, if any, would form: 
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Scheme 4-12 
 
The 1-(2’-azidobenzoyl)-4-vinyl-azetidin-2-one (278) was dissolved in CHCl3 and heated at reflux 
temperature. After 72 hours, TLC analysis indicated that the product had been consumed. Analysis 
of the purified product by 13C (125MHz) NMR spectroscopy revealed the presence of two methyl 
groups and inferred the formation of the methyl imine product (280). The 13C NMR spectrum 
showed a CH2 at 43.6 ppm, and a quaternary carbon for the imine C=N at 155.2 ppm. The 
Chapter 4  Discussion Part III 
 
84 
 
quaternary carbon bearing the second methyl appeared at 73.3 ppm. The four CHs of the benzene 
ring appeared at 126.5 to 134.3 ppm and the two carbonyl signals at 158.1 and 204.2 ppm. The 
presence of two methyls in the 1H (500 MHz) NMR spectrum at 2.00 (3H, s), 2.49 (1H, s), the single 
CH2 giving two signals coupled together at 3.42 (1H, d, J 16.0), 3.77 ppm (1H, d, J 16.0) and the 
four aromatic signals was consistent with the structural assignment of the methyl imine product 
(280) which was formed in 22% yield. Accurate mass measurement was consistent with the desired 
[M+H]+ at 229.0978 and also confirmed that the product had lost nitrogen discounting the formation 
of structure (279, in Scheme 4-12). 
4.3 The synthesis of the thiolactam derivatives. 
 
The N-(2-azidobenzoyl)-4-vinyl-azetidin-2-one (278) discussed above gave the cyclic imine (280) 
rather than the aziridine (281). In order to explore this chemistry fully, it was decided to investigate 
if the azetidine-2-thione would behave in the same manner.  
4.3.1 Synthesis of 4-vinyl-azetidinethione (282). 
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Scheme 4-13 
 
The first stage in this process was the synthesis of the thiolactam (282), which was easily prepared 
using Lawesson’s reagent,137 a reaction believed to proceed via the mechanism, shown in the Figure 
4-5. Successful reaction was shown by the 13C (100 MHz) NMR spectra which showed the loss of 
the quaternary carbon 167.6 ppm and the appearance of a peak at 202.2 ppm which is consistent with 
the new (C=S). Further proof came from the IR spectrum which showed the loss of the amide C=O 
signal at max 1720 cm-1.  
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Figure 4-5 
4.3.2 Synthesis of the 2-(2’-azidobenzoyl)-4-vinyl-azetidin-2-thione (283). 
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Scheme 4-14 
 
The next stage in the synthesis was the coupling of the thiolactam (282) to the acid chloride (246). 
The acid chloride (246) was made in the usual way and was coupled up to the thiolactam (282) using 
DMAP and Et3N to yield the coupled product in 84% yield. The 1H (400 MHz) NMR spectrum 
showed the disappearance of the broad peak for the azetidine NH around 8.78 ppm and the 
appearance of the aromatic carbons of the benzene ring at 7.20 (1H, d), 7.24 (1H, dt), 7.36 (1H, dd) 
and 7.54 ppm (1H, dt). The 13C (100 MHz) NMR spectrum showed the presence of four aromatic CH 
carbons at 125.1, 128.9, 132.1 and 137.7 ppm as well as the characteristic signals of the alkene 
downfield at 116.4 (CH2) and 118.5 ppm (CH). The IR spectrum confirmed the presence of the azide 
peak at max 2131 cm-1. The correct high resolution mass spectrum peak of 295.0623 for the ion 
[M+Na]+ supported the structural assignment.  
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4.3.3 The cyclisation of the thiolactam alkene with the azide.  
 
The intramolecular 1,3-dipolar cycloaddition between the alkene and azide groups was the next step 
in the synthesis and was carried out by heating compound (283) in CHCl3 at reflux. The anticipated 
possible structural outcomes of this reaction are shown in Scheme 4-15: 
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Scheme 4-15 
  
After 36 hours a major new spot had appeared on TLC and the starting material has disappeared so 
the reaction products were purified and analysed. At first glance the main change to note was in the 
1H (500 MHz) spectrum which  showed that there was only one methyl peak, a feature which was 
confirmed by 13C (125MHz) NMR spectroscopy. This discounted the dimethyl structure (285). The 
analysis of the product by HRMS showed the mass of the ion [M+Na]+ to be 295.0622 which was 
the same as the mass as starting compound (283), showing no loss of nitrogen. The IR spectrum 
showed no azide peak at max 2131 cm-1 which showed the azide had reacted and confirmed that the 
product was not the starting material (283). The 1H (400 MHz) NMR spectrum showed signals for 
the CH2 of the triazoline ring at 4.37 (1H, dd, J 6.1, 17.7), 4.71 (1H, dd, J 12.2, 17.7) and a CH at 
4.27 ppm (1H, dd, J 6.1, 12.2) which was also confirmed in the 13C (100 MHz) NMR spectra with 
peaks at 59.6 (CH) and 70.4 ppm (CH2). This led to the identification of the product as the 
triazolinoazetidobenzodiazepine (284) which was formed in 61% yield. 
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Further exposure of compound (284) to boiling in chloroform gave solely the azetidino-
benzodiazepine (285) in a yield of 32%, the structure of which was determined by the loss of 28 
mass giving the mass 267.0551 along with an extra methyl in both the 1H (400 MHz) at 2.47 ppm 
and 26.3 ppm in the 13C (100 MHz) NMR spectra.  
 
In conclusion, 4-vinyl-azetidinones proved to be useful substrates for the synthesis of some novel 
azetidinoaziridinobenzodiazepines and their non-aziridino (methyl imine) analogues. 
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5 Discussion: Intramolecular Azide Cycloadditions Using Highly Substituted 
Benzene Rings.  
 
In this, the penultimate part of the discussion, the synthesis discussed in the previous chapters will be 
exploited to make direct analogues of DC-81. This functionality has been explored vastly in the 
literature (as discussed in the Section 1.2), both in order to produce DC-81 itself and to produce 
natural & synthetic analogues of DC-81. 
 
The transformations that will be discussed in this section are summarised in the Figure 5-1 and 
broadly parallels the processes discussed above i.e. eventual intramolecular 1,3-dipolar cycloaddition 
between an azide and a nitrile, alkyne and alkene. Due to the fact that these routes require the 
synthesis of the 2-azidobenzoic acid (294), this section is detailed separately to the routes described 
previously in this thesis, although some of the later steps will be seen to be similar.  
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Figure 5-1 
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5.1.1 Synthesis of 4-benzyloxy-5-methoxy-2-azidobenzoic acid (294): Step 1 – Benzyl protection 
and nitration of vanillic acid. 
 
290 291
PhCH2Cl, THF,
O
OH
O
OH
MeO
PhH2CO
MeO
HO
NaOH, 
 
Scheme 5-1 
 
The synthesis started by the protection of the hydroxyl group of vanillic acid as this needs to be 
protected for the coupling procedure later in the synthesis. Thurston et al,96 provided a quick two 
step synthesis to the nitro derivative (292); starting from vanillic acid (290). Benzyl chloride was 
added slowly to vanillic acid in 2M NaOH and the whole was heated at reflux. The product (291) 
was isolated by acidification with HCl to form the product from the sodium salt. Spectroscopic 
analysis was consistent with the literature and with the expected structure. 
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PhH2CO NO2
O
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PhH2CO
SnCl4, DCM,
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291 292
 
Scheme 5-2 
 
Nitration of the benzene ring system with a tin(IV)chloride-nitric acid96 complex afforded the 
product (292) in 63% yield which was characterised by comparison to the literature values and by 1H 
(500 MHz) NMR spectroscopy which showed two singlets downfield at 7.31 (1H, s) and 7.70 ppm 
(1H, s) showing the 1, 2, 4, 5-substitution pattern of the central benzene ring. The 13C (125MHz) 
NMR spectrum showed one less aromatic carbon downfield compared to the starting material. The 
IR spectrum showed peaks at max 1351 and 1537 cm-1 giving strong evidence for the N-O stretches. 
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The correct mass of 326.1 for the measured ion [M+Na]+ provided further strong evidence that the 
correct product was formed.  
5.1.2 Synthesis of the 4-benzyloxy-5-methoxy-2-azidobenzoic acid (294): Step 2 - nitro reduction. 
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PhH2CO
SnCl2.2H2O,
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MeO
PhH2CO
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Scheme 5-3 
 
The synthesis of the amine (293) was the next step in the process. Results were variable and methods 
capricious with some reactions working to give the amine in excellent yield and other reactions 
failing. A solution was not found to this capriciousness, but a variety of methods where examined 
over a long period. A method by Eguchi et al,138 which used tin(II)chloride dehydrate worked best to 
give a white solid in 88% yield, but this method was unreliable, and had to be performed numerous 
times to enable access to the desired product. 
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Scheme 5-4 
 
The next method attempted was also from the group of Eguchi and utilised NiCl2.6H2O and sodium 
borohydride as the reducing agent which gave impure product in around 25% yield. Other reactions 
were carried out using iron dust and acetic acid99 which proved to be unsuccessful. Analysis was 
carried by 1H, 13C NMR and IR spectroscopy which, together with mass spectrometry, confirmed the 
structural assignment. It should be pointed out that this apparently simple transformation proved 
extremely troublesome and took up a significant amount of time and effort.  
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5.1.3 Synthesis of the 4-benzyloxy-5-methoxy-2-azidobenzoic acid (294): Step 3 - azidation. 
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Scheme 5-5 
 
With the amine (293) in hand the next stage was to convert the amine to the azide moiety. This was 
carried out by literature methods69,138 to give the azide in 47% yield. Analysis by IR spectroscopy 
showed the successful azidation by the loss of the aryl NH2 peaks at max 3354 and 3530 cm-1 and the 
appearance of the azide peak at max 2099 cm-1. Further proof was given by the correct mass of 
322.0789 for the measured ion [M+Na]+ which was consistent with the assigned structure of the 
azide (294).  
5.1.4 Coupling to Prolinamide and Subsequent Nitrile Formation.  
2. L-prolinamide,
K2CO3, r.t.
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Scheme 5-6 
The next stage was to couple the azide (294) to L-prolinamide. Coupling was achieved by converting 
the acid into the acid chloride using thionyl chloride. The acid chloride was added slowly to a basic 
solution of potassium carbonate and the L-prolinamide. The coupled product was not isolated as the 
primary amide (295) but, as with a previous example, dehydration occurred spontaneously to give 
the nitrile product (296) in 56% yield. The successful coupling and dehydration was shown by 1H 
(400 MHz) NMR spectroscopy which showed the inclusion of the pyrrolidine ring system with 
signals upfield at 2.17-2.44 (3H), 3.39-3.52 (2H), 3.75-3.82 (1H) and 4.92 ppm (1H). The aromatic 
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protons were found downfield at 6.72 (1H, s), 6.92 (1H, s) and 7.37-7.51 (5H) with the methoxy at 
3.94 ppm (3H, s, OCH3), and the benzyl CH2 at 5.24 ppm (2H, s, OCH2). The absence of no broad 
signals in the spectrum inferred that there were no OH or NH groups present in the structure. The 
13C-Dept 135 (100 MHz) NMR spectrum showed the presence of the methylene carbons at 25.0, 
30.5, 47.7 ppm for the pyrrolidine ring system with the pyrrolidine CH at 46.4 ppm. The more 
deshielded methoxy and OCH2 were found at 56.5 and 71.4 ppm respectively. The 13C (100 MHz) 
NMR spectra also showed the presence of seven quaternary carbons with only one quaternary carbon 
in the carbonyl region of 167.0 ppm which is consistent with the dehydration of the molecule. The 
IR spectrum showed the presence of the azide at max 2114 cm-1 and also the presence of the nitrile at max 2253 cm-1. The correct accurate mass of 378.1566 for the measured ion [M+H]+ was consistent 
with the assignment of the structure.  
5.1.5 Synthesis of the DC-81 Tetrazolo analogue (297). 
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Scheme 5-7 
 
With the successful coupling and dehydration achieved, the final step in the synthesis of this 
analogue of DC-81 was carried out by heating the nitrile (296) at reflux in CHCl3 for 72 hours to 
yield the product (297) in 58% yield. Analysis by 1H (400 MHz) showed the pyrrolidine ring system 
was present with the signals at 2.04 - 2.18 (2H), 2.42 - 2.52 (1H), 3.06 - 3.13 (1H), 3.61 - 3.68 (1H), 
3.73 - 3.79 (1H) and 4.68 ppm (1H). The benzene ring systems and substituents were shown by the 
signals at 3.93 (3H, s), 5.15 (1H, d), 5.26 (1H, d), 7.19 (1H, s), 7.25 - 7.41 (5H) and 7.53 ppm (1H, 
s). The 13C (100 MHz) NMR spectra confirmed the presence of the three methylenes of the 
pyrrolidine ring and the OCH2  with signals at 23.5, 28.2, 48.2 and 71.3 ppm, the methoxy at 56.4 
ppm, one CH at 49.8 ppm along with the five aromatic CH’s downfield and seven quaternary 
Chapter 5  Discussion Part IV 
 
94 
 
carbons. Key information was provided by the IR spectrum which showed the lack of the azide peak 
at max 2131 cm-1, the disappearance of the nitrile signal at 2253 cm-1 and the correct mass of 
378.1564 for the measured ion [M+H]+ in the high resolution mass spectrum. 
 
5.2 Synthesis of the DC-81 Triazole Analogue. 
 
With the synthesis of the tetrazole example completed the next task was the synthesis of the triazole 
analogue. As described previously the triazole unit would be synthesised by the cyclisation between 
the alkyne and azide functional groups. Molina et al,69 have already shown how prolinol can be 
coupled to the DC-81 carboxylic acid, and hence no problems were anticipated with this reaction. 
Once the prolinol coupled product was synthesised, the next step would be conversion into the 
alkyne. 
5.2.1 Synthesis of DC-81 prolinol derivative (298). 
 
1. SOCl2, 
298294
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                 r.t.
 
Scheme 5-8 
 
The coupling of S-prolinol to the acid chloride was achieved by heating the carboxylic acid in a 
solution of SOCl2 and toluene. The acid chloride was used directly by addition to a mixed phase 
basic solution of K2CO3 and prolinol. After purification of this reaction mixture, the desired product 
(298) was isolated in 87% yield, the structure of which was confirmed by the 1H (400 MHz) NMR 
spectrum which was consistent with that of Molina.69 
 
The 13C (100 MHz) NMR spectra showed the five CH2 signals at 24.5, 28.5, 49.6, 66.6 and 71.2 ppm 
for the pyrrolidine ring, alkyl chain and the OCH2 as well a signal for the methoxy at 56.3 ppm. A 
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single CH for the pyrrolidine ring system at 61.2 ppm with five aromatic CH signals at 104.2, 110.7, 
127.3, 128.2 and 128.7 ppm. The presence of six quaternary carbons was consistent with the 
structural assignment. The IR spectrum showed the broad peak between max 3145-3593 cm-1 for the 
O-H stretch and also the azide intact with a sharp peak at max 2109 cm-1. The correct mass of 
383.1708 for the ion [M+H]+ gave further evidence for the structural assignment. 
5.2.2 The Swern Oxidation of the DC-81 alcohol derivative.  
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Scheme 5-9 
 
As previously, the next step was the conversion of the alcohol group to the aldehyde, under the 
Swern conditions. The product (299) was isolated as a mixture of rotamers in 65% yield as was 
shown by the presence of two doublets at 9.22 & 9.62 ppm as well as the disappearance of the alkyl 
chain protons in the 1H (400 MHz) NMR spectrum. The 13C (100 MHz) NMR spectrum showed a 
new peak at 198.0/199.4 ppm and the loss of the CH2 at 71.2 ppm confirming the presence of the 
aldehyde moiety. The presence of peaks at max 1731 cm-1 for the carbonyl of the aldehyde and the 
lack of the broad peak at max ~ 3330 cm-1 in the IR spectrum and the correct mass of 403.1375 for 
the measured ion [M+Na]+ supported the structural assignment. 
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5.2.3 Formation of the triazolo DC-81 derivative (301). 
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Scheme 5-10 
 
With the aldehyde (299) in hand the next stage was the conversion of the aldehyde moiety to the 
terminal alkyne utilising the Bestmann-Ohira reagent as discussed previously. In this case the 
terminal alkyne (300) could not be isolated as 1,3-dipolar cycloaddition between the terminal alkyne 
and the azide occurred spontaneously to give the triazole (301) in 84% yield.  
 
The formation of the cyclised product (301) was confirmed by 1H (400 MHz) NMR spectroscopy 
which gave three aromatic singlets at 7.47, 7.50 and 7.52 ppm for the benzene ring and the new CH 
of the aromatic triazole ring. The signals at 1.98-2.09 (2H), 2.41-2.50 (2H), 3.63-3.73 (2H) and 4.63 
ppm (1H) showed that the pyrrolidine ring system was still intact. The presence of signals at 5.12 
(1H) and 5.24 (1H) with the aromatic protons at 7.23-7.28 (1H, m, ArH), 7.27-7.33 (2H, m, ArH) 
and 7.38-7.40 ppm (2H, m, ArH) showed the presence of the benzyl group. The methoxy appeared at 
3.91 (3H, s). The 13C (100 MHz) NMR spectrum showed the disappearance of the distinctive 
aldehyde CH above 190 ppm. The presence of six aromatic CH signals [for the two benzene rings 
and one for the new triazole] as well at the expected seven quaternary carbons [one in the newly 
formed triazole] gave evidence for the cyclisation. The IR spectrum showed the disappearance of the 
sharp peak for the azide at max 2109 cm-1, which together with the correct mass of 377.1600 for the 
ion [M+H]+ in the high resolution mass spectrum supported the structural assignment. 
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5.3  Investigations of DC-81 Analogue Synthesis from Alkene Cycloadditions. 
 
In this part of the discussion the aim was to analyse intramolecular 1,3-dipolar cycloadditions 
between alkene derived analogues of the DC-81 systems discussed thus far in this chapter. The first 
system that was explored was the synthesis of the alkene (302a) and its potential cyclisation to give 
the aziridino DC-81 analogue (304) or the DC-81 methyl imine (306) (as shown in the Figure 5-2 
below). In the event, all attempts to synthesise the alkene (302) were unsuccessful, and hence other 
routes to alkenes (303) were explored. These routes are described in the preceeding sections.  
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Figure 5-2 
5.3.1 The synthesis of other alkene based systems. 
 
For ease of synthesis, the analogue that was chosen for exploration was the ethyl carboxylate (302b) 
which was anticipated to be readily available from the aldehyde (299), which has been synthesised 
before, see section 5.2.2. 
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Scheme 5-11 
 
Compound (302b) was formed from the Wittig reaction of (carbethoxymethylene)-
triphenylphosphorane with the aldehyde (299) in toluene at room temperature. The expected product 
(302b, shown in the Scheme 5-11) was not isolated. 
 
The IR spectrum confirmed that there was no azide present which, with the lack of a sharp peak at max 2109 cm-1 discounted the uncyclised product (302b). Also, peaks were present which were 
consistent with the presence of a N-H stretch. The 13C (125MHz) NMR spectra showed the presence 
of two CH signals at 50.1 and 62.7 ppm upfield of five types of aromatic CH carbons at 108.1, 
113.1, 127.4, 128.0 and 128.4 ppm. Also, a total of six CH2 signals were present, three for the 
proline ring, one for the benzyl protection group, one for the ethyl group and the *CH2 (shown in 
Scheme 5-11). 
 
Interestingly, mass spectroscopy showed a molecular ion 447.1895 [M+Na]+ which is two mass units 
higher than either compounds (305) and (307). This, combined with the extra CH and CH2 led to the 
assignment of structure (308) as the product. 1H (500 MHz) NMR spectroscopy was fully consistent 
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with an extra CH2 at 2.31–2.34 and an extra CH at 3.43–3.47. 2D NMR (HMBC, HSQC and COSY) 
confirmed the connectivity. 
 
The Figure 5-3 shows a possible mechanism whereby 1,3-dipolar cycloaddition is followed by facile 
extrusion of N2 and subsequent proton abstraction by the resultant diradical. 
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Figure 5-3 
Conclusion 
 
This section shows that the azide to nitrile, alkyne and alkene cycloaddition processes are applicable 
to the benzene substitution pattern present in DC-81. 
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6 Discussion: The Attempted Synthesis of PBDs via Cyclopropenone Additions. 
 
In this final section, the following route to the PBD nucleus will be explored. This route relies upon 
the fact that electron rich imines (imidates) are known to react with cyclopropenones139 (311) to 
form pyrrolidinones as shown in the Figure 6-1.  
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Figure 6-1 
 
In order to explore this as a potential route to PBDs a rapid access to the cyclic amine (310) was 
required. Wiklund et al,140 have synthesised 1,4-benzodiazepin-3,5-diones which could allow the 
introduction of the imine bond which upon addition of DPP could potentially give rise to a unique 
route to novel PBDs. 
 
6.1.1 Synthesis of the 1,4-benzodiazepin-3,5-dione (310): Step 1 
 
1) 2-chloroacetamide, 
   NaOH, Na2CO3, OH
O
NH2 NH
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O
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2.) 2M HCl
 
Scheme 6-1 
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The first stage in the synthesis was to repeat the literature coupling of 2-chloroacetamide with 
anthranilamide in the presence of sodium hydroxide and sodium carbonate.140 After heating to reflux 
the product was isolated from the sodium salt by acidification with hydrochloric acid to give the 
product (312) in 53% yield after vacuum filtration. Analysis showed the presence of signals at 3.78 
(2H, s), 7.19 (1H, bs) and 7.53 ppm (1H, bs) for the CH2 and the amide protons in the 1H (400 MHz) 
NMR spectrum. The secondary amine and the acid proton were present at 8.15 (1H, bs) and 12.60 
(1H, bs) respectively along with the expected four signals for the aromatic protons at 6.50 (1H, d), 
6.57 (1H, t), 7.36 (1H, dt) and 7.79 ppm (1H, dd). The 13C (100 MHz) NMR spectrum showed 
signals at 45.9, 170.1 and 171.4 ppm for the presence of the CH2 and the two carbonyls. The further 
presence of the two quaternary carbons of the benzene ring at 111.1 and 150.5 and the four aromatic 
CHs at 111.8, 115.0 132.1 and 134.9 ppm was consistent with the structure. The IR spectrum 
showed peaks at max 1604, 1661, 3170, 3451 cm-1 which was consistent with two carbonyls, the 
amine and amide stretches, respectively. Further evidence was given by the correct mass 
measurement of 217.0582 for the ion [M+Na]+ in the mass spectrum. Careful analysis of the 
spectroscopic data was necessary in order to clarify some ambiguity in the literature.140 
6.1.2 Synthesis of the 1,4-benzodiazepin-3,5-dione (310): Step 2 
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Et3N,  
N
H
OH
O
NH2
O
N
N
O H
O
EtO2C
312 313
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Scheme 6-2 
 
The next stage was a literature140 precedented ring closure by heating (312) to reflux in MeCN in the 
presence of ethyl chloroformate and triethylamine with simultaneous protection of the secondary 
amine with the ethyl chloroformate by further heating to reflux. After workup in citric acid and 
cooling, the solid product was collected by vacuum filtration in 48% yield. The disappearance of the 
broad singlet for the acidic proton in the 1H (500 MHz) NMR spectrum and the loss of one NH, plus 
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the inclusion of the ester group in the 1H and 13C NMR spectra indicated that the reaction was 
successful. The accurate mass measurement of 271.0687 for the ion [M+Na]+ in the mass spectrum 
confirmed the structural assignment. Cyclopropenones react with imidates/thio imidates and hence 
the next step was to convert compound (313) into either the imidate (314) or thioimidate (315) 
(shown in Figure 6-2): 
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Figure 6-2 
 
All attempts at O-alkylation failed to give compound (314). In order to access the thioimidate (315), 
conversion of the 1,4-benzodiazepin-3,5-dione (313) into the 3-thione compound was required.  
 
6.1.3 Synthesis of 1,4-benzodiazepin-5-on-3-thione (316). 
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Scheme 6-3 
  
The thionation of the carbonyl at the 3-position was the next step in the synthesis. As there was a 
possibility of the thionation of three different carbonyls, the reaction was carefully monitored by 
TLC. After treatment with 0.5 equivalents of Lawsseson’s reagent and heating to reflux for 2 hours 
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in THF only one major spot was observed, so the reaction was stopped, purified and analysed. The 
1H (500 MHz) NMR spectrum showed a major shift downfield of the amide proton from 8.75 ppm to 
10.08 ppm which is consistent with the NH environment having changed. The 13C (125MHz) NMR 
spectrum showed only one peak at 204.6 ppm which was consistent with the conversion of only one 
carbonyl to the thiocarbonyl. The presence of one CH3 and two CH2 signals at 14.3, 59.8 and 63.0 
ppm, and the observation of quaternary carbonyls at 162.7 and 153.5 ppm showed that the diazepine 
ring was intact. The expected four CH signals for the benzene ring were present at 127.1, 127.4, 
133.4 and 134.2 ppm. The IR spectrum showed absorbances at max 1154, 1313, 1648 and 1716 cm-1 
which was consistent for the C=S plus two carbonyls.  
 
In order to confirm the regiochemistry of the thionation reaction, the solid product was recrystallised 
and X-Ray crystallographic analysis was carried out (structure shown in Figure 6-3). This confirmed 
that thiation had occurred exclusively at the desired position. 
 
 
Figure 6-3 
N
N
O
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H
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6.1.4  Attempted S-alkylation of the thioamide. 
 
N
N
O
SMe
EtO2C
N
N
O
H
S
EtO2C 316 317
 
Scheme 6-4 
 
Alkylation of the thioamide utilising dimethyl sulfate or Meerwein’s reagent was the next step in the 
synthesis. Unfortunately the alkylation methods attempted all proved to be unsuccessful and time 
restrictions prevented a more comprehensive study in this thesis. However, the successful production 
of the 1,4-benzodiazepin-3-thione discussed above is currently underway to discover a successful S-
alkylation procedure, and it can be concluded that this route to the PBD nucleus may well turn out to 
be successful. 
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7 Experimental: Section 1 Tetrazolo & Triazolo- PBDs and PBTDs. 
7.1 Tetrazolo PBDs and PBTDs. 
7.1.1 Synthesis of 2-azidobenzoic acid. 
 
NH2
OH 1.NaNO2, HCl, 0°C
2. NaN3, 0°C N3
OH
231a 232a
O O
 
Scheme 7-1 
 
Anthranilic acid (2.00 g, 14.6 mmol, 1.0 eq) was suspended in 6M HCl (22 mL), NaNO2 (1.24 g, 
17.5 mmol, 1.2 eq) in water (6 mL) was added dropwise and the mixture was stirred at 0°C for 30 
minutes. The resultant solution was added dropwise to a solution of NaOAc (15 g, 183 mmol, 12.5 
eq), NaN3 (1.17 g, 17.5 mmol, 1.2 eq) in water (22 mL) and stirred for 2 hours at 0°C. The 
precipitate was collected by vacuum filtration, washed with ice cooled water (2 x 40 mL) and dried 
in an oven overnight at 80-100°C to afford the product as a peachy solid (1.77 g, 95%) mp = 156-
160C, identical to that reported in the literature.141 
 
δH (500 MHz, d6-DMSO): 7.15 (1H, t, J 8.2, ArH), 7.20 (1H, d, J 8.2, ArH), 7.49 (1H, t, J 7.7, ArH), 
7.67 (1H, d, J 7.7, ArH). 
 
δC (125MHz, d6-DMSO): 121.4 (CH), 124.2 (q), 125.9 (CH), 132.2 (CH), 134.4 (CH), 139.9 (q), 
168.4 (q). 
 max (thin film cm-1): 1078 (m), 1172 (m), 1264 (s), 1303 (m), 1406 (m), 1445 (s), 1459 (s), 1484 (s), 
1576 (s), 1596 (s), 1668 (s), 2123 (s), 2623-2920 (br). 
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LRMS (ESI+): Found 186.0 [M+Na]+. 
 
HRMS (ESI+): Found 186.0274 [M+Na]+, C7H5N3NaO2 requires 186.0280. 
7.1.2 Synthesis of (2S)-N-(2’-azidobenzoyl)-pyrrolidine-2-carbonitrile. 
 
2. L-prolinamide, 
K2CO3, r.t.
1. SOCl2, 
233a 234a
232a
N3
OH
N3
N
C
N
-H2O
N3
N
OH2N
O O O
 
Scheme 7-2 
 
A solution of 2-azidobenzoic acid (710 mg, 4.36 mmol, 2.49 eq) in thionyl chloride (5 mL) was 
heated at reflux under a nitrogen atmosphere at 85C for 3 hours. The reaction mixture was allowed 
to reach room temperature before the excess thionyl chloride was removed in vacuo. Washing with 
DCM (2 x 10 mL) afforded the crude 2-azidobenzoyl chloride as a brown-black solid.  
 
Potassium carbonate (1.00 g, 7.25 mmol, 4.14 eq) dissolved in water (5 mL) was added in one 
portion to a stirring solution of L-prolinamide (200 mg, 1.75 mmol, 1.0 eq) in DCM (5 mL). After 
stirring for 5 minutes, 2-azidobenzoyl chloride (~0.7 g, 2.5 eq) in DCM (5 mL) was added to the 
reaction mixture dropwise and the mixture was stirred for 20 hours. The organic phase was separated 
and the aqueous layer was extracted with DCM (3 x 10 mL). The combined organic phases were 
dried (MgSO4), filtered and the solvent removed in vacuo to yield the crude product. Purification by 
silica column chromatography (EtOAc:Hex; 1:1) yielded (2S)-N-(2’-azidobenzoyl)-pyrrolidine-2-
carbonitrile as a mixture of rotamers in the form of a yellow oil (140 mg, 33%).  
 
δH (400 MHz, CDCl3): 2.01-2.10 (1H, m, CHH), 2.11-2.25 (1H, m, CHH), 2.27-2.41 (1H, m, CHH), 
3.27-3.34 (1H, m, CHH), 3.37-3.45 (1H, m, NCHH), 3.72-3.83 (1H, m, NCHH), 4.92 (1H, dd, J 3.8, 
7.5, CHCN), 7.23 (2H, m, ArH), 7.34 (1H, dd, J 7.8, 1.6, ArH), 7.48 (1H, dt, J 7.8, 1.6, ArH). 
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δC (100 MHz, CDCl3): 22.6/24.3 (CH2), 29.8/31.6 (CH2), 45.1/47.0 (CH2), 45.5/48.2 (CH), 
117.4/117.6 (q), 117.9/118.0 (CH), 124.6/124.8 (CH), 127.2/127.5 (q), 127.4 (CH), 130.5/130.7 
(CH), 135.8 (q), 166.5 (q). 
 max (thin film cm-1): 1094 (w), 1125 (m), 1151 (w), 1200 (w), 1292 (m), 1342 (m), 1410 (vs), 1450 
(s), 1489 (s), 1578 (m), 1642 (vs), 2112 (s), 2131 (vs). 
 
LRMS (ESI+): Found 264.1 [M+Na]+, 288.3 [M+2Na]+, 505.1 [2M+Na]+. 
 
HRMS (ESI+): Found [M+NH4]+ 259.1304, C12H15N6O requires 259.1302. 
 
7.1.3 An alternative synthesis of the nitriles. 
235a, X = CO
235b, X = SO2
N3
NX
N
N3
NX
OH
NH3 , I2,
234a, X = CO
234b, X = SO2
 
Scheme 7-3 
 
To the nitrile (235) (580 mg, 2.37 mmol, 1 eq) in a mixture of conc. ammonia:water ; 7:3 (60ml) was 
added freshly ground iodine (6.01 g, 46.7 mmol, 10 eq) in small portions. The whole was heated to 
reflux at 85C for 68 hours whilst being monitored by TLC. After several attempts at this reaction 
only minor amounts of product was present by TLC so the route was abandoned.  
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7.1.4 Synthesis of tetrazolo[1,5-a] pyrrolo[2,1-c][1,4] benzodiazepine-5-one. 
 
234a 241a
Toluene, 
N3
N
C
N
N
N
N N
N
OO
 
Scheme 7-4 
 
A solution of (2S)-N-(2’-azidobenzoyl)-pyrrolidine-2-carbonitrile (100 mg, 0.415 mmol) in 
anhydrous toluene (5 mL) was heated to reflux for 6 hours under a dry nitrogen atmosphere. The 
reaction mixture was allowed to cool to ambient temperature and the solvent removed in vacuo to 
yield a pale yellow oil, which was purified by silica chromatography (EtOAc:Hex; 3:1) to yield the 
tetrazolo pyrrolo[2,1-c][1,4]benzodiazepin-5-one as a white solid (40 mg, 40%). 
 
δH (400 MHz, CDCl3): 2.16-2.40 (2H, m, NCH2CH2), 2.53-2.63 (1H, m, CHH), 3.16-3.23 (1H, m, 
CHCHH), 3.70-3.77 (1H, m, NCHH), 3.85-3.91 (1H, m, NCHH), 4.83 (1H, dd, J 8.4, 3.2, CHCN), 
7.64 (1H, dt, J 7.8, 0.9, ArH), 7.76 (1H, dt, J 7.8, 1.4  ArH), 7.94 (1H, dd, J 8.0, 0.9, ArH), 8.18 (1H, 
dd, J 8.0, 1.4 ArH). 
 
δC (100 MHz, CDCl3): 23.5 (CH2), 28.2 (CH2), 48.2 (CH2), 49.7 (CH), 122.5 (CH), 127.2 (q), 129.8 
(CH), 130.3 (q), 132.3 (CH), 133.1 (CH), 154.5 (q), 163.4 (q). 
 max (thin film cm-1): 832 (m), 1023 (m), 1095 (m), 1125 (m), 1151 (m), 1241 (m), 1409 (s), 1470 
(s), 1489 (s), 1605 (s), 1635 (s), 1735 (m), 2893 (m), 2923 (m). 
 
 LRMS (ESI+): Found 264.1 [M+Na]+, 505.2 [2M+Na]+. 
 
HRMS (ESI+): Found 242.1034 [M+H]+, C12H12N5O requires 242.1036.  
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7.1.5 Synthesis of 2-azidobenzenesulfonic acid. 
 
S
NH2
OH
1.NaNO2, H2SO4, 
0°C
2. NaN3, 0°C
S
N3
OH
231b 232b
O O O O
 
Scheme 7-5 
 
To a suspension of aniline-2-sulfonic acid (5.79 g, 33.4 mmol, 1 eq) in water (22 mL) at 0C, was 
added cooled conc. H2SO4 (7.5 mL) dropwise. A solution of NaNO2 (3.0 g, 43.4 mmol, 1.3 eq) in 
water (15 mL) cooled to 0C was added to the suspension dropwise and the whole stirred for 30mins 
before a cooled solution of NaN3 (4.34 g, 66.8 mmol, 2 eq) in water (15 mL) was added dropwise 
and the reaction was allowed to warm to room temperature. The resulting solution was crash cooled 
in an ice bath to afford the 2-azidobenzenesulfonic acid as a precipitate which was collected by 
vacuum filtration and dried in the oven at 80-100°C to give the product as a pale grey solid (4.91 g, 
74%). 
 
δH (400 MHz, d6-DMSO): 7.15 (1H, t, J  7.6, ArH), 7.28 (1H, d, J 8.0, ArH), 7.45 (1H, dt, J 7.8, 1.5, 
ArH), 7.7 (1H, dd, J 7.8, 1.5, ArH). 
 
δC (100 MHz, d6-DMSO): 121.1 (CH), 125.4 (CH), 129.4 (CH), 132.7 (CH), 136.7 (q), 137.7 (q). 
 max (thin film cm-1): 665 (s), 740 (m), 765 (s), 1024 (s), 1087 (s), 1133 (m), 1145 (m), 1161 (m), 
1199 (s), 1213 (s), 1237 (m), 1261 (m), 1279 (s), 1439 (m), 1472 (m), 1574 (w), 2122 (s). 
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7.1.6 Synthesis of 2(S)-N-(2’-azidobenzenesulfonyl)-2-prolinamide. 
 
O O O O
2. L-prolinamide, 
K2CO3, r.t.
1. (COCl)2, DMF, 
233b
232b
S
N3
OH
S
N3
N
OH2N
 
Scheme 7-6 
 
To 2-azidobenzenesulfonic acid (900 mg, 4.52 mmol, 2.6 eq) was added a 2M solution of oxalyl 
chloride in DCM (6 mL, 12.00 mmol, 6.85 eq) followed by the addition of DMF (50l). The 
resultant mixture was heated to reflux for 15 hours under nitrogen at 80C.  The excess oxalyl 
chloride was removed in vacuo and the residue was washed with DCM (2 x 10 mL) to give the crude 
sulfonyl chloride as an orange solid. 
 
A solution of potassium carbonate (1.32 g, 9.57 mmol, 5.5 eq) in water (10 mL) was added in one 
portion to L-prolinamide (200 mg, 1.75 mmol, 1 eq) in DCM (10 mL). The sulfonyl chloride was 
dissolved in DCM (5 mL) and was added dropwise to this solution. The reaction was allowed to stir 
at room temperature for 20 hours before the organic layer was separated and the aqueous layer 
washed with DCM (2 x 10 mL). The combined organic phases were dried (MgSO4), filtered, 
concentrated and purified by silica column chromatography (EtOAc: Hex; 10:1) to yield the product 
as a brown oil (330 mg, 62%).  
 
δH (400 MHz, CDCl3): 1.74-1.99 (3H, m, CH2+CHH), 2.31-2.40 (1H, m, CHH), 3.26-3.38 (1H, m, 
NCHH), 3.43-3.53 (1H, m, NCHH), 4.64-4.67 (1H, m, NCH), 5.72 (1H, bs, NH), 6.90 (1H, bs, NH), 
7.29 (1H, t, J 7.7, ArH), 7.34 (1H, d, J 8.0, ArH), 7.64 (1H, t, J 7.7, ArH), 8.03 (1H, d, J 8.0, ArH). 
 
δC (100 MHz, CDCl3): 24.6 (CH2), 29.7 (CH2), 49.1 (CH2), 62.3 (CH), 119.9 (CH), 124.9 (CH), 
127.8 (q), 133.0 (CH), 134.7 (CH), 138.4 (q), 174.2 (q). 
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 max (thin film cm-1): 759 (m), 1157 (s), 1198 (s), 1334 (m), 1574 (m), 1670 (s), 2122 (m), 2132 (s), 
3145 (m), 3476 (m). 
 
LRMS (ESI+): Found 318.1 [M+Na]+. 
 
HRMS (ESI+): Found 313.1077 [M+NH4]+ C11H17N6O3S requires 313.1077. 
7.1.7 Synthesis of 2(S)-N-(2’-azidobenzenesulfonyl)-pyrrolidine-2-carbonitrile. 
 
O O O O
233b 234b
S
N3
N
C
N
Pyridine, 
TsCl, r.t.S
N3
N
OH2N
 
Scheme 7-7 
 
To a solution of the 2(S)-N-(2’-azidobenzenesulfonyl)-2-prolinamide (300 mg, 1.02 mmol, 1 eq) in 
DCM (5 mL) at room temperature was added pyridine (620 mg, 0.63 mL, 7.84 mmol, 7.7 eq) 
followed by neat tosyl chloride (1.27 g, 6.67 mmol, 6.5 eq). The resultant mixture was heated to 
reflux under a nitrogen atmosphere for 6 hours at 50C. The solvent was removed in vacuo and the 
crude product was purified by silica chromatography (EtOAc: Hex; 1:1) to yield the product as a 
brown oil (90 mg, 37%). 
 
δH (500 MHz, CDCl3): 2.06-2.34 (4H, m, 2 x CH2), 3.41-3.47 (1H, m, NCHH), 3.59 (1H, ddd, J 3.6, 
7.6, 9.5, NCHH), 4.95 (1H, dd, J 2.8, 7.2, CH), 7.28 (1H, t, J 7.7, ArH), 7.33 (1H, d, J 8.1, ArH), 
7.64 (1H, dt, J 7.7, 1.5, ArH), 8.02 (1H, d, J 8.1, 1.5, ArH). 
 
δC (125MHz, CDCl3): 24.8 (CH2), 32.2 (CH2), 47.7 (CH2), 48.8 (CH), 118.3 (q), 119.8 (CH), 124.7 
(CH), 129.0 (q), 131.7 (CH), 134.6 (CH), 138.4 (q). 
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 max (thin film cm-1): 896 (s), 1164 (m), 1265 (vs), 1347 (m), 1422 (m), 1473 (m), 2122 (m), 2134 
(s), 2987 (m), 3054 (s). 
 
LRMS (ESI+): Found 300.1 [M+Na]+. 
 
HRMS (ESI+): Found 295.0972 [M+NH4]+ C11H15N6O2S requires 295.0972. 
7.1.8 Synthesis of tetrazolo[1,5-d]-pyrrolo[1,2-b][1,2,5]benzothiadiazepin-9,9-dioxide. 
 
234b 241b
Toluene, S
N3
N
C
N
N
NS
N N
N
O O O O
 
Scheme 7-8 
 
(S)-N-(2’-azidobenzenesulfonyl)-pyrrolidine-2-carbonitrile (90 mg, 0.325 mmol) was heated to 
reflux temperature in dry toluene (8 mL) under a nitrogen atmosphere for 72 hours. The solvent was 
removed in vacuo and the crude product was purified by silica chromatography (EtOAc: Hex; 2:1) to 
yield the product as a white solid (90 mg, 100%).  
 
δH (500 MHz, CDCl3): 1.80 (1H, m, CHH), 1.94 (1H, m, CHH), 2.08 (1H, m, CHH), 2.61 (1H, m, 
CHH), 3.04 (1H, ddd, J 9.8, 7.5, 7.4, CHH), 3.64 (1H, ddd, J 4.7, 7.2, 9.8, CHH), 5.59 (1H, dd, J 
7.2, 7.4, NCCHN), 7.65 (1H, dt, J 7.8, 0.8, ArH), 7.83 (1H, dt, J 7.8, 1.4, ArH), 8.12 (1H, dd, J 8.0, 
1.4, ArH), 8.16 (1H, dd, J 8.0, 0.8, ArH).  
 
δC (125MHz, CDCl3): 24.5 (CH2), 34.5 (CH2), 49.3 (CH2), 56.1 (CH), 125.1 (CH), 129.4 (CH), 
129.7 (CH), 130.7 (q), 131.1 (q), 134.6 (CH), 155.4 (q). 
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max (thin film cm-1): 895 (m), 1174 (s), 1265 (s), 1363 (m), 1421 (m), 1482 (m), 1590 (w), 2986 
(m), 3054 (m). 
 
LRMS (ESI+): Found 278.1 [M+H]+, 577.1 [2M+Na]+, 854.2 [3M+Na]+. 
 
HRMS (ESI+): Found 278.0707 [M+H]+, C11H12N5O2S requires 278.0706. 
 
7.2 Triazolo- PBDs and PBTDs. 
7.2.1 Synthesis of N-Boc-dibromoethenyl pyrrolidine. 
 
238 243
N
Boc
H
O
N
Boc
Br
Br
tBuOK,
Ph3P+CHBr2.Br-
r.t.
 
Scheme 7-9 
 
To dibromo-methyltriphenylphosphonium bromide (1.3 g, 2.52 mmol, 3 eq) in anhydrous THF (20 
mL) was added a solution of 1M tBuOK in methyl-2-propanol (2.8 mL, 2.62 eq) dropwise and the 
whole stirred for 5 minutes under nitrogen at room temperature. A solution of the N-protected 
aldehyde (238, 0.20 mL, 213 mg, 1.07 mmol, 1 eq) in THF (5 mL) was injected into the first solution 
dropwise over 10 minutes. After 1 hour the reaction was quenched with water (20 mL) and the 
organic layer was collected. The aqueous layer was extracted with EtOAc (3 x 20 mL), the combined 
organic layers were dried (MgSO4), filtered and concentrated under reduced pressure to yield a 
brown solid. Purification by silica chromatography (30 g) (EtOAc: Hex; 3:2) yielded the product as a 
yellow oil (355 mg, 94%) which was used immediately in the next step. 
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7.2.2 Synthesis of 1,2,3-triazolo-[1,5-a]-pyrrolo-[2,1-c] benzodiazepine-5-one (242). 
 
243 244
237a 242a
N
N
N N
N
Boc
Br
Br
N
Boc
N
H
N3
N
COCl
N3
tBuOK
Et3N
TFA
1,3-Dipolar
245
246a
cycloaddition
OO
 
Scheme 7-10 
N-Boc-dibromoethenyl pyrrolidine (350 mg, 0.985 mmol) was dissolved in THF (10 mL) and 1M 
tBuOK in 2-methyl-2-propanol (2.5 mL, 2.5 mmol) was added under nitrogen. The reaction was 
quenched after stirring for 45 minutes with water (20 mL) and the organic layer was separated. The 
aqueous layer was extracted with EtOAc (2 x 10 mL) and the combined organic layers were dried 
(MgSO4) and the solvent was removed in vacuo. The crude product was purified by silica column 
chromatography (30 g) (EtOAc: Hex; 3:2) to yield the air sensitive N-Boc protected alkyne (top spot, 
255 mg, 1.39 mmol, 1 eq). The alkyne was dissolved in DCM (6 mL); TFA (0.46 mL, 710 mg, 6.23 
mmol, 4.5 eq) was added dropwise and the mixture was stirred under nitrogen at r.t. for 3 hours. The 
reaction was quenched with 2M NaOH (6 mL) and the pH was adjusted to 7 using 2M HCl.  The 
organic layer was separated and the aqueous layer extracted with DCM (3 x 10 mL). The combined 
organic layers were washed with saturated brine solution (1 x 10ml), dried (MgSO4) and the volume 
was reduced in vacuo to approximately 15 mL. To this solution, Et3N (0.3 mL, 280 mg, 2.78 mmol, 
2 eq) and the acid chloride* (246a, 249 mg, 1.39 mmol, 1 eq) were added dropwise under nitrogen at 
0°C. The whole reaction was stirred under nitrogen for 48 hours; the reaction was diluted with water 
(20 mL). The organic layer was separated, the aqueous layer was extracted with DCM (2 x 10 mL), 
the combined organic layers were dried (MgSO4), filtered and concentrated under reduced pressure. 
The crude product was purified by silica column chromatography (40 g) (EtOAc: Hex; 10:1) to yield 
the product as a white solid (10 mg, 3%). 
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*Note : The carboxylic acid chloride was prepared by heating the 2-azidobenzoic acid (225 mg, 1.39 
mmol, 1 eq) at reflux in SOCl2 (2 mL) under nitrogen at 85°C for 3 hours. The excess SOCl2 was 
removed in vacuo and the brown/black solid was redissolved in fresh DCM (2 x 10 mL), which was 
evaporated to remove excess SOCl2. 
 
Bestmann Ohira,
N3
N
O
N
N
N N
N3
N
236a 237a 242a
O O O
K2CO3, MeOH, r.t.
 
Scheme 7-11 
 
Method B: The aldehyde [See part 7.2.6] (672 mg, 2.75 mmol, 1 eq) was dissolved in dry methanol 
(5 mL); K2CO3 (760 mg, 5.51 mmol, 2.0 eq) and the Bestmann-Ohira reagent (635 mg, 3.30 mmol, 
1.2 eq) were added and the whole was stirred for 5 hours under nitrogen at room temperature. The 
reaction was quenched with saturated aqueous solution of NH4Cl (10 mL), the organic phase was 
separated and the aqueous phase was extracted with DCM (3 x 10 mL). The combined organic 
phases were dried (MgSO4), filtered and concentrated in vacuo to yield a yellow solid (632 mg, 
96%). Purification by silica chromatography (40 g) (EtOAc:Hex; 9:1) yielded the product as a white 
solid (550 mg, 83%). 
 
δH (400 MHz, CDCl3): 2.03-2.12 (2H, m, CH2), 2.44-2.56 (2H, m, CH2), 3.64-3.78 (2H, m, NCH2), 
4.70 (1H, dd, J 7.2, 4.9, NCH), 7.49 (1H, dt, J  7.6, 1.1, ArH), 7.57 (1H, s, CHNN), 7.62 (1H, dt, J 
7.6, 1.5, ArH), 7.92 (1H, dd, J 8.1, 1.1, ArH), 8.04 (1H, dd, J 7.9, 1.5, ArH). 
 
δC (100 MHz, CDCl3): 23.7 (CH2), 29.4 (CH2), 47.7 (CH2), 49.6 (CH), 123.0 (CH), 127.2 (q), 128.8 
(CH), 129.0 (CH), 131.8 (CH), 132.8 (CH), 133.1 (q), 138.9 (q), 164.0 (q). 
 max (thin film cm-1): 986 (m), 1127 (m), 1245 (m), 1412 (s), 1434 (s), 1473 (s), 1579 (m), 1634 (s), 
2963(m), 2981(m). 
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LRMS (ESI+): Found 241.1 [M+H]+. 
 
HRMS (ESI+): Found 241.1083 [M+H]+, C13H13N4O requires 241.1084. 
 
7.2.3 Synthesis of the Bestmann-Ohira Reagent. 
 
SO2Cl
Me
Me
P
MeO
O
MeO
N2
O
Me
P
MeO
O
MeO
O
NaN3, H2O, NaH, THF, 0
oC
SO2N3
Me
Acetone, 0oC
 
Scheme 7-12 
 
A solution of tosylchloride (8.00 g, 42 mmol) in acetone (120ml) was added to NaN3 (2.73 g, 42.0 
mmol) in water (120ml) and the whole was stirred at 0C for 2 hours. The reaction mixture was 
concentrated in vacuo to approximately 20ml and the mixture was extracted with Et2O (3 x 120ml). 
The combined organics were dried (MgSO4), filtered and concentrated to approximately 20ml to 
yield an ethereal solution of the tosyl azide. 
 
A solution of NaH (1.65g of 60% dispersion in oil) was washed with hexane (3 x 10ml) to give oil 
free NaH (0.99 g, 41.5 mmol) which was suspended in THF (100ml) and cooled to 0C. Dimethyl 
(2-oxopropyl)phosphonate (6.26 g, 37.7 mmol) in THF (100ml) was added dropwise and the whole 
was stirred at 0C for an hour before the tosyl azide was added in three portions and stirred at 0C 
for 10mins. The mixture was concentrated and purified by silica chromatography (100 g) (neat 
EtOAc) to yield the product as pale yellow oil (4.27 g, 59%). 
 
δH (400 MHz, CDCl3): 2.19 (3H, s, COCH3), 3.76 (3H, s, OCH3), 3.79 (3H, s, OCH3). 
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δC (100 MHz, CDCl3): 27.2 (CH3), 53.6 (CH3), 53.7 (CH3), 126.4 (q), 189.9 (q). 
 
7.2.4 Synthesis of 1,2,3-triazolo[1,5-d]-pyrrolo[1,2-b][1,2,5]benzothiadiazepin-9,9-dioxide.  
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Scheme 7-13 
 
Method A: N-Boc-dibromoethenyl pyrrolidine (355 mg, 1.00 mmol) was dissolved in THF (10 mL); 
1M tBuOK in 2-methyl-2-propanol (2.5 mL, 2.5 mmol) was added under nitrogen. The reaction was 
quenched after stirring for 45 minutes by the addition of water (20 mL) and the organic layer was 
separated. The aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organic 
layers were dried (MgSO4) and the solvent was removed in vacuo to give an orange oil. The crude 
product was purified by silica chromatography (30 g) (EtOAc: Hex; 3:2) to yield the air sensitive 
alkyne (top spot, 110 mg, 0.564 mmol, 1.3 eq). The alkyne was dissolved in anhydrous DCM (6 
mL); TFA (0.15 mL, 220 mg, 1.93 mmol, 4.6 eq) was added dropwise and the mixture was stirred 
under nitrogen at r.t. for 3 hours. The reaction was quenched with 2M aqueous NaOH (2 mL, 4.0 
mmol, 9.5 eq) and the pH was adjusted to 7 using 2M HCl. The organic layer was separated and the 
aqueous layer extracted with DCM (3 x 10 mL). The combined organic layers were washed with 
saturated brine solution (1 x 10ml), dried (MgSO4), filtered and reduced in vacuo to 15 mL. To this 
solution Et3N (0.12 mL, 87 mg, 0.86 mmol, 1.95 eq) and the sulfonyl chloride (246b)* (approx 1 eq) 
were added dropwise under nitrogen at 0°C. The whole reaction was allowed to warm slowly to 
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room temperature over 2 hours and stirred under nitrogen for 48 hours before being diluted with 
water (20 mL). The organic layer was separated and the aqueous layer was extracted with DCM (2 x 
10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated under reduced 
pressure. The crude product was purified by silica chromatography (20 g) (EtOAc: Hex; 2:1) to yield 
the product as an orange solid (bottom spot, 23 mg, 14%). 
 
*Note : The 2-azidobenzenesulfonyl chloride was prepared using 2-azidobenzenesulfonic acid (84 
mg, 0.422 mmol, 1.0 eq) suspended in dry DCM (3 mL), to which was added 2M oxalyl chloride in 
DCM (0.6 mL), followed by DMF (50µl). The mixture was heated to reflux under nitrogen at 85°C 
for 3 hours. The reaction was allowed to cool to room temperature before the excess oxalyl chloride 
was removed in vacuo to give 2-benzenesulfonyl chloride as an orange solid after washing with 
DCM (2 x 5 mL). 
 
Bestmann Ohira,
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N
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N N
S
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N
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O O O OO O
K2CO3, MeOH, 
r.t.
 
Scheme 7-14 
 
Method B: The aldehyde (300 mg, 1.07 mmol, 1 eq) was dissolved in dry methanol (5 mL); K2CO3 
(296 mg, 2.14 mmol, 2.0 eq) and the Bestmann-Ohira reagent (247 mg, 1.29 mmol, 1.2 eq) were 
added and the whole was stirred for 22 hours under nitrogen. The reaction was quenched with 
saturated aqueous NH4Cl (10 mL), the organic phase was separated and the aqueous phase was 
extracted with DCM (3 x 10 mL). The combined organic phases were dried (MgSO4), filtered and 
concentrated in vacuo to yield an orange solid. Purification by silica chromatography (20 g) 
(EtOAc:Hex;3:1) yielded the product as a pale yellow solid (295 mg, 100%). 
 
δH (400 MHz, CDCl3): 1.63-1.73 (1H, m, CHH), 1.88-2.09 (2H, m, CH2), 2.27 (1H, dddd, J 2.8, 6.6, 
6.2, 12.4, CHH), 3.12 (1H, ddd, J 6.6, 9.9, 9.9, CHHN), 3.68 (1H, ddd, J 2.4, 7.5, 9.9, CHHN), 5.19 
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(1H, dd, J 6.2, 10.2, NCHCN), 7.62 (1H, dt, J 1.0, 7.7, ArH), 7.79 (1H, s, NCCHN), 7.83 (1H, dt, J 
1.5, 7.8, ArH), 8.10 (1H, dd, J 1.5, 7.8, ArH), 8.15 (1H, dd, J 1.0, 8.0, ArH).  
 
δC (100 MHz, CDCl3): 24.4 (CH2), 35.4 (CH2), 50.0 (CH2), 55.1 (CH), 125.4 (CH), 128.7 (CH), 
129.3 (CH), 130.9 (q), 133.5 (q), 134.1 (CH), 134.4 (CH), 136.8 (q). 
 max (thin film cm-1): 1119 (m), 1170 (s), 1265 (m), 1356 (m), 1457 (w), 1485 (w), 1541 (w), 1558 
(w), 1654 (s), 2924 (w). 
 
LRMS (ESI+): Found 299.1 [M+Na]+, 575.2 [2M+Na]+. 
 
HRMS (ESI+): Found 277.0752 [M+H]+, C12H13N4O2S r equires 277.0754. 
7.2.5 Synthesis of (2S)-N-(2’-azidobenzoyl)-2-(hydroxymethyl) pyrrolidine. 
 
232a 235a
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OH
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N
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1. SOCl2, 
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O O
 
Scheme 7-15 
 
A solution of 2-azidobenzoic acid (770 mg, 4.72 mmol, 1 eq) in thionyl chloride (5 mL) was heated 
to reflux under a nitrogen atmosphere at 85C for 3 hours. The reaction mixture was cooled to room 
temperature before the excess thionyl chloride was removed in vacuo, and washed with DCM (2 x 
10 mL) to yield the crude 2-azidobenzoyl chloride as a dark brown solid. 
 
A solution of potassium carbonate (2.07 g, 15 mmol, 3.2 eq) dissolved in water (5 mL) was added in 
one portion to a stirring solution of S-prolinol (780 mg, 7.71 mmol, 1.63 eq) in DCM (15 mL). After 
stirring for 15 minutes the 2-azidobenzoyl chloride in DCM (10 mL) was added to the reaction 
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mixture dropwise and the whole was stirred at room temperature for 20 hours. The organic phase 
was separated and the aqueous phase extracted with DCM (3 x 10 mL). The combined organic layers 
were dried (MgSO4), filtered and concentrated to yield the crude product as a black oil. Purification 
by silica chromatography (EtOAc:Hex; 2:1) yielded the product as a yellow solid (720 mg, 62%) mp 
= 99-103C. [lit 98-100C].69 
 
δH (400 MHz, CDCl3): 1.60-1.84 (3H, m, CHH+CH2), 2.04-2.14 (1H, m, CHH), 3.15-3.26 (2H, m, 
NCH2), 3.66 (1H, dd, J 7.1, 11.5, NCHCH2), 3.75-3.78 (1H, m, CHHOH),  4.28-4.31 (1H, m, 
CHHOH), 4.67 (1H, brs, OH), 7.10-7.15 (2H, m, ArH), 7.24 (1H, dd, J 1.5, 8.0, ArH), 7.37 (1H, dt, 
J 1.5, 8.0, ArH). 
 
δC (100 MHz, CDCl3): 24.5 (CH2), 28.6 (CH2), 49.6 (CH2), 61.3 (CH), 66.5 (CH2), 118.5 (CH), 
125.3 (CH), 127.8 (CH), 129.3 (q), 130.7 (CH), 136.0 (q), 169.0 (q). 
 max (thin film cm-1): 1217 (m), 1265 (s), 1294 (m), 1428 (s), 1454 (s), 1614 (s), 2130 (s), 2882 (w), 
2983 (w), 3019 (w), 3053 (w), 3100-3500 (br). 
 
LRMS (ESI+): Found 269.1 [M+Na]+, 512.2 [2M+Na]+.  
 
HRMS (ESI+): Found 269.1008 [M+Na]+, C12H14N4NaO2 requires 269.1009. 
 
7.2.6 Synthesis of (2S)-N-(2’-azidobenzoyl)-2-methylpyrrolidinal. 
 
N3
N
OH
N3
N
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PCC, Et2O, r.t.
O O
 
Scheme 7-16 
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Method A: The alcohol (540 mg, 2.20 mmol, 1 eq) was dissolved in dry DCM (10 mL) and 
pyridinium chlorochromate (946 mg, 4.40 mmol, 2 eq) was added and the mixture stirred at room 
temperature under nitrogen for 18 hours. The reaction was quenched with Et2O (1 x 20 mL) and the 
organic supernatant was decanted off. The resultant black tar was washed with EtOAc (5 x 20 mL) 
in an ultrasound bath. The combined organic layers were collected, dried (MgSO4), filtered, and 
concentrated in vacuo to yield a brown/black oil (482 mg). Purification by silica chromatography (40 
g) (EtOAc:Hex; 3:1) yielded the aldehyde as a yellow oil (80 mg, 15%). 
(COCl)2, DMSO,
N3
N
OH
N3
N
HO
235a 236a
O O
Et3N, -78oC
 
Scheme 7-17 
Method B: A solution of 2M oxalyl chloride in DCM (1.8 mL, 3.66 mmol, 1.2 eq) was cooled to -
78C and diluted with dry DCM (4 mL). To this, DMSO (0.63 mL, 693 mg, 8.87 mmol, 2.9 eq) in 
dry DCM (5 mL) and the alcohol (750 mg, 3.05 mmol, 1 eq) in dry DCM (5 mL) were added 
dropwise over 15 minutes. After 10 minutes stirring at -78C, Et3N (1.12 mL, 813 mg, 8.04 mmol, 
2.64 eq) was added dropwise and the reaction was allowed to reach room temperature over an hour. 
The reaction was quenched with a mixture of Et2O (10 mL) and H2O (10 mL). The organic layer was 
separated and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated in vacuo to yield the crude product as brown 
oil. Purification by silica chromatography (50 g) (EtOAc:Hex; 3:1) yielded the product as a mixture 
of rotamers in the form of a yellow oil (544 mg, 73%).  
 
δH (400 MHz, CDCl3) rotamers: 1.80-1.93 (2H, m, CH2), 1.95-2.05 (1H, m, CHH), 2.09-2.20 (1H, 
m, CHH), 3.25-3.38 & 3.64-3.81 (2H, m, CH2), 4.10-4.12 & 4.52-4.56 (1H, m & ddd, J  8.0, 1.9, 5.7, 
CHCHO), 7.05-7.17 (2H, m, ArH), 7.20 & 7.29 (1H, dd, J 7.5, 1.3 & 7.4, 1.2, ArH), 7.34 & 7.39 
(1H, dt, J 7.8, 1.5 & 7.8, 1.5), 9.22 & 9.62 (1H, d, J 1.9, CHO). 
Chapter 7  Experimental Part I 
122 
 
 
δC (100 MHz, CDCl3) rotamers: 22.8/24.8 (CH2), 26.4/27.8 (CH2), 46.6/48.6 (CH2), 64.7/66.4 (CH), 
118.6 (CH), 125.1/125.2 (CH), 127.5/128.0 (CH), 128.48/128.51 (q), 130.9/131.0 (CH), 136.0/136.2 
(q), 167.3/167.6 (q), 198.0/199.3 (CH). 
 max (thin film cm-1): 896 (m), 1265 (s), 1422 (m), 1453 (m), 1633 (s), 1732 (m), 2131 (s), 2986 (m), 
3054 (m). 
 
LRMS (ESI+): Found 245.1 [M+H]+. 
 
HRMS (ESI+): Found 245.1032 [M+H]+, C12H13N4O2 requires 245.1033. 
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8 Experimental:The Synthesis of Triazolo and Tetrazolo Benzodiazepines and 
Benzothiadiazepines. 
8.1 The Synthesis of the Triazolo-Benzodiazepine and Benzothiadiazepines. 
8.1.1 Synthesis of (S)-N-(2’-azidobenzoyl)alaninol. 
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Scheme 8-1 
 
2-Azidobenzoic acid (596 mg, 3.65 mmol, 1 eq) was heated at reflux under nitrogen in SOCl2 (5 
mL). The excess thionyl chloride was removed under reduced pressure to yield the acid chloride as a 
crude oil which was washed with fresh DCM (2 x 10 mL) and concentrated under reduced pressure. 
 
To a stirring solution of S-alaninol (0.50 mL, 482 mg, 6.40 mmol, 1.8 eq) in DCM (15 mL) was 
added K2CO3 (2.01 g, 14.6 mmol, 4 eq) in water (5 mL) in one portion. After 5 mins of stirring at 
room temperature, the acid chloride in fresh DCM (10ml) was added dropwise. The whole was 
stirred for 18 hours before the organic layer was separated. The aqueous layer was extracted with 
DCM (3 x 10 mL). The combined organic layers were dried (MgSO4), filtered and solvent was 
removed in vacuo to yield the crude product as a peachy brown solid (917 mg). Purification by silica 
chromatography (80 g) (EtOAc:Hex;3:1) yielded the product as a peachy solid (306 mg, 38%). 
 H (400 MHz, CDCl3): 1.22 (3H, d, J 6.8, CH3), 3.18 (1H, bs, OH), 3.55-3.60 (1H, m, CHHOH), 
3.48-3.72 (1H, m, CHHOH), 4.16-4.26 (1H, dsextet, J 6.8, 3.7, CHCH3), 7.11 (1H, d, J 8.0, ArH), 
7.16 (1H, t, J  7.6, ArH), 7.42 (1H, dt, J  7.6, 1.6 ArH), 7.55 (1H, bd, J 5.4, NH), 8.03 (1H, dd, J 8.0, 
1.6, ArH). 
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δC (100 MHz, CDCl3): 17.1 (CH3), 48.5 (CH), 67.2 (CH2), 118.4 (CH), 124.8 (q), 125.2 (CH), 132.2 
(CH), 132.5 (CH), 137.1 (q), 165.3 (q). 
 max (thin film cm-1): 1046 (m), 1163 (m), 1311 (s), 1480 (m), 1541 (s), 1597 (m), 1635 (s), 2133 (s), 
2976 (m), 3317 (s). 
 
LRMS (ESI+): Found 243.1 [M+Na]+, 463.2 [2M+Na]+. 
 
HRMS (ESI+): Found 243.0854 [M+Na]+, C10H12N4NaO2 requires 243.0852. 
 
8.1.2 Synthesis of (S)-N-(2’-azidobenzoyl)alaninol. 
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Scheme 8-2 
 
A 2M solution of oxalyl chloride in DCM (0.84 mL, 1.67 mmol, 1.2 eq) was diluted with dry DCM 
(1 mL) and cooled to -78C. DMSO (0.24 mL, 264 mg, 3.39 mmol, 2.4 eq) in dry DCM (1 mL) and 
the alcohol (306 mg, 1.39 mmol, 1 eq) in dry DCM (5 mL) were added dropwise over 15 mins to the 
cooled solution. Et3N (0.969 mL, 703 mg, 6.95 mmol, 2 eq) was added dropwise after 10 mins of 
stirring at -78C and the reaction was allowed to reach ambient temperature over an hour. The 
reaction was quenched with a mixture of Et2O (10 mL) and H2O (10 mL). The organic phase was 
separated and the aqueous phase was extracted with DCM (3 x 10 mL). The combined organic layers 
were dried (MgSO4), filtered, concentrated in vacuo to give a purple solid (396 mg). Purification by 
silica chromatography and repeated attempts gave no identifiable product.  
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8.1.3 Synthesis of (S)-N-(2’-azidobenzoyl)phenylalaninol. 
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Scheme 8-3 
 
2-Azidobenzoic acid (317 mg, 1.95 mmol, 1 eq) was heated at reflux under nitrogen at 80C in 
SOCl2 (5 mL). The excess thionyl chloride was removed under reduced pressure to yield the acid 
chloride as a crude oil which was washed with fresh DCM (2 x 10 mL) and concentrated under 
reduced pressure. 
 
To a stirring solution of L-phenylalaninol (500 mg, 3.31 mmol, 1.7 eq) in DCM (10 mL) was added 
K2CO3 (1.83 g, 13.2 mmol, 6.8 eq) in water (5 mL) in one portion and after 5 mins of stirring the 
acid chloride in fresh DCM (10ml) was added. The whole was stirred for 6 hours before the organic 
layer was separated. The aqueous layer was extracted with DCM (3 x 10 mL) and the combined 
organic layers were dried (MgSO4), filtered and solvent was removed in vacuo to yield the crude 
product as a brown solid. Purification by silica chromatography (50 g) (EtOAc:Hex; 3:1) yielded the 
product as a pale yellow solid (538 mg, 93%). 
 
δH (400 MHz, CDCl3): 2.88 (1H, dd, J 7.4, 13.8, CHHPh), 2.95  (1H, dd, J 6.9, 13.8, CHHPh), 3.44 
(1H, bs, OH), 3.60 (1H, dd, J 11.0, 5.2, CHHOH), 3.68-3.71 (1H, m, CHHOH), 4.23-4.37 (1H, m, 
NHCH), 7.04 (1H, d, J 8.0, ArH), 7.08-7.27 (6H, m, ArH), 7.38 (1H, t, J 8.0, ArH), 7.65 (1H, bs, 
NH), 7.99 (1H, d, J 8.0, ArH). 
 
δC (100 MHz, CDCl3): 37.0 (CH2), 54.1 (CH), 64.5 (CH2), 118.4 (CH), 124.6 (q), 125.2 (CH), 126.8 
(CH), 128.6 (CH), 129.5 (CH), 132.2 (CH), 132.5 (CH), 137.1 (q), 137.5 (q), 165.3 (q). 
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max (thin film cm-1): 1039 (m), 1287 (s), 1445 (m), 1480 (m), 1496 (m), 1532 (s), 1597 (m), 1636 
(s), 2130 (s), 2930 (w), 3027 (w), 3063 (w), 3250-3550 (br). 
 
LRMS (ESI+): Found 319.1 [M+Na]+, 615.2 [2M+Na]+. 
 
HRMS (ESI+): Found 319.1150 [M+Na]+, C16H16N4NaO2 requires 319.1165. 
 
8.1.4 Synthesis of (S)-N-(2’-azidobenzoyl)phenylalaninal. 
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Scheme 8-4 
 
A 2M solution of oxalyl chloride in DCM (1.00 mL, 2.06 mmol, 1.2 eq) was diluted with dry DCM 
(2 mL) and cooled to -78C. DMSO (0.29 mL, 322 mg, 4.12 mmol, 2.4 eq) in dry DCM (2 mL) and 
(S)-N-(2’-azidobenzoyl)phenylalaninol (508 mg, 1.72 mmol, 1 eq) in dry DCM (5 mL) were added 
dropwise, over 15 minutes. The reaction was maintained at -78°C for 10 mins before Et3N (1.20 mL, 
871 mg, 8.61 mmol, 5 eq) was added dropwise. The reaction was allowed to reach room temperature 
over an hour before being quenched with a mixture of Et2O (10 mL) and H2O (10 mL). The organic 
phase was separated and the aqueous phase was extracted with DCM (4 x 10 mL). The combined 
organic layers were dried (MgSO4), filtered, concentrated in vacuo and purified by silica 
chromatography (52 g) (EtOAc:Hex;1:1) to yield the product as a yellow oil (365 mg, 72%). 
 
δH (400 MHz, CDCl3): 3.14 (1H, dd, J 14.1, 6.5, CHHPh), 3.19 (1H, dd, J  14.1, 6.6, CHHPh), 4.76 
(1H, dt, J 6.6, 6.5, CHCH2Ph), 7.07 (1H, d, J 8.0, ArH), 7.13-7.27 (6H, m, ArH), 7.42 (1H, dt, J 7.9, 
1.6, ArH), 7.98 (1H, bs, NH), 8.06 (1H, dd, J 7.9, 1.6 ArH), 9.61 (1H, s, CHO). 
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δC (100 MHz, CDCl3): 34.2 (CH2), 60.1 (CH), 117.9 (CH), 123.0 (q), 124.5 (CH), 126.6 (CH), 128.1 
(CH), 128.8 (CH), 131.7 (CH), 132.2 (CH), 135.1 (q), 136.7 (q), 164.0 (q), 198.6 (CH). 
 max (thin film cm-1): 1266 (s), 1447 (m), 1480 (m), 1524 (m), 1598 (s), 1645 (s), 2131 (s), 2848 (w), 
2917 (w). 
 
LRMS (ESI+): Found 295.1 [M+H]+, 611.2 [2M+Na]+. 
 
HRMS (ESI+): Found 295.1190 [M+H]+, C16H15N4O2 requires 295.1190. 
  
8.1.5 Synthesis of (S)-N-(2’-azidobenzoyl)-3-amino-4-phenylbut-1-yne. 
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Scheme 8-5 
 
The aldehyde (266 mg, 0.905 mmol) was dissolved in dry methanol (10 mL); K2CO3 (250 mg, 1.81 
mmol, 2 eq) and the Bestmann-Ohira reagent (208 mg, 1.09 mmol, 1.2 eq) were added. The whole 
was stirred and monitored by TLC (EtOAc:Hex; 3:1) for 6 hours. The reaction was quenched with 
saturated aqueous NH4Cl (10 mL) solution and the organic layer was separated. The aqueous layer 
was extracted with DCM (3 x 10 mL) and the combined organics were dried (MgSO4), filtered, 
concentrated in vacuo to yield a brown oil. Purification by silica chromatography (50 g) 
(EtOAc:Hex; 3:1) yielded the alkyne (212 mg, 81%) as a unstable yellow oil. 
 
δH (400 MHz, CDCl3): 2.26 (1H, d, J  2.4, HCCCH), 2.99 (1H, dd, J  13.4, 7.2, PhCHH), 3.07 (1H, 
dd,  J  13.4, 5.0, PhCHH), 5.13-5.20 (1H, m, HNCHCH2Ph), 7.07 (1H, dd, J 8.0, 0.7, ArH), 7.15 (1H, 
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dt, J 7.6, 1.0, ArH), 7.17-7.31 (5H, m, Ph), 7.40 (1H, dt, J 8.0, 1.6, ArH), 7.68 (1H, bd, J 7.8, NH), 
8.08 (1H, dd, J 7.8, 1.6 ArH). 
 
δC (100 MHz, CDCl3): 40.8 (CH2), 42.9 (CH), 72.3 (q), 82.5 (CH), 118.4 (CH), 124.0 (q), 125.1 
(CH), 127.1 (CH), 128.1 (CH), 130.0 (CH), 132.4 (CH), 132.6 (CH), 136.1 (q), 137.0 (q), 163.4 (q). 
 max (thin film cm-1): 1088 (w), 1165 (m), 1216 (m), 1295 (s), 1445 (m), 1480 (s), 1518 (s), 1597 
(m), 1651 (s), 2131 (s), 2926 (w), 3010 (m), 3303 (s). 
 
MS product decomposed before analysis. 
8.1.6 Synthesis of (S)-3-benzyl-1,2,3-triazolo[1,5-a][1,4]benzodiazepine-5-one. 
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Scheme 8-6 
 
The alkyne (212 mg, 0.731 mmol) was heated to reflux under an atmosphere of nitrogen in CHCl3 
and monitored by TLC (EtOAc:Hex;1:1). After 72 hours the solvent was removed in vacuo and the 
crude was purified by silica chromatography (23 g) (EtOAc:Hex;1:1) to yield the product as a pale 
grey solid (208 mg, 98%). 
 
δH (400 MHz, CDCl3): 3.25-3.33 (2H, m, CH2Ph), 4.70-4.75 (1H, dt, J 6.2, 8.6, CHCH2Ph), 7.19-
7.30 (5H, m, CH2Ph), 7.58 (1H, dt, J 7.7, 1.1, ArH), 7.62 (1H, s, N3CH), 7.73 (1H, dt, J 7.7, 1.5, 
ArH), 8.02 (1H, d, J 8.1, ArH), 8.07 (2H, m, ArH + NH). 
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δC (100 MHz, CDCl3): 46.7 (CH), 60.3 (CH2), 122.9 (CH), 126.4 (q), 127.4 (CH), 128.9 (CH), 129.1 
(CH), 129.8 (CH), 131.8 (CH), 133.2 (CH), 135.5 (q), 139.1 (q) 167.6 (q). 
 max (thin film cm-1): 1215 (s), 1391 (m), 1473 (m), 1487 (m), 1605 (m), 1660 (s), 2925 (w), 3019 
(m), 3188 (m). 
 
LRMS (ESI+): Found 313.1 [M+Na]+, 603.2 [2M+Na]+, 893.3 [3M+Na]+. 
 
HRMS (ESI+): Found 313.1059 [M+Na]+ C17H14N4NaO requires 313.1060. 
8.1.7 Synthesis of (S)-N-(2’-azidobenzenesulfonyl)-alaninol. 
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Scheme 8-7 
 
2-Azidobenzenesulfonyl acid (2.55 g, 12.8 mmol, 3.3 eq) was suspended in 2M solution of (COCl)2 
in DCM (12 mL, 24 mmol, 6.2 eq). DMF (50l) was added and the whole was heated at reflux under 
nitrogen at 80C for 5 hours. The crude product was concentrated under reduced pressure to yield the 
acid chloride as a crude oil which was re-dissolved in fresh DCM (2 x 10 mL), concentrated under 
reduced pressure and finally dissolved in fresh DCM (10 mL) and added to the following reaction 
mixture dropwise. 
 
To a stirring solution of (S)-alaninol (0.30 mL, 289 mg, 3.85 mmol, 1.0 eq) in DCM (10 mL) was 
added K2CO3 (2.08 g, 15.1 mmol, 3.9 eq) in water (5 mL) in one portion and the whole stirred for 5 
mins before the acid chloride solution from above was added. The whole was stirred for 18 hours 
before the organic layer was separated and the aqueous layer was extracted with DCM (3 x 10 mL). 
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The combined organic layers were dried (MgSO4), filtered and solvent was removed in vacuo to 
yield the crude product as a yellow solid. Purification by silica chromatography (50 g) 
(EtOAc:Hex;1:1) yielded the product as a pale yellow solid (802 mg, 81%). 
 
δH (400 MHz, CDCl3): 0.96 (3H, d, J 6.6, CH3), 2.50 (1H, bs, OH), 3.26 (1H, m, NCHCH3), 3.37 
(1H, dd, J 6.0, 11.1, CHHOH), 3.46 (1H, dd, J 4.1, 11.1, CHHOH), 5.41-5.43 (1H, bd, J 6.0, 
SO2NH), 7.18 (1H, t, J 7.7, ArH), 7.23 (1H, d, J 7.7, ArH), 7.52 (1H, t, J 7.8, ArH), 7.89 (1H, d, J  
7.8, ArH). 
 
δC (100 MHz, CDCl3): 17.4 (CH3), 51.9 (CH), 66.0 (CH2), 119.6 (CH), 124.8 (CH), 130.4 (CH), 
130.45 (q), 134.1 (CH), 137.8 (q). 
 max (thin film cm-1): 1146 (m), 1165 (s), 1215 (s), 1289 (m), 1333 (m), 1473 (s), 1578 (m), 1637 (s), 
2134 (s), 3250-3450 (br). 
 
LRMS (ESI+): Found 279.1 [M+Na]+, 535.1 [2M+Na]+. 
 
HRMS (ESI+): Found 279.0521 [M+Na]+, C9H12N4NaO3S requires 279.0522. 
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8.1.8 Attempted synthesis of (S)-N-(2-azidobenzenesulfonyl)-alaninal. 
 
(COCl)2, DMSO,
S
N
N3
O H
OH
Me
O
S
N
N3
O H
O
Me
O
247bi 248bi
Et3N, -78oC
 
Scheme 8-8 
 
A 2M solution of oxalyl chloride in DCM (1.23 mL, 2.45 mmol, 1.2 eq) was diluted with dry DCM 
(2 mL) and cooled to -78C. DMSO (0.348 mL, 383 mg, 4.90 mmol, 2.4 eq) in dry DCM (3 mL) and 
the alcohol (523 mg, 2.04 mmol, 1 eq) in dry DCM (5 mL) were added respectively dropwise over 
15 mins to the cooled solution. Et3N (1.42 mL, 1.03 g, 10.2 mmol, 5 eq) was added dropwise after 
10 mins of stirring at -78C and the whole was allowed to reach room temperature, over a period of 
2 hours. The reaction was quenched with a mixture of Et2O (10 mL) and H2O (10 mL) and the 
organic phase was separated. The aqueous phase was extracted with DCM (3 x 10 mL), the 
combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. Purification by 
silica chromatography gave no identifiable products and all subsequent efforts at oxidation failed.  
 
8.1.9 Synthesis of (S)-N-(2’-azidobenzenesulfonyl)phenylalaninol. 
 
1. (COCl)2, DMF, 
2. L-phenylalaninol,
K2CO3, r.t.
S
OH
N3
O
S
N
N3
O H
OH
Ph
OO
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Scheme 8-9 
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2-Azidobenzenesulfonic acid (1.48 g, 7.45 mmol, 2.5 eq) was suspended in 2M solution of (COCl)2 
in DCM (7.5 mL, 14.9 mmol, 5.0 eq). DMF (50l) was added and the whole heated at reflux under 
nitrogen at 80C for 4 hours. The crude product was concentrated under reduced pressure to yield the 
acid chloride as a crude oil which was re-dissolved in fresh DCM (2 x 10 mL), concentrated under 
reduced pressure and finally dissolved in fresh DCM (10 mL) and added to the following reaction 
mixture dropwise. 
 
To a stirring solution of (S)-phenylalaninol (450 mg, 2.98 mmol, 1 eq) in DCM (15 mL) was added 
K2CO3 (1.64 g, 11.9 mmol, 4 eq) in water (10 mL) in one portion. After 10mins of stirring the acid 
chloride solution from above was added. The whole was stirred for 18 hours before the organic layer 
was separated and the aqueous layer was extracted with DCM (3 x 10 mL). The combined organic 
layers were dried (MgSO4), filtered and the solvent was removed in vacuo. Purification by silica 
chromatography (25 g) (EtOAc:Hex;1:1) yielded the product as a pale yellow solid (769 mg, 81%). 
 
δH (400 MHz, CDCl3): 2.28 (1H, bs, OH), 2.66 (1H, dd, J 8.6, 14.1, PhCHH), 2.82 (1H, dd, J 6.0, 
14.1, PhCHH), 3.35-3.43 (1H, m, NHCHCH2OH), 3.54 (1H, bd, J 10.8, CHHOH), 3.64 (1H, bd J  
10.8, CHHOH), 5.21 (1H, d, J 6.0, NH), 6.91-6.94 (2H, m, CH2PhH), 6.98 (1H, d, J 8.0, ArH), 7.08-
7.11 (3H, m, CH2PhH),  7.13 (1H, t, J 7.8, ArH), 7.45 (1H, dt, J 7.8, 1.5, ArH), 7.84 (1H, dd, J 8.0, 
1.5, ArH). 
 
δC (100 MHz, CDCl3): 37.7 (CH2), 57.3 (CH), 64.6 (CH2), 119.4 (CH), 124.4 (CH), 126.8 (CH), 
128.5 (2 x CH), 128.9 (2 x CH), 129.5 (q), 130.1 (CH), 133.7 (CH), 136.6 (q), 137.6 (q). 
 max (thin film cm-1): 1024 (s), 1050 (m), 1147 (s), 1161 (s), 1224 (w), 1327 (s), 1427 (m), 1471 (s), 
1583 (s), 2138 (s), 3225-3497 (br). 
 
LRMS (ESI+): Found 355.1 [M+Na]+, 687.2 [2M+Na]+. 
 
HRMS (ESI+): Found 355.0819 [M+Na]+, C15H16N4NaO3S requires 355.0835. 
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8.1.10 Synthesis of (S)-N-(2’-azidobenzenesulfonyl)phenylalaninal. 
 
(COCl)2, DMSO,
S
N
N3
O H
OH
Ph
O
S
N
N3
O H
O
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O
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Scheme 8-10 
 
A 2M solution of oxalyl chloride in DCM (0.82 mL, 1.64 mmol, 1.2 eq) was diluted with dry DCM 
(3 mL) and cooled to -78C. DMSO (0.23 mL, 256 mg, 3.28 mmol, 2.4 eq) in dry DCM (3 mL) and 
(S)-N-(2’-azidobenzenesulfonyl)phenylalaninol (440 mg, 1.32 mmol, 1 eq) in dry DCM (5 mL) were 
added dropwise, over 15 mins and the whole was stirred for 10 mins at -78°C. Et3N (0.950 mL, 690 
mg, 6.83 mmol, 5 eq) was added dropwise at -78C and the reaction was allowed to reach room 
temperature over 2 hours. The reaction was quenched with a mixture of Et2O (10 mL) and H2O (10 
mL) and the organic phase was separated. The aqueous phase was extracted with DCM (4 x 10 mL), 
the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo to give a yellow 
oil (820 mg) which was purified by silica chromatography (80 g) (EtOAc:Hex;1:2) to give the 
aldehyde (296 mg, 65%) which was used directly in the next step. 
8.1.11 Synthesis of (S)-N-(2’-azidobenzenesulfonyl)-3-amino-4-phenylbut-1-yne. 
Bestmann Ohira,S N
N3
O H
O
Ph
O
S
N
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O H
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O
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Scheme 8-11 
 
The aldehyde (296 mg, 0.897 mmol, 1 eq) was dissolved in dry methanol (10 mL); K2CO3 (248 mg, 
1.79 mmol, 2 eq) and the Bestmann-Ohira reagent (207 mg, 1.08 mmol, 1.2 eq) were added and the 
whole was stirred for 6 hours. The reaction was quenched with saturated aqueous NH4Cl (10 mL), 
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the organic layer was separated and the aqueous layer was extracted with DCM (4 x 10 mL). The 
combined organic phases were dried (MgSO4), filtered, concentrated in vacuo and purified by silica 
chromatography (30 g) (EtOAc:Hex;1:1) yielding the terminal alkyne (92 mg, 31%) together with 
the cyclised product (48 mg, 16%). 
 
δH (400 MHz, CDCl3): 2.08 (1H, s, HC≡C), 3.05 (1H, dd, J 7.0, 13.5, PhCHH), 3.10 (1H, dd, J 5.7, 
13.5, PhCHH), 4.32-4.39 (1H, m, PhCH2CH), 5.37 (1H, bs, NH), 7.23-7.38 (7H, m, ArH), 7.61 (1H, 
dt, J 7.9, 1.4, ArH), 8.00 (1H, dd, J 7.9, 1.4, ArH). 
  
δC (100 MHz, CDCl3): 42.0 (CH2), 46.5 (CH), 73.5 (CH), 80.7 (q), 119.2 (CH), 127.4 (CH), 128.5 (2 
x CH), 129.8 (2 x CH), 130.0 (q), 130.3 (CH), 134.1 (CH), 135.2 (q), 138.0 (q). 
 
LRMS (ESI+): Found 349.1 [M+Na]+, 675.2 [2M+Na]+. 
 
HRMS (ESI+): Found 349.0720 [M+Na]+, C16H14N4NaO2S requires 349.0730. 
 
8.1.12 Synthesis of 3-benzyl-1,2,3 triazolo[1,5-d][1,2,5]benzodiazepin-5,5-dioxide. 
CHCl3, S N
N3
O H
Ph
O
N
NS
N N
O H
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Scheme 8-12 
 
The terminal alkyne (92 mg, 0.282 mmol) was heated at reflux under nitrogen in CHCl3 (10 mL) and 
monitored by TLC (EtOAc:Hex;1:1). After 72 hours the solvent was removed under reduced 
pressure and purified by silica chromatography (10 g) (EtOAc:Hex;1:1) to yield the product as a pale 
grey solid (91 mg, 99%). 
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δH (400 MHz, CDCl3): 3.03 (1H, dd, J 6.8, 13.8, PhCHH), 3.06 (1H, dd, J  6.9, 13.8, PhCHH), 4.76 
(1H, dd, J  6.9, 6.8, CHCH2Ph), 6.90-6.94 (2H, m, CH2PhH), 7.02-7.10 (3H, m, CH2PhH), 7.44 (1H, 
dt, J 7.7, 1.0, ArH), 7.50 (1H, s, N3CHC), 7.60 (1H, dt, J 7.8, 1.4, ArH), 7.78 (1H, d, J 7.8, 1.0, 
ArH), 7.85 (1H, dd, J 7.7, 1.4, ArH), 8.00 (1H, bs, NH). 
 
δC (100 MHz, CDCl3): 45.8 (CH2), 54.3 (CH), 129.8 (CH), 131.0 (CH), 132.0 (CH), 133.3 (2 x CH), 
133.8 (CH), 134.2 (2 x CH), 137.9 (q), 138.5 (CH), 138.7 (CH), 139.1 (q), 140.0 (q), 140.7 (q). 
 max (thin film cm-1): 1171 (m), 1215 (s), 1380 (m), 1337 (m), 1486 (m), 2922 (w), 3019 (s), 3143 
(w), 3260 (s). 
 
LRMS (ESI+): Found 327.1 [M+H]+. 
 
HRMS (ESI+): Found 327.0910 [M+H]+, C16H15N4O2S requires 327.0910. 
 
8.1.13 Synthesis of (S)-N-(2’-azidobenzoyl)valinol. 
 
1. SOCl2 , 
2. S-valinol,
      K2CO3, r.t.
OH
N3
O
N
N3
O
H
OH
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Me
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Scheme 8-13 
 
2-azidobenzoic acid (295 mg, 1.81 mmol, 1 eq) was heated at reflux under nitrogen in SOCl2 (5 mL) 
at 85C for 3 hours.  The excess SOCl2 was removed under reduced pressure to yield the acid 
chloride as a crude oil which was re-dissolved in fresh DCM (2 x 10 mL), concentrated under 
reduced pressure and finally dissolved in fresh DCM (5 mL) and added to the following reaction 
mixture dropwise. 
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(S)-Valinol (400 mg, 3.88 mmol, 2.15 eq) was dissolved in DCM (10 mL) and to this K2CO3 (1.00 g, 
7.23 mmol, 4 eq) in water (5 mL) was added in one portion. The acid chloride in DCM (5 mL) was 
added dropwise and the whole was stirred overnight. The organic phase was separated and the 
aqueous phase extracted with DCM (3 x 10 mL). The combined organic layers were dried (MgSO4), 
filtered, concentrated under reduced pressure and purified by silica chromatography (30 g) 
(EtOAc:Hex; 3:2) to give the product as a black oil (394 mg, 88%). 
 
δH (400 MHz, CDCl3): 0.92 (3H, d, J 6.8, CH3CHCH3), 0.93 (3H, d, J 6.8, CH3CHCH3), 1.93 (1H, 
oct, J 6.8, CH(CH3)2), 3.53 (1H, bs, OH), 3.61-3.69 (2H, m, CH2OH), 3.84-3.91 (1H, m, NHCH), 
7.06 (1H, d, J 8.1, ArH), 7.11 (1H, t, J 7.9, ArH), 7.38 (1H, dt, J 8.1, 1.5, ArH), 7.55 (1H, bd, J 8.0, 
NH), 7.95 (1H, dd, J 7.9, 1.4, ArH). 
 
δC (100 MHz, CDCl3): 18.7 (CH3), 19.7 (CH3), 29.0 (CH), 57.9 (CH), 63.8 (CH2), 118.4 (CH), 125.0 
(q), 125.1 (CH), 132.1 (CH), 132.4 (CH), 137.0 (q), 165.6 (q). 
 max (thin film cm-1): 755 (s), 908 (s), 1216 (m), 1277 (m), 1480 (s), 1536 (s), 1598 (m), 1641 (s), 
2130 (s), 2875 (m), 2964 (s), 3010 (m), 3200-3500 (br). 
 
LRMS (ESI+): Found 271.1 [M+Na]+, 519.2 [2M+Na]+. 
 
HRMS (ESI+): Found 271.1154 [M+Na]+, C12H16N4NaO2 requires 271.1165. 
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8.1.14 Synthesis of (S)-N-(2’-azidobenzoyl)valinol. 
 
N
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Scheme 8-14 
 
2M oxalyl chloride in DCM (0.86 mL, 1.73 mmol, 1.2 eq) was diluted with DCM (3 mL) and cooled 
to -78C. DMSO (0.245 mL, 270 mg, 3.45 mmol, 2.4 eq) in dry DCM (3 mL) and the alcohol (357 
mg, 1.44 mmol, 1 eq) in dry DCM (5 mL) were added dropwise, over 15 mins and the whole was 
stirred for 10 mins.  Et3N (1.00 mL, 726 mg, 7.20 mmol, 5.0 eq) was added dropwise and the whole 
was allowed to reach room temperature over an hour before being quenched with a mixture of Et2O 
(10 mL) and H2O (10 mL). The organic layer was separated and the aqueous phase was extracted 
with DCM (4 x 10 mL). The combined organic layers were dried (MgSO4), filtered, concentrated 
under reduced pressure and purified by silica chromatography (50 g) (EtOAc:Hex; 1:1) to yield the 
product as a yellow oil (177 mg, 50%). 
 
δH (400 MHz, CDCl3): 0.99 (3H, d, J 7.0, CH3CHCH3), 1.01 (3H, d, J 7.0, CH3CHCH3), 2.37 (1H, 
dsept, J 7.0, 4.5, (CH3)2CH), 4.67 (1H, dd, J 7.4, 4.5, NHCH), 7.15 (1H, d, J 7.9, ArH), 7.17 (1H, t, 
J 7.6, ArH), 7.44 (1H, dt, J 7.6, ArH), 7.97 (1H, bd, J 6.5, NH), 8.06 (1H, d, J 7.9, ArH), 9.64 (1H, s, 
CHO). 
 
δC (100 MHz, CDCl3): 17.3 (CH3), 18.5 (CH3), 28.4 (CH), 63.5 (CH), 117.7 (CH), 123.6 (q), 124.5 
(CH), 131.6 (CH), 132.0 (CH), 136.3 (q), 164.1 (q), 199.3 (CH). 
 max (thin film cm-1): 909 (s), 1277 (m), 1481 (m), 1526 (s), 1598 (s), 1651 (s), 1732 (s), 2131 (s), 
2967 (m), 3379 (m). 
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LRMS (ESI+): Found 515.2 [2M+Na]+. 
 
HRMS (ESI+): 515.2127 [2M+Na]+, C24H28N8NaO4 requires 515.2126. 
 
8.1.15 Synthesis of (S)-N-(2’-azidobenzoyl)-3-amino-4-methylpent-1-yne. 
 
N
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Scheme 8-15 
 
The aldehyde (118 mg, 0.480 mmol, 1 eq) was dissolved in dry MeOH (6 mL) to which K2CO3 (132 
mg, 0.959 mmol, 2 eq) and the Bestmann-Ohira reagent (111 mg, 0.576 mmol, 1.2 eq) were added. 
After 4 hours the reaction was quenched with saturated aqueous NH4Cl (10 mL), the organic layer 
was separated and the aqueous phase was extracted with DCM (4 x 10 mL). The combined organic 
phases were dried, filtered, concentrated under reduced pressure and purified by silica 
chromatography (20 g) (EtOAc:Hex;1:3) yielding the alkyne as a yellow solid (90 mg, 78%). 
 
δH (400 MHz, CDCl3): 0.99 (6H, d, J 6.8, (CH3)2CH), 1.99 (1H, dsept, J 6.8, 5.6, CH(CH3)2), 2.22 
(1H, d, J 2.4, HC≡C), 4.79 (1H, ddd, J 2.4, 5.6, 8.1, NHCH), 7.10 (1H, dd, J 8.0, 0.9, ArH), 7.14 
(1H, dt, J 7.9, 0.9, ArH), 7.41 (1H, dt, J 8.0, 1.6, ArH), 7.66 (1H, bd, J 8.1, NH), 8.05 (1H, dd, J 7.9, 
1.6, ArH). 
 
δC (100 MHz, CDCl3): 17.7 (CH3), 18.9 (CH3), 32.6 (CH), 47.5 (CH), 72.0 (CH), 81.7 (q), 118.4 
(CH), 124.5 (q), 125.2 (CH), 132.4 (CH), 132.6 (CH), 137.0 (q), 163.6 (q). 
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max (thin film cm-1): 1060 (m), 1087 (m), 1153 (m), 1369 (m), 1445 (m), 1481 (s), 1525 (s), 1598 
(s), 1650 (s), 2129 (s), 2417 (w), 2873 (m), 2930 (m), 2963 (s), 3067 (w). 
 
LRMS (ESI+): Found 265.1 [M+Na]+, 507.2 [2M+Na]+. 
 
HRMS (ESI+): Found 265.1053 [M+Na]+ requires C13H14N4NaO 265.1060. 
 
8.1.16 Synthesis of 3-isoproyl-1,2,3-triazolo[1,5-a][1,4]benzodiazepine-5-one. 
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Scheme 8-16 
 
The alkyne (73 mg, 0.30 mmol) was heated at reflux at 75C in CHCl3 (10 mL) under a dry 
atmosphere of nitrogen for 72 hours. The reaction was cooled to room temperature and the solvent 
was removed in vacuo. Purification by silica chromatography (10 g) (EtOAc:Hex; 1:1) yielded the 
cyclised product as a pale yellow solid (72 mg, 99%). 
 
δH (400 MHz, CDCl3): 1.00 (3H, d, J 6.0, CH3CHCH3), 1.18 (3H, d, J 6.6, CH3CHCH3), 2.23 (1H, 
bm, CH3CHCH3), 4.13 (1H, dd, J 6.4, 8.9, NHCH), 7.59 (1H, dt, J 7.7, 1.1, ArH), 7.68 (1H, s, 
CHN3), 7.74 (1H, dt, J  8.0, 1.5, ArH), 8.05 (1H, dd, J 8.0, 0.8, ArH), 8.11 (2H, dd + brs, J 7.7, 1.5, 
ArH + CHNH).  
 
δC (100 MHz, CDCl3): 19.2 (CH3), 20.3 (CH3), 29.3 (CH), 52.2 (CH), 123.0 (CH), 126.2 (q), 129.1 
(CH), 130.6 (CH), 131.7 (CH), 133.3 (CH), 133.5 (q), 138.4 (q), 168.1 (q). 
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max (thin film cm-1): 754 (s), 842 (m), 990 (m), 1245 (m), 1350 (m), 1395 (s), 1469 (s), 1580 (m), 
1605 (m), 1651 (s), 2860 (w), 2958 (w), 3047 (m), 3174 (m). 
 
LRMS (ESI+): Found 265.1 [M+Na]+, 507.2 [2M+Na]+. 
 
HRMS (ESI+): Found 265.1064 [M+Na]+, C13H14N4NaO requires 265.1060. 
 
8.1.17 Synthesis of (S)-N-(2’-azidobenzenesulfonyl)valinol. 
 
2. S-valinol,
      K2CO3, r.t.
1. (COCl)2, 
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Scheme 8-17 
 
2-Azidobenzenesulfonic acid (1.24 g, 6.25 mmol, 2.5 eq) was suspended in 2M oxalyl chloride in 
DCM (6.25 mL, 12.5 mmol, 5.0 eq) and a drop of DMF was added. The whole was heated at reflux 
under nitrogen for 4 hours before the excess oxalyl chloride was removed under reduced pressure to 
yield the acid chloride as a crude oil which was re-dissolved in fresh DCM (2 x 10 mL), 
concentrated under reduced pressure and finally dissolved in fresh DCM (10 mL) and added to the 
following reaction mixture dropwise. 
 
To a stirring solution of (S)-valinol (258 mg, 2.5 mmol, 1.0 eq) in DCM (15 mL), K2CO3 (1.38 g, 10 
mmol, 4 eq) in water (10 mL) was added in one portion and the acid chloride in DCM (10 mL) was 
added dropwise. The whole was stirred overnight before the organic layer was separated and the 
aqueous phase was extracted with DCM (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered, concentrated under reduced pressure and purified by silica chromatography (50 g) 
(EtOAc:Hex; 1:2) giving the alcohol as a yellow-orange solid (384 mg, 55%). 
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δH (400 MHz, CDCl3): 0.76 (3H, d, J 6.9, CHCH3CH3), 0.79 (3H, d, J 6.9, CHCH3CH3), 1.76 (1H, 
oct, J 6.9, CH[CH3]2,) 2.20 (1H, bs, CH2OH), 2.94-3.00 (1H, m, NHCH), 3.35-3.42 (1H, m, 
CHHOH), 3.48-3.52 (1H, m, CHHOH), 5.37 (1H, bd, J 8.2, SO2NH), 7.16 (1H, dt, J 7.6, 0.9, ArH), 
7.22 (1H, dd, J 8.0, 0.9, ArH), 7.51 (1H, dt, J 7.6, 1.4, ArH), 7.87 (1H, dd, J 8.0, 1.4, ArH). 
 
δC (100 MHz, CDCl3): 18.6 (CH3), 19.0 (CH3), 29.5 (CH), 61.5 (CH), 62.5 (CH2), 119.6 (CH), 124.7 
(CH), 130.0 (CH), 130.9 (q), 133.9 (CH), 137.8 (q). 
 max (thin film cm-1): 909 (s), 1042 (m), 1067 (m), 1216 (m), 1324 (m), 1472 (s), 1575 (s), 2101 (s), 
2926 (m), 2965 (m), 3021 (m), 3163 (w), 3400-3600 (br). 
 
LRMS (ESI+): Found 307.1 [M+Na]+, 591.2 [2M+Na]+. 
 
HRMS (ESI+): Found 307.0821 [M+Na]+, C11H16N4NaO3S requires 307.0835. 
 
8.1.18 Synthesis of (S)-N-(2’-azidobenzenesulfonyl)valinal. 
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Scheme 8-18 
 
2M oxalyl chloride in DCM (0.81 mL, 1.62 mmol, 1.2 eq) was diluted with DCM (3 mL) and cooled 
to -78C. DMSO (0.23 mL, 253 mg, 3.24 mmol, 2.4 eq) in dry DCM (3 mL) and the alcohol (384 
mg, 1.35 mmol, 1 eq) in dry DCM (5 mL) were added dropwise, over 15 minutes and the whole was 
stirred for 10 mins. Et3N (0.94 mL, 684 mg, 6.76 mmol, 5.0 eq) was added and the reaction was 
allowed to reach room temperature before being quenched with a mixture of Et2O (10 mL) and H2O 
Chapter 8  Experimental Part II 
142 
 
(10 mL). The organic layer was separated and the aqueous phase was extracted with DCM (4 x 10 
mL). The combined organic layers were dried (MgSO4), filtered, concentrated under reduced 
pressure and purified by silica chromatography (50 g) (EtOAc:Hex; 1:1) to yield the product as an 
unstable white solid (284 mg, 75%).  
 
δH (400 MHz, CDCl3): 0.86 (3H, d, J  6.9, CH3), 0.99 (3H, d, J  6.9, CH3), 2.20 (1H, dsept, J  6.9, 4.0, 
CH[CH3]2), 3.75 (1H, dd, J 4.0, 7.3, CHCHO), 5.83 (1H, bd, J 7.3, NH), 7.14 (1H, dt, J  7.7, 1.0, 
ArH), 7.22 (1H, dd, J  8.0, 1.0, ArH), 7.51 (1H, t, J  7.7, 1.5,  ArH), 7.81 (1H, d, J 8.0, 1.5, ArH), 9.38 
(1H, s, CHO). 
 
δC (100 MHz, CDCl3): 17.3 (CH3), 18.9 (CH3), 29.5 (CH), 67.3 (CH), 119.6 (CH), 124.5 (CH), 129.7 
(q), 130.1 (CH), 134.2 (CH), 138.2 (q), 198.4 (CH). 
 max (thin film cm-1): 759 (s), 1170 (s), 1290 (m), 1348 (m), 1472 (s), 1586 (m), 1730 (s), 2135 (s), 
2968 (m), 3020 (s), 3310 (w). 
 
LRMS (ESI+): Found 305.1 [M+Na]+, 587.1 [2M+Na]+, C11H14N4NaO3 requires 305.1. 
 
HRMS: decomposed before analysis was possible. 
 
8.1.19 Synthesis of 3-isoproyl-1,2,3-triazolo [1,5-d][1,2,5]benzothiadiazepin-5,5-dioxide. 
 
Bestmann Ohira,S N
N3
O H
O
O
Me
Me
S
N
N3
O H
N
NS
N N
O HOO
Me
Me Me
Me
248biii 249biii 250biii
K2CO3, MeOH, r.t.
 
Scheme 8-19 
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The aldehyde (244 mg, 0.865 mmol, 1.0 eq) was dissolved in MeOH (10 mL), K2CO3 (239 mg, 1.73 
mmol, 2.0 eq) and the Bestmann-Ohira reagent (200 mg, 1.04 mmol, 1.2 eq) were added and the 
whole was stirred at room temp for 6 hours. The reaction was quenched with saturated aqueous 
NH4Cl (10 mL). The organic phase was separated and the aqueous phase was extracted with DCM (4 
x 10 mL). The combined organic layers were dried (MgSO4), filtered, concentrated and purified by 
silica chromatography (30 g) (EtOAc:Hex; 1:1) giving the cyclised product as a white solid (131 mg, 
54%). 
 
δH (400 MHz, CDCl3): 0.90 (3H, d, J  6.7, CH3), 1.04 (3H, d, J  6.7, CH3), 2.18 (1H, dsept, J  5.3, 6.7, 
CH[CH3]2), 4.58 (1H, m, NHCH), 5.35 (1H, bs, NH), 7.62 (1H, dt, J 7.8, 1.4, ArH), 7.77 (1H, s, 
CHN3), 7.80 (1H, dt, J 7.8, 1.4, ArH), 8.05 (1H, dd, J 8.0, 1.2, ArH), 8.10 (1H, dd, J 8.0, 1.2, ArH). 
 
δC (100 MHz, CDCl3): 17.7 (CH3), 18.9 (CH3), 32.8 (CH), 54.5 (CH), 125.4 (CH), 126.7 (CH), 129.2 
(CH), 133.5 (q), 133.9 (q), 134.2 (CH), 134.4 (CH), 135.1 (q). 
 max (thin film cm-1): 734 (s), 760 (s), 908 (s), 1101 (w), 1172 (m), 1215 (s), 1337 (m), 1370 (m), 
1483 (w), 1590 (w), 2876 (w), 3019 (m). 
 
LRMS (ESI+): Found 301.1 [M+Na]+, 579.2 [2M+Na]+. 
 
HRMS (ESI+): Found 301.0717 [M+Na]+, C12H14N4NaO2S requires 301.0730. 
8.1.20 Synthesis of (S)-N-(2’-azidobenzoyl)tryptophanol. 
 
1. SOCl2, 
2. L-tryptophenol,
K2CO3, r.t.
OH
N3
O
N
N3
O
H
OH
N
H247aiv232a
 
Scheme 8-20 
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Azidobenzoic acid (252 mg, 1.55 mmol, 1 eq) was heated at reflux under nitrogen at 85°C in SOCl2 
(5 mL) for 3 hours. The excess SOCl2 was removed under reduced pressure to yield the acid chloride 
as a crude oil which was re-dissolved in fresh DCM (2 x 10 mL), concentrated under reduced 
pressure and finally dissolved in fresh DCM (5 mL). 
 
K2CO3 (854 mg, 6.2 mmol, 4 eq) in water (5 mL) was added in one portion to a stirring solution of 
L-tryptophanol (500 mg, 2.63 mmol, 1.7 eq) in DCM (10 mL). The crude acid chloride in DCM (5 
mL) was added dropwise and the whole was stirred overnight. The organic layer was separated and 
the aqueous phase was extracted with DCM (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered, concentrated under reduced pressure and purified by silica chromatography (40 g) 
(EtOAc: Hex; 4:1) yielding the product as a fluffy yellow solid (497 mg, 90%). 
 
δH (400 MHz, CDCl3): 3.13 (1H, dd, J 6.9, 15.0, CHHCHNH), 3.17 (1H, dd, J  6.9, 15.0, 
CHHCHNH), 3.56 (1H, bs, OH), 3.75-3.85 (2H, m, CH2OH), 4.49-4.57 (1H, m, NHCHCH2OH), 
7.08 (1H, d, J 7.8, ArH), 7.10 (1H, s, ArH), 7.14 (1H, t, J 7.0, ArH), 7.19 (1H, t, J 7.8, ArH), 7.20 
(1H, t, J  7.0, ArH), 7.37 (1H, d, J 8.0, ArH), 7.45 (1H, dt, J 8.0, 1.5, ArH), 7.72 (1H, d, J  7.8, ArH), 
7.83 (1H, bd, J 6.9, CONHCH), 8.11 (1H, dd, J 7.8, 1.5, ArH), 8.47 (1H, bs, ArNH). 
 
δC (100 MHz, CDCl3): 26.5 (CH2), 53.3 (CH), 64.9 (CH2), 111.2 (CH), 111.3 (q), 118.3 (CH), 118.7 
(CH), 119.5 (CH), 122.1 (CH), 123.0 (CH), 124.5 (q), 125.0 (CH), 127.6 (q), 132.0 (CH), 132.4 
(CH), 136.2 (q), 137.0 (q), 165.5 (q). 
 max (thin film cm-1): 1215 (s), 1281 (m), 1457 (m), 1480 (m), 1529 (s), 1598 (m), 1636 (s), 2131 (s), 
2928 (w), 3019 (m), 3200-3500 (br). 
 
LRMS (ESI+): Found 358.1 [M+Na]+, 693.3 [2M+Na]+. 
 
HRMS (ESI+): Found 358.1273 [M+Na]+, C18H17N5NaO2 requires 358.1274. 
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8.1.21 Synthesis of (S)-N-(2’-azidobenzoyl)tryptophanal. 
 
(COCl)2, DMSO,N
N3
O
H
OH
N
H
N
N3
O
H
O NH247aiv 248aiv
Et3N, -78oC
 
Scheme 8-21 
 
2M oxalyl chloride in DCM (0.86 mL, 1.73 mmol, 1.2 eq) was diluted with DCM (3 mL) and cooled 
to -78°C. DMSO (0.24 mL, 269 mg, 3.44 mmol, 2.4 eq) in dry DCM (3 mL) and the alcohol (481 
mg, 1.44 mmol, 1 eq) in DCM (5 mL) were added respectively dropwise over 15 minutes. Et3N 
(1.00 mL, 726 mg, 7.18 mmol, 5 eq) was added after 10 mins stirring at -78°C. The whole was 
allowed to reach room temperature over an hour, before being quenched with a mixture of Et2O (10 
mL) and H2O (10 mL). The organic layer was separated and the aqueous phase was extracted with 
DCM (4 x 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated in 
vacuo. Purification by silica chromatography (50 g) (EtOAc:Hex;1:2) yielded the product as a 
yellow solid (33 mg, 7%) which was highly unstable and so was used quickly in the next step. 
 
δH (400 MHz, CDCl3): 3.36 (1H, dd, J 6.4, 14.9, CHHCHNHCO), 3.49 (1H, dd, J  6.4, 14.9, 
CHHCHNHCO), 4.95 (1H, q, J 6.4, CH2CHNHCO), 7.10 (1H, s, ArH indole), 7.11 (1H, d, J 8.2, 
ArH), 7.14 (1H, t, J 8.1, ArH), 7.21 (1H, t, J  8.1, ArH), 7.23 (1H, t, J 7.8, ArH), 7.37 (1H, d, J 8.0 
ArH), 7.49 (1H, dt, J 7.7, 1.6, ArH), 7.66 (1H, d, J 7.9, ArH), 8.17 (1H, dd, J  7.9, 1.6, ArH), 8.20 
(1H, bs, NH), 8.42 (1H, bs, ArNH), 9.71 (1H, s, CHO). 
 
δC (100 MHz, CDCl3): 24.8 (CH2), 60.2 (CH), 109.8 (q), 111.4 (CH), 118.4 (CH), 118.7 (CH), 119.9 
(CH), 122.5 (CH), 123.2 (CH), 123.8 (q), 125.1 (CH), 127.3 (q), 132.3 (CH), 132.9 (CH), 136.2 (q), 
137.5 (q), 164.8 (q), 200.3 (CH). 
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max (thin film cm-1): 1215 (s), 1278 (m), 1480 (m), 1525 (m), 1598 (m), 1643 (s), 2131 (s), 3019 
(m). 
 
MS: Product decomposed before analysis was possible. 
8.1.22 Synthesis of 3-(3’-methyltryptophano)-1,2,3-triazolo[1,5-d][1,4]benzodiazepin-5-one. 
 
Bestmann Ohira,N
N3
O
H
O NH
N
N3
O
H
N
N
N N
O H
N
H NH248aiv 249aiv 250aiv
K2CO3, MeOH, r.t.
 
Scheme 8-22 
The aldehyde (33 mg, 0.1 mmol, 1 eq) was dissolved in dry MeOH (5 mL), and K2CO3 (27 mg, 0.2 
mmol, 2 eq) and the Bestmann-Ohira reagent (23 mg, 0.12 mmol, 1.2 eq) were added. After 24 hours 
of stirring at room temperature, the reaction was quenched with saturated aqueous NH4Cl   (5 mL). 
The organic layer was separated and the aqueous layer was extracted with DCM (3 x 5ml). The 
combined organic layers were dried (MgSO4), filtered, concentrated under reduced pressure and 
purified by silica chromatography (15 g) (EtOAc:Hex; 1:2) to yield the cyclised product as an orange 
solid (11 mg, 33%). 
 
δH (400 MHz, CDCl3): 3.35 (1H, dd, J  9.9, 14.9, CHHCH), 3.60 (1H, dd, J 4.8, 14.9, CHHCH), 4.77 
(1H, dt, J 4.8, 9.9, CHCH2), 6.67 (1H, bs, CONH), 7.05 (1H, dt, J  7.9, 0.8, ArH), 7.07 (1H, s, ArH 
indole), 7.17 (1H, dt, J 7.6, 0.8, ArH), 7.33 (1H, d, J 8.2, ArH), 7.43 (1H, d, J 8.2, ArH), 7.49 (1H, 
dt, J 7.6, 1.0 ArH), 7.66 (1H, dt, J 7.9, 1.5, ArH), 7.70 (1H, s, N3CH), 7.97 (1H, dd, J 7.9, 1.5, ArH), 
8.00 (1H, dd, J 8.2, 1.0, ArH), 8.23 (1H, bs, ArNH). 
 
δC (100 MHz, CDCl3): 29.7 (CH2), 53.1 (CH), 108.9 (q), 111.7 (CH), 118.0 (CH), 120.0 (CH), 122.8 
(CH), 123.1 (CH), 123.4 (CH), 125.7 (q), 126.6 (q), 129.1 (CH), 129.6 (CH), 132.1 (CH), 133.3 (q), 
133.4 (CH), 136.5 (q), 139.3 (q), 167.5 (q).  
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 max (thin film cm-1): 1041(m), 1215 (s), 1458 (w), 1656 (s), 2854 (w), 2927 (m). 
 
LRMS (ESI+): Found 330.1 [M+H]+. 
 
HRMS (ESI+): Found 330.1348 [M+H]+, C19H16N5O requires 330.1349. 
 
8.2 Cycloaddition Reactions involving nitriles. 
8.2.1 Synthesis of N-(2’-azidobenzoyl)phenylalanine. 
 
2. L-phenylalanine,
K2CO3, r.t.
1. SOCl2, OH
N3
O
N
N3
O
H
OH
Ph
O
232a 251a
 
Scheme 8-23 
 
2-Azidobenzoic acid (560 mg, 3.43 mmol, 1.0 eq) was heated at reflux under nitrogen in SOCl2 (8 
mL) for 4 hours. The reaction was allowed to reach room temperature before the excess SOCl2 was 
removed under reduced pressure to yield the acid chloride as a crude oil which was re-dissolved in 
fresh DCM (2 x 10 mL), concentrated under reduced pressure and finally dissolved in fresh DCM (5 
mL). 
 
K2CO3 (1.90 g, 13.7 mmol, 4 eq) in water (5 mL) was added in one portion to L-phenylalanine (963 
mg, 5.83 mmol, 1.7 eq) in DCM (10 mL). The acid chloride in DCM (5 mL) was added dropwise 
and the whole was stirred overnight before the mixture was acidified to pH 2 with 2M HCl. The 
organic phase was separated and the aqueous phase was extracted with DCM (3 x 10 mL). The 
combined organic layers were dried (MgSO4), filtered, concentrated under reduced pressure to give a 
black oil (1.01 g, 95%) which was not purified any further. 
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δH (500 MHz, CDCl3): 3.30 (1H, dd, J 14.0, 6.3, PhCHHCH), 3.37 (1H, dd, J 14.0, 5.6, PhCHHCH), 
5.10 (1H, dt, J 6.3, 5.6, PhCH2CHNH), 7.16 (1H, d, J 8.0, ArH), 7.25 (1H, t, J 7.7, ArH), 7.27-7.38 
(5H, m, CH2ArH), 7.51 (1H, dt, J 7.7, 1.5, ArH), 8.06 (1H, bd, J 6.9, NH), 8.16 (1H, dd, J 8.0, 1.5, 
ArH), 10.26 (1H, bs, COOH). 
 
δC (125MHz, CDCl3): 37.1 (CH2), 54.3 (CH), 118.5 (CH), 123.5 (q), 125.2 (CH), 127.4 (CH), 128.6 
(CH), 129.5 (CH), 132.4 (CH), 132.9 (CH), 135.7 (q), 137.4 (q), 164.8 (q), 175.5 (q). 
 max (thin film cm-1): 733 (s), 908 (s), 1217 (m), 1279 (s), 1481 (m), 1532 (s), 1597 (m), 1642 (s), 
1724 (s), 2132 (s), 2929 (m), 3030 (m), 3351 (bm). 
 
LRMS (ESI+): Found 333.1 [M+Na]+, 643.2 [2M+Na]+.  
 
HRMS (ESI+): Found 333.0944 [M+Na]+, C16H14N4NaO3 requires 333.0958. 
 
8.2.2 Synthesis of N-(2’-azidobenzoyl)phenylalanamide. 
N
N3
O
H
OH
Ph
O
N
N3
O
H
O
PhMethod B
BOP, NH4Cl, Et3N,  
H2N
Method A
SOCl2, NH3, 
251a 252a
 
Scheme 8-24 
 
Method A: The phenylalanine coupled product (380 mg, 1.23 mmol, 1 eq) was heated at reflux in 
SOCl2 (4 mL) under nitrogen for 4 hours. The excess SOCl2 was removed under reduced pressure 
and the crude acid chloride was dissolved in DCM and re-concentrated (3 x 10 mL). Concentrated 
ammonia solution (2 mL) was added dropwise to the crude acid chloride in dry THF (~10 mL) and 
the whole was stirred overnight before saturated aqueous NH4Cl solution (20 mL) was added. The 
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organic phase was separated and the aqueous phase was extracted with EtOAc (3 x 10 mL). The 
combined organics where dried (MgSO4), filtered, concentrated and purification by silica 
chromatography (23 g) (EtOAc:Hex; 4:1) afforded a yellow solid (146 mg) from which no products 
could be identified. 
 
Method B: The carboxylic acid (325 mg, 1.05 mmol, 1 eq) was dissolved in dry DCM (5 mL), 
followed by the addition of Et3N (0.146 mL, 106 mg, 1.05 mmol, 1 eq) and BOP (464 mg, 1.05 
mmol, 1 eq). The whole was stirred for 5 mins before NH4Cl (solid) (84 mg, 1.58 mmol, 1.5 eq) and 
Et3N (0.22 mL, 160 mg, 1.58 mmol, 1.5 eq) were added. After 3 hours of stirring at ambient 
temperature, the reaction was diluted with DCM (15 mL), washed with 3M HCl (3 x 10 mL), 
saturated sodium carbonate solution (3 x 10 mL) and brine (3 x 10 mL). The organic phase was dried 
(MgSO4), filtered, concentrated under reduced pressure and purified by silica chromatography (20 g) 
(EtOAc:Hex; 3:1) to yield the product as a yellow solid (232 mg, 72%). 
 
δH (400 MHz, CDCl3): 2.96-3.05 (2H, m, PhCH2CH), 4.71 (1H, dt, J 6.7, 7.2, PhCH2CH), 5.98 (1H, 
bs, CONHH), 6.61 (1H, bs, CONHH), 6.90-7.10 (7H, m, ArH), 7.28 (1H, dt, J 7.8, 1.6, ArH), 7.75 
(1H, dd, J 7.8, 1.6, ArH), 7.82 (1H, bd, J 7.3, NHCHCH2Ph). 
 
δC (100 MHz, CDCl3): 37.9  (CH2), 54.8 (CH), 118.5 (CH), 124.7 (q), 125.0 (CH), 126.9 (CH), 128.4 
(CH), 129.5 (CH), 131.7 (CH), 132.4 (CH), 136.7 (q), 137.3 (q), 164.6 (q), 173.3 (q). 
 max (thin film cm-1): 909 (s), 988 (s), 1199 (s), 1249 (s), 1299 (s), 1479 (s), 1523 (m), 1642 (s), 1696 
(s), 1731 (s), 2132 (s), 2930 (s), 2999 (m), 3190 (m), 3365 (m). 
 
LRMS (ESI+): Found 332.1 [M+Na]+. 
 
HRMS (ESI+): Found 332.1110 [M+Na]+,  C16H15N5NaO requires 322.1118. 
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8.2.3 Synthesis of N-(2’-azidobenzoyl)-2-amino-3-phenylpropionitrile. 
 
N
N3
O
H
O
Ph
H2N
N
N3
O
H
N
Ph
Pyridine,
252a 253a
Tosyl chloride, 
 
Scheme 8-25 
 
To the amide (563 mg, 1.82 mmol, 1 eq) in dry DCM (12 mL) at room temp was added pyridine 
(0.737 mL, 721 mg, 9.1 mmol, 5 eq) followed by neat tosyl chloride (694 mg, 3.64 mmol, 2 eq) and 
the reaction was heated at reflux under nitrogen for 48 hours. The reaction was allowed to cool to 
room temperature before being quenched with saturated aqueous NH4Cl (30 mL). The organic layer 
was separated and the aqueous phase was extracted with DCM (3 x 10 mL). The combined organics 
were dried (MgSO4), filtered, concentrated and purified by silica chromatography (24 g) 
(EtOAc:Hex; 2:1) yielding a yellow solid (345 mg, 65%). 
 
δH (400 MHz, CDCl3): 3.19 (1H, dd, J 6.9, 13.8, PhCHH), 3.29 (1H, dd, J  5.2, 13.8, PhCHH), 5.37 
(1H, ddd, J 5.2, 6.9, 7.8, PhCH2CH), 7.19 (1H, dd, J 8.0, 0.8, ArH), 7.28 (1H, dt, J 7.7, 1.0, ArH), 
7.37-7.46 (5H, m, ArH), 7.56 (1H, dt, J 7.7, 1.6, ArH), 8.04 (1H, bd, J 7.8, CONH), 8.23 (1H, dd, J 
8.0, 1.6, ArH). 
 
δC (100 MHz, CDCl3): 38.5 (CH2), 42.1 (CH), 118.2 (q), 118.5 (CH), 122.7 (q), 125.4 (CH), 128.2 
(CH), 128.9 (CH), 129.8 (CH), 132.8 (CH), 133.4 (CH), 134.0 (q), 137.3 (q), 163.8 (q). 
 max (thin film cm-1): 1266 (s), 1296 (s), 1483 (m), 1520 (s), 1578 (w), 1597 (s), 1658 (s), 3058 (w), 
3272 (m). 
 
LRMS (ESI+): Found 314.1 [M+Na]+, 605.2 [2M+Na]+. 
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HRMS (ESI+): Found 314.1017 [M+Na]+, C16H13N5NaO  requires 314.1012. 
8.2.4 Synthesis of 2-amino-3-benzyl-1,4-benzodiazepin-5-one. 
 
N
N3
O
H
N
Ph N
N
O H
PhMethod A: Xylene, 
NH2
Method B: Toluene,
 CuCl, 
253a 259a
 
Scheme 8-26 
Method A: The nitrile (141 mg, 0.485 mmol) was heated at reflux in xylene (10 mL) under nitrogen 
at 175C for 36 hours. The reaction was allowed to reach room temperature before being 
concentrated and purified by silica chromatography (20 g) (EtOAc:Hex; 1:3) giving the product as a 
yellow oil (18 mg, 14%). 
 
Method B:  The nitrile (204 mg, 0.7 mmol) was heated at reflux under nitrogen in toluene for 5 days 
with the addition of copper (I) chloride (10 mg). The reaction was concentrated and purified by silica 
chromatography (22 g) (EtOAc:Hex;1:3) to yield the product as a yellow oil (14 mg, 8%). 
 
δH (400 MHz, CDCl3): 3.17 (1H, dd, J 7.2, 13.8, PhCHH), 3.23 (1H, dd, J  5.8, 13.8, PhCHH), 5.21-
5.24 (1H, m, PhCH2CH), 5.58 (2H, bs, NCNH2), 6.48 (1H, bd, J 8.2, CONHCH), 6.63 (1H, t, J 7.1, 
ArH), 6.69 (1H, d, J 8.2, ArH), 7.19-7.45 (7H, m, ArH).   
 
δC (100 MHz, CDCl3): 38.8 (CH2), 41.7 (CH), 113.5 (q), 114.8 (CH), 116.7 (CH), 117.6 (q), 127.2 
(CH), 128.0 (CH), 128.9 (CH), 129.5 (CH), 133.3 (CH), 134.0 (q), 149.3 (q), 168.3 (q). 
 max (thin film cm-1): 698 (s), 747 (s), 1159 (m), 1256 (s), 1295 (m), 1454 (m), 1496 (s), 1514 (s), 
1586 (s), 1612 (s), 1650 (s), 2853 (w), 2923 (s), 3025 (w), 3357 (m), 3474 (w). 
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LRMS (ESI+): Found 266.1 [M+H]+, 531.3 [2M+H]+. 
 
HRMS (ESI+): Found 266.1270 [M+H]+, C16H16N5O requires 266.1288. 
8.2.5 Synthesis of N-(2’-azidobenzoyl)-valine. 
 
2.  L-valine,
    K2CO3, r.t.
1. SOCl2 , OH
N3
O
N
N3
O
H
OH
Me
Me
O
232a 251b
 
Scheme 8-27 
 
2-Azidobenzoic acid (396 mg, 2.43 mmol, 1 eq) was heated at reflux under nitrogen for 5 hours in 
SOCl2 (5 mL). The excess SOCl2 was removed under reduced pressure to yield the acid chloride as a 
crude oil which was re-dissolved in fresh DCM (2 x 10 mL), concentrated under reduced pressure 
and finally dissolved in fresh DCM (5 mL). 
 
K2CO3 (1.34 g, 9.72 mmol, 4 eq) in water (5 mL) was added in one portion to L-valine (711 mg, 
6.07 mmol, 2.5 eq) in DCM (10 mL). The acid chloride in DCM (5 mL) prepared above was added 
dropwise and the whole was stirred overnight. The reaction mixture was acidified with 2M HCl to 
pH 2-3 and the organic layer was separated. The aqueous phase was extracted with EtOAc (3 x 10 
mL), the combined organic layers were dried (MgSO4), filtered and concentrated under reduced 
pressure to give a black oil (528 mg, 83%), which was in the next step used without further 
purification. 
 
δH (400 MHz, CDCl3): 1.06 (3H, d, J 6.8, CH3CHCH3), 1.07 (3H, d, J 6.8, CH3CHCH3), 2.38 (1H, 
dsept, J 6.8, 4.6, [CH3]2CH), 4.81 (1H, dd, J 8.3, 4.6, NHCHCOOH), 7.22 (1H, t, J 8.4, ArH), 7.25 
(1H, d, J 8.4, ArH), 7.52 (1H, dt, J 7.9, 1.5, ArH), 8.11 (1H, bd, J 8.3, CONH), 8.14 (1H, dd, J 7.9, 
1.5, ArH). 
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δC (100 MHz, CDCl3): 17.9 (CH3), 19.2 (CH3), 31.1 (CH), 58.0 (CH), 118.4 (CH), 124.1 (q), 125.2 
(CH), 132.4 (CH), 132.8 (CH), 137.4 (q), 165.0 (q), 176.0 (q). 
 max (thin film cm-1): 909 (s), 1216 (m), 1276 (s), 1553 (s), 1598 (s), 1643 (s), 1719 (s), 2131 (s), 
2252 (m), 2967 (s), 3365 (s). 
 
LRMS (ESI+): Found 285.1 [M+Na]+, 547.2 [2M+Na]+. 
 
HRMS (ESI+): Found 285.0945 [M+Na]+, C12H14N4NaO3 requires 285.0958. 
 
8.2.6 Synthesis of N-(2’-azidobenzoyl)-valinamide. 
 
N
N3
O
H
OH
Me
Me
O
N
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O
H
O
Me
Me
H2N
BOP, NH4Cl,
252b251b
Et3N, 
 
Scheme 8-28 
 
The valine derived starting material (322 mg, 1.23 mmol, 1 eq) was dissolved in dry DCM (5 mL). 
BOP (544 mg, 1.23 mmol, 1 eq) and Et3N (0.171 mL, 124 mg, 1.23 mmol, 1 eq) were added 
respectively and the whole was stirred for 10 mins. Saturated aqueous NH4Cl (solid) (99 mg, 1.85 
mmol, 1.5 eq) and Et3N (0.258 mL, 187 mg, 1.85 mmol, 1.5 eq) were added and the whole was 
stirred overnight. The reaction was diluted with DCM (15 mL) and washed successively with 3M 
HCl (3 x 10 mL), saturated NaHCO3 solution (3 x 10 mL) and saturated brine (3 x 10 mL). The 
organic layer was dried (MgSO4), filtered, concentrated under reduced pressure and purified by silica 
chromatography (23 g) (EtOAc:Hex;2:1) to yield the amide as a yellow solid (293 mg, 91%). 
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δH (400 MHz, CDCl3): 1.08 (3H, d, J 6.8, CH3CHCH3), 1.09 (3H, d, J 6.8, CH3CHCH3), 2.35 (1H, 
oct, J 6.8, [CH3]2CH), 4.60 (1H, dd, J 6.2, 8.3, NHCHCONH2), 5.83 (1H, bs, CONHH), 6.67 (1H, 
bs, CONHH), 7.25 (1H, dd, J 7.8, 0.9, ArH), 7.27 (1H, dt, J 7.8, 0.9, ArH), 7.55 (1H, dt, J 7.9, 1.6, 
ArH), 8.00 (1H, bd, J 8.3, CONH), 8.11 (1H, dd, J  7.9, 1.6, ArH). 
 
δC (100 MHz, CDCl3): 18.2 (CH3), 19.4 (CH3), 30.7 (CH), 58.8 (CH), 118.4 (CH), 124.6 (q), 125.2 
(CH), 132.1 (CH), 132.6 (CH), 137.3 (q), 164.9 (q), 173.4 (q). 
 max (thin film cm-1): 747 (s), 984 (s), 1067 (s), 1197 (s), 1297 (s), 1460 (s), 1656 (s), 2129 (s), 2806 
(m), 2848 (m), 2894 (m), 2923 (s), 2997 (s). 
 
LRMS (ESI+): Found 284.1 [M+Na]+, 545.2 [2M+Na]+. 
 
HRMS (ESI+): Found 284.1111 [M+Na]+, C12H15N5NaO2 requires 284.1118. 
8.2.7 Synthesis of N-(2’-azidobenzoyl)-2-amino-3-methyl-butanonitrile. 
 
Pyridine,N
N3
O
H
O
Me
Me
H2N
N
N3
O
H
N
Me
Me
252b 253b
Tosyl chloride, 
 
Scheme 8-29 
 
The valine derived amide (533 mg, 2.04 mmol, 1 eq) was dissolved in dry DCM (10 mL). Pyridine 
(0.83 mL, 808 mg, 10.2 mmol, 5 eq) and tosyl chloride (779 mg, 4.08 mmol, 2 eq) were added and 
the whole was heated at reflux under nitrogen for 24 hours. The reaction was quenched with 
saturated aqueous NH4Cl (20 mL) and the organic layer was separated. The aqueous phase was 
extracted with EtOAc (3 x 30 mL), the combined organic layers were dried (MgSO4), filtered, 
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concentrated under reduced pressure and purified by silica chromatography (40 g) (EtOAc:Hex;1:3) 
to yield the product as a yellow solid (199 mg, 40%). 
 
δH (400 MHz, CDCl3): 1.07 (3H, d, J 6.8, CH3CHCH3), 1.10 (3H, d, J 6.8, CH3CHCH3), 2.11 (1H, 
oct, J 6.8, [CH3]2CH), 4.92 (1H, dd, J  6.8, 8.4, NHCHCN), 7.14 (1H, d, J  8.0, ArH), 7.18 (1H, t, J 
7.7, ArH), 7.48 (1H, dt, J  7.7, 1.5, ArH), 7.97 (1H, bd, J 8.4, CONH), 8.07 (1H, dd, J 8.0, 1.5, ArH). 
 
δC (100 MHz, CDCl3): 18.2 (CH3), 18.8 (CH3), 31.6 (CH), 47.1 (CH), 117.8 (q), 118.5 (CH), 123.2 
(q), 125.4 (CH), 132.6 (CH), 133.3 (CH), 137.3 (q), 164.1 (q). 
 max (thin film cm-1): 754 (s), 1165 (m), 1216 (s), 1277 (s), 1447 (m), 1481 (s), 1522 (s), 1577 (s), 
1598 (s), 1658 (s), 2131 (s), 2244 (w), 2854 (m), 2876 (m), 2928 (s), 2967 (s). 
 
LRMS (ESI+): Found 266.1 [M+Na]+, 509.2 [2M+Na]+, C12H13N5NaO requires 266.1 
 
HRMS (ESI+): Found 266.1001 [M+Na]+, C12H13N5NaO requires 266.1012. 
8.2.8 Synthesis of 2-amino-3-(ipropyl)-4-amino-1,4-benzodiazepin-5-one. 
 
NH2
Toluene, CuCl, N
N3
O
H
N
Me
Me N
N
O H
Me
Me
253b 259b
 
Scheme 8-30 
 
The nitrile (36 mg, 0.148 mmol) was heated at reflux in toluene (10 mL) with the addition of copper 
(I) chloride (10  mg) under nitrogen at 120°C for 3 days. The toluene was removed under reduced 
pressure and the crude product was purified by silica chromatography (22 g) (EtOAc:Hex;1:4) to 
yield the product as an orange solid (16 mg, 50%). 
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δH (400 MHz, CDCl3): 1.15 (3H, d, J 6.7, CH3CHCH3), 1.18 (3H, d, J 6.7, CH3CHCH3), 2.16 (1H, 
oct, J 6.7, CH[CH3]2), 4.98 (1H, dd, J 6.3, 8.6, NHCH), 5.56 (2H, bs, NH2), 6.39 (1H, bd, J 8.6, 
CHNH), 6.70 (1H, dt, J 8.1, 0.9, ArH), 6.72 (1H, dd, J 8.1, 0.9, ArH), 7.27 (1H, dt, J 7.8, 1.4, ArH), 
7.35 (1H, dd, J 7.8, 1.4, ArH).  
 
δC (100 MHz, CDCl3): 18.1 (CH3), 18.8 (CH3), 31.8 (CH), 46.6 (CH), 113.8 (q), 116.7 (CH), 117.6 
(CH), 118.0 (q), 127.1 (CH), 133.3 (CH), 149.2 (q), 168.4 (q). 
 max (thin film cm-1): 1155 (m), 1260 (s), 1299 (s), 1352 (m), 1488 (s), 1539 (s), 1584 (s), 1635 (s), 
2245 (w), 2875 (m), 2962 (m), 3301 (s), 3382 (s), 3483 (s). 
 
LRMS (ESI+): Found 218.1 [M+H]+. 
 
HRMS (ESI+): Found 218.1283 [M+H]+, C12H16N3O requires 218.1288. 
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9 Experimental: Synthesis of benzene ring with the DC-81 substitution pattern. 
9.1.1 Synthesis of 4-(benzyloxy)-3-methoxybenzoic acid. 
 
290 291
PhCH2Cl, THF,
O
OH
O
OH
MeO
PhH2CO
MeO
HO
NaOH, 
 
Scheme 9-1 
 
4-Hydroxy-3-methoxybenzoic acid (30 g, 178 mmol, 1 eq) was dissolved in a mixture of THF (90 
mL) and 2M aqueous NaOH (250 mL). Benzyl chloride (25 mL, 217 mmol, 1.22 eq) in THF (90 
mL) was added to the ice cooled solution over 15 minutes. The mixture was allowed to reach room 
temperature before heating at reflux for 48 hours. The aqueous phase was separated and washed with 
hexane (2 x 150 mL). Some remaining THF in the aqueous phase was removed in vacuo and the 
aqueous solution was acidified to pH 1 with HCl (36% ~80 mL). The pale peach precipitate was 
collected by vacuum filtration on a sinter glass. Recrystallisation from EtOAc afforded a pale peach 
solid which was collected by vacuum filtration on a sinter (32.87 g, 74%) mp=169-173C [lit 171-
173C].96 
 
δH (500 MHz, d6-DMSO): 3.78 (3H, s, OMe), 5.12 (2H, s, OCH2), 7.10 (1H, d, J 8.4, ArH), 7.32 
(1H, t, J 7.3, ArH), 7.38 (2H, t, J 7.3, ArH), 7.43 (2H, d, J 7.3, ArH), 7.45 (1H, s, ArH), 7.54 (1H, d, 
J 8.4, ArH), 12.58 (1H, bs, CO2H). 
 
δC (125MHz, d6-DMSO): 55.8 (CH3), 70.2 (CH2), 112.4 (CH), 112.7 (CH), 123.5 (CH), 128.3 (CH), 
128.4 (CH), 128.9 (CH), 136.8 (q), 148.9 (q), 151.9 (q), 167.6 (q).  
 max (thin film cm-1): 996 (m), 1023 (s), 1227 (s), 1270 (s), 1303 (m), 1348 (m), 1425 (s), 1452 (m), 
1517 (m), 1584 (m), 1671 (s). 
Chapter 9  Experimental Part III 
158 
 
 
LRMS (ESI+): Found 281.1 [M+Na]+. 
 
HRMS (ESI+): Found 281.0772 [M+Na]+, C15H14NaO4 requires 281.0784. 
9.1.2 Synthesis of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid. 
 
O
OH
MeO
PhH2CO NO2
O
OH
MeO
PhH2CO
SnCl4, DCM,
291 292
HNO3, -10oC
 
Scheme 9-2 
 
4-(Benzyloxy)-3-methoxybenzoic acid (8.70 g, 28.7 mmol, 1 eq) in DCM (120 mL) was cooled to -
10C before a mixture of SnCl4 (10.02 g, 4.5 mL, 39 mmol, 1.33 eq) and conc. HNO3 (2.39 mL, 3.34 
g, 57 mmol, 1.98 eq) in DCM (34 mL) was added dropwise. The reaction was maintained at -10C 
for 30mins before being quenched with water (200 mL) and allowed to reach room temperature. 
Some solid product formed in the reaction was retained by vacuum filtration. The organic phase was 
separated and the aqueous layer was extracted with EtOAc (2 x 150 mL). The combined organic 
layers were dried (MgSO4), filtered and solvent removed in vacuo to afford crude 4-(benzyloxy)-5-
methoxy-2-nitrobenzoic acid (10.5 g). Recrystallisation from EtOAc/Hexane yielded a yellow solid 
(6.53g combined, 63%) which was collected through vacuum filtration, mp=178-182C [lit 180-
183C].96 
 
δH (500 MHz, d6-DMSO): 3.90 (3H, s, CH3), 5.23 (2H, s, CH2), 7.31 (1H, s, ArH), 7.32-7.48 (5H, m, 
ArH), 7.70 (1H, s, ArH), 13.62 (1H, bs, CO2H). 
 
δC (125MHz, d6-DMSO): 56.5 (CH3), 70.6 (CH2), 108.4 (CH), 111.4 (CH), 121.5 (q), 128.2 (CH), 
128.3 (CH), 128.6 (CH), 135.9 (q), 141.2 (q), 149.0 (q), 152.1 (q), 166.0 (q). 
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 max (thin film cm-1): 975 (m), 1010 (m), 1048 (s), 1185 (s), 1212 (s), 1275 (s), 1351 (s), 1415 (s), 
1454 (m), 1537 (m), 1583 (m), 1603 (s), 1683 (s), 2838 (w). 
 
LRMS (ESI+): Found 326.1 [M+Na]+,  C15H13NNaO6 requires 326.1. 
9.1.3 Synthesis of 2-amino-4-(benzyloxy)-5-methoxybenzoic acid.  
 
292 293
NO2
O
OH
MeO
PhH2CO NH2
O
OH
MeO
PhH2CO
1. NiCl2.6H2O, NaBH4, 
MeOH, 0oC to r.t.
2. 6M HCl, NH3
 
Scheme 9-3 
 
Method A: To a stirring solution of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid (1.00 g, 3.3 mmol, 
1 eq) and NiCl2.6H2O (1.57 g, 6.6 mmol, 2 eq) in MeOH (8 mL) at 0C was added portionwise 
NaBH4 (500 mg, 13.2 mmol, 4 eq). The solvent was removed in vacuo after 30mins of stirring at 
room temperature. The residue was dissolved in 6M HCl, and adjusted to pH8 with 2M ammonia 
solution. The organic layer was separated and the aqueous layer was extracted with EtOAc (6 x 40 
mL). The combined organic phases were dried (Na2SO4), filtered and the solvent removed in vacuo 
to yield a black solid (360 mg). Purification by silica chromatography (EtOAc:Hex; 1:1) yielded the 
product as a white solid (200 mg, 25%).  
 
292 293
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MeOH, 
 
Scheme 9-4 
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Method B: A mixture of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid (2.4 g, 8 mmol, 1 eq) and 
SnCl2.H2O (7.2 g, 32 mmol, 4 eq) was heated at reflux for 3 hours in MeOH (24 mL). The solvent 
was removed in vacuo and the yellow syrup was redissolved in EtOAc (25 mL). A solution of 5% 
NaHCO3 (25 mL) was added and the mixture was stirred overnight at room temperature. The 
precipitate was collected by filtration under vacuum to yield a white solid (1.92 g, 88%) which 
needed no further purification. 
 
δH (500 MHz, d6-DMSO): 3.73 (3H, s, CH3), 5.09 (2H, s, CH2), 6.99 (1H, s, ArH), 7.32-7.45 (8H, m, 
NH2+ 6 x ArH), 11.48 (1H, bs, CO2H). 
 
δC (125MHz, d6-DMSO): 56.3 (CH3), 70.3 (CH2), 106.0 (CH), 113.7 (CH), 128.3 (q), 128.4 (2 x 
CH), 128.6 (CH), 128.9 (2 x CH), 136.3 (2 x q), 144.7 (q), 152.7 (q), 167.9 (q). 
 max (thin film cm-1): 881 (m), 981 (m), 1069 (m), 1170 (s), 1211 (s), 1254 (m), 1280 (s), 1505 (s), 
1526 (m), 1701 (s), 2200-3250 (OH-br), 3354 (N-H), 3530 (N-H). 
 
LRMS (ESI+): Found 274.1 [M+H]+, 296.1 [M+Na]+. 
 
HRMS (ESI+): Found 274.1076 [M+H]+, C15H16NO4 requires 274.1074. 
 
9.1.4 Synthesis of 2-azido-4-(benzyloxy)-5-methoxybenzoic acid. 
 
1. NaNO2, HCl, 
0°C
2. NaN3, NaOAc, 
0°C
293 294
NH2
O
OH
MeO
PhH2CO N3
O
OH
MeO
PhH2CO
 
Scheme 9-5 
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To a stirred ice cooled solution of the amine (1.15 g, 4.21 mmol, 1 eq) in 6M HCl (20 mL) was 
added portionwise NaNO2 (420 mg, 6.09 mmol, 1.45 eq) in water (5 mL) and the mixture stirred for 
30 minutes. This solution was added dropwise to a stirred solution of NaOAc (9.43 g, 115 mmol, 
27.3 eq) and NaN3 (340 mg, 5.23 mmol, 1.24 eq) in water (20 mL). After stirring for a further 90 
minutes, the precipitates were filtered, washed with water, and redissolved in CHCl3. The solution 
was dried (Na2SO4) stripped of solvent in vacuo to yield (990 mg, 78%) of crude product. 
Recrystallisation from toluene gave the product as a black solid (600 mg, 47%). mp= 138-141C [lit 
139-141C].138 
 
δH (400 MHz, CDCl3): 3.82 (3H, s, CH3), 5.14 (2H, s, CH2), 6.60 (1H, s, ArH), 7.24-7.37 (5H, m, 
ArH), 7.51 (1H, s, ArH), 10.82 (1H, bs, CO2H). 
 
δC (100 MHz, CDCl3): 55.2 (CH3), 70.2 (CH2), 104.5 (CH), 112.6 (q), 114.8 (CH), 127.3 (CH), 
128.1 (CH), 128.5 (CH), 134.1 (q), 135.4 (q), 146.6 (q), 153.0 (q), 168.1 (q). 
 max (thin film cm-1): 820 (m), 874 (m), 923 (m), 1179 (s), 1205 (s), 1250 (s), 1415 (m), 1463 (m), 
1513 (s), 1573 (m), 1602 (m), 1666 (s), 2103 (s), 2614-2940 (br). 
 
LRMS (ESI+): Found 322.1 [M+Na]+, 621.2 [2M+Na]+. 
 
HRMS (ESI+): Found 322.0789 [M+Na]+, C15H13N3NaO4 requires 322.0798. 
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9.1.5 Synthesis of 2-cyano-1-[2’-azido-4-(benzyloxy)-5-methoxybenzoyl]pyrrolidine. 
 
2. L-prolinamide,
K2CO3, r.t.
294 295
N3
N
NH2O
MeO
PhH2CO
O
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1. SOCl2,  
 
Scheme 9-6 
 
The azide (250 mg, 0.836 mmol, 2.4 eq) was dissolved in toluene (5 mL) and SOCl2 (1.5 mL) was 
added. The whole was heated to reflux under nitrogen for 3 hours. The reaction mixture was 
concentrated in vacuo, and the residue was dissolved in DCM (2 x 10 mL) to remove excess SOCl2, 
to yield the crude acid chloride. 
 
K2CO3 (193 mg, 1.4 mmol, 4 eq) dissolved in water (3 mL) was added in one portion to a stirring 
solution of L-prolinamide (40 mg, 0.35 mmol, 1 eq) in DCM (3 mL). After stirring for 30mins at 
ambient temperature the acid chloride redissolved in DCM (5 mL) was added dropwise and the 
mixture was stirred overnight. The organic layer was separated and the aqueous layer extracted from 
DCM (2 x 15 mL). The combined organic layers were dried (MgSO4), filtered and concentrated in 
vacuo to yield a black-brown oil (460 mg). Purification by silica chromatography (40 g) (EtOAc: 
Hex; 3:1) yielded the product as a grey solid (74 mg, 56%).  
 
δH (400 MHz, CDCl3): 2.17-2.44 (3H, m, CH2+CHH), 3.39-3.52 (2H, m, CH2), 3.75-3.82 (1H, m, 
CHH), 3.94 (3H, s, OCH3), 4.92 (1H, dd, J 3.8, 7.5, NCCHN), 5.24 (2H, s, OCH2), 6.72 (1H, s, 
ArH), 6.92 (1H, s, ArH), 7.37-7.51 (5H, m, ArH). 
 
δC (100 MHz, CDCl3): 25.0 (CH2), 30.5 (CH2), 46.4 (CH), 47.7 (CH2), 56.5 (CH3), 71.4 (CH2), 104.4 
(CH), 111.3 (CH), 118.4 (q), 120.0 (q), 127.4 (2 x CH), 128.4 (CH), 128.8 (2 x CH), 135.9 (2 x q), 
147.4 (q), 150.3 (q), 167.0 (q). 
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max (thin film cm-1): 910 (s), 1181 (m), 1211 (m), 1245 (s), 1386 (m), 1425 (s), 1453 (m), 1512 (s), 
1606 (m), 1638 (s), 2114 (s), 2253 (s), 2937 (w). 
 
LRMS (ESI+): Found 377.2 [M]+, 378.2 [M+H]+. 
 
HRMS (ESI+): Found 378.1566 [M+H]+, C20H20N5O3 requires 378.1561. 
 
9.1.6 Synthesis of tetrazolo[1,5-a]-4-(benzyloxy)-5-methoxy-pyrrolo[2,1-c][1,4]benzodiazepine. 
 
CHCl3, 
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Scheme 9-7 
 
The starting material (50 mg, 0.133 mmol) was heated at reflux under nitrogen in CHCl3 (10 mL) for 
72 hours. The solvent was removed in vacuo and the crude was purified by silica chromatography 
(20 g) (EtOAc: Hex; 3:1) to yield the product as a white solid (29 mg, 58%). 
 
δH (400 MHz, CDCl3): 2.04-2.18 (2H, m, CH2), 2.42-2.52 (1H, m, CHH), 3.06-3.13 (1H, m, CHH), 
3.61-3.68 (1H, m, CHH) , 3.73-3.79 (1H, m, CHH), 3.93 (3H, s, OCH3), 4.68 (1H, dd, J 3.2, 8.4, 
NCCHN), 5.15 (1H, d, J  12.0, OCHH), 5.26 (1H, d, J 12.0, OCHH) 7.19 (1H, s, ArH), 7.25- 7.41 
(5H, m, ArH), 7.53 (1H, s, ArH).  
 
δC (100 MHz, CDCl3): 23.5 (CH2), 28.2 (CH2), 48.2 (CH2), 49.8 (CH), 56.4 (CH3), 71.3 (CH2), 106.5 
(CH), 113.3 (CH), 119.8 (q), 124.2 (q), 127.6 (CH), 128.5 (CH), 128.8 (CH), 135.3 (q), 150.3 (q), 
151.7 (q), 154.1 (q), 163.4 (q). 
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max (thin film cm-1): 1242 (m), 1269 (s), 1374 (s), 1429 (s), 1453 (m), 1517 (s), 1606 (s), 1631 (s), 
2853 (s), 2924 (s). 
 
LRMS (ESI+): Found 377.2 [M]+, 378.2 [M+H]+. 
 
HRMS (ESI+): Found 378.1564 [M+H]+, C20H20N5O3 requires 378.1561. 
9.1.7 Synthesis of 1-[2’-azido-4-(benzyloxy)-5-methoxybenzoyl]prolinol. 
 
1. SOCl2, 
298294
N3
O
OH
MeO
PhH2CO N3
N
O
MeO
PhH2CO
OH
2. S-prolinol,
   K2CO3, r.t.
 
Scheme 9-8 
 
The protected azidobenzoic acid (236 mg, 0.789 mmol, 1.0 eq) was dissolved in dry toluene (5 mL) 
and SOCl2 (1.5 mL) was added. The solution was placed in a preheated oil bath at 85C for 3 hours. 
The reaction was cooled to ambient temperature, concentrated in vacuo, dissolved in fresh DCM (3 x 
10 mL) and concentrated in vacuo, to remove the excess SOCl2.  
 
K2CO3 (218 mg, 1.58 mmol, 2 eq) in water (2 mL) was added in one portion to a stirring solution of 
S-prolinol (0.162 mL, 168 mg, 1.66 mmol, 2.1 eq) in DCM (2 mL) and the whole was stirred for 10 
minutes. The acid chloride in DCM (5 mL) was added dropwise and the whole was stirred at 
ambient temperature overnight before the organic layer was separated. The aqueous phase was 
extracted with DCM (3 x 10 mL) and the combined organic layers were dried (MgSO4), filtered, 
concentrated and purified by silica chromatography (20 mg) (EtOAc:Hex; 3:1) to yield the product 
as an orange oil (262 mg, 87%). 
 
δH (400 MHz, CDCl3): 1.56-1.84 (3H, m, CH2 +CHH), 2.06-2.13 (1H, m, CHH), 3.20-3.30 (2H, m, 
CH2), 3.62-3.67 (1H, m, CHHOH), 3.73-3.77 (1H, m, CHHOH), 3.80 (3H, s, OMe), 4.23-4.29 (1H, 
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m, CHCH2OH), 4.69 (1H, bs, CH2OH), 5.10 (2H, s, OCH2), 6.59 (1H, s, ArH), 6.76 (1H, s, ArH), 
7.24-7.38 (5H, m, ArH). 
 
δC (100 MHz, CDCl3): 24.5 (CH2), 28.5 (CH2), 49.6 (CH2), 56.3 (CH3), 61.2 (CH), 66.6 (CH2), 71.2 
(CH2), 104.2 (CH), 110.7 (CH), 121.4 (q), 127.3 (CH), 128.2 (CH), 128.7 (CH), 135.9 (q), 147.2 (q), 
149.8 (q), 168.8 (q). 
 max (thin film cm-1): 742 (s), 1004 (m), 1048 (m), 1077 (m), 1178 (s), 1214 (s), 1242 (s), 1433 (s), 
1511 (s), 1603 (s), 2109 (s), 2882 (w), 2937 (w), 3145-3593 (br). 
 
LRMS (ESI+): Found 383.2 [M+H]+, 765.3 [2M+H]+, 787.3 [2M+Na]+. 
 
HRMS (ESI+): Found 383.1708 [M+H]+, C20H23N4O4 requires 383.1714. 
 
9.1.8 Synthesis of 1-[2’-azido-4-(benzyloxy)-5-methoxybenzoyl]prolinal.  
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Et3N, -78oC
 
Scheme 9-9 
 
DMSO (0.14 mL, 154 mg, 1.97 mmol, 3.01 eq) in DCM (1 mL) and the alcohol (250 mg, 0.654 
mmol, 1 eq) in DCM (2 mL) where added dropwise respectively, over 15 minutes, to a solution of 
2M oxalyl chloride (0.39 mL, 0.785 mmol, 1.2 eq) at -78C in DCM (1 mL). After 10 mins, Et3N 
(0.24 mL, 174 mg, 1.72 mmol, 2.63 eq) was added dropwise to the mixture at -78ºC. The whole was 
allowed to reach room temperature over two hours before being quenched with a mixture of Et2O 
(10 mL) and H2O (10 mL). The organic layer was separated and the aqueous layer was extracted 
with DCM (3 x 10 mL). The combined organics were dried (MgSO4), filtered, concentrated and 
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purified by silica chromatography (20 g) (EtOAc:Hex; 3:1) to give the product as a mixture of 
rotamers in the form of an orange oil (161 mg, 65%). 
 
δH (400 MHz, CDCl3): 1.79-1.89 (2H, m, CH2), 1.97-2.04 (1H, m, CHH), 2.07-2.20 (1H, m, CHH), 
3.28-3.34 & 3.35-3.41 (2H, m, NCH2), 3.76 & 3.81 (3H, 2 x s, OCH3), 4.12-4.17 & 4.52-4.57 (1H, 
m, NCHCHO), 5.08 & 5.12 (2H, 2 x s, OCH2), 6.53 & 6.61 (1H, 2 x s, ArH), 6.72 & 6.80 (1H, 2 x s, 
ArH), 7.24-7.39 (5H, m, ArH), 9.22 & 9.62 (1H, 2 x d, J 1.4 & 1.8, CHO). 
 
δC (100 MHz, CDCl3): 24.9/26.4 (CH2), 46.8/48.6 (CH2), 56.3/56.4 (CH3), 60.4 (CH2), 64.8/66.5 
(CH), 71.3/71.3 (CH2), 104.2/104.4 (CH), 111.2/111.5 (CH), 120.7/120.8 (q), 127.4 (CH), 128.3 
(CH), 128.8 (CH), 135.9/136.0 (q), 147.3/147.3 (q), 150.0/150.1 (q), 167.2/167.4 (q), 198.0/199.4 
(CH). 
 max (thin film cm-1): 1245 (s), 1430 (s), 1454 (s), 1512 (s), 1604 (s), 1622 (s), 1731 (m), 2110 (s), 
2942 (m). 
 
LRMS (ESI+): Found 381.2 [M+H]+, 403.1 [M+Na]+ , 783.3 [2M+Na]+.  
 
HRMS (ESI+): Found 403.1375 [M+Na]+, C20H20N4NaO4 requires 403.1377.  
9.1.9 Synthesis of 3-benzyloxy-4-methoxy-1,2,3-triazolo[1,5-a][1,4]pyrrolo[2,1-c]benzodiazepin-
5-one. 
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Scheme 9-10 
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The aldehyde (113 mg, 0.30 mmol, 1 eq) was dissolved in dry MeOH (3 mL). K2CO3 (82 mg, 0.60 
mmol, 2 eq) and Bestmann Ohira reagent (68 mg, 0.36 mmol, 1.2 eq) were added and the whole was 
stirred for 6 hours. The reaction was quenched with saturated aqueous NH4Cl (10 mL) and the 
organic layer was separated. The aqueous phase was extracted with DCM (3 x 10 mL) and the 
combined organics were dried (MgSO4), filtered, concentrated and purified by silica chromatography 
(22 g) (EtOAc:Hex; 9:1) to yield the cyclised product as a white solid (95 mg, 84%).  
 
δH (400 MHz, CDCl3): 1.98-2.09 (2H, m, CH2), 2.41-2.50 (2H, m, CH2), 3.63-3.73 (2H, m, CH2), 
3.91 (3H, s, OMe), 4.63 (1H, t, J  5.2 CHCH2), 5.12 (1H, d, J 11.9, PhCHHO), 5.24 (1H, d, J 11.9, 
PhCHHO), 7.23-7.28 (1H, m, ArH), 7.27-7.33 (2H, m, ArH), 7.38-7.40 (2H, m, ArH), 7.47 (1H, s, 
ArH), 7.50 (1H, s, ArH), 7.52 (1H, s, ArH). 
 
δC (100 MHz, CDCl3): 23.0 (CH2), 28.7 (CH2), 47.0 (CH2), 49.0 (CH), 55.6 (CH3), 70.4 (CH2), 106.3 
(CH), 112.4 (CH), 119.0 (q), 126.5 (q), 126.9 (CH), 127.7 (CH), 127.9 (CH), 128.1 (CH), 134.9 (q), 
137.9 (q), 148.9 (q), 150.7 (q), 163.2 (q). 
 max (thin film cm-1): 1135 (m), 1269 (s), 1366 (m), 1430 (s), 1453 (m), 1516 (s), 1584 (m), 1629 (s), 
2927 (m). 
 
LRMS (ESI+): Found 377.2 [M+H]+.  
 
HRMS (ESI+): Found 377.1600 [M+H]+, C21H21N4O3 requires 377.1608. 
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9.1.10 Synthesis of 3-benzyloxy-4-methoxy-11-ethyl-ethanoyl-[1,4]-pyrrolo[2,1-c] benzodiazepin-
5-one. 
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Scheme 9-11 
 
The aldehyde (198 mg, 0.581 mmol, 1.0 eq) was dissolved in toluene (10 mL) and 
(carbethoxymethylene)-triphenylphosphorane (180 mg, 0.521 mmol, 1 eq) was added in one portion 
and the whole was stirred for 18 hours. The reaction was concentrated in vacuo and purified by silica 
chromatography (30 g) (EtOAc:Hex; 4:1) to yield the product as a yellow oil (52 mg, 21%). 
 
δH (500 MHz, CDCl3): 1.32 (3H, t, J 7.2, CO2CH2CH3), 1.74-1.80 (1H, m, CHH), 1.93-2.19 (3H, m, 
CHH + CH2), 2.31-2.24 (2H, m, CH2CO2Et), 3.43-3.47 (1H, m, NHCH), 3.62-3.66 (1H, m, 
NCHCH), 3.68-3.73 (1H, m, NCHH), 3.76-3.80 (1H, m, NCHH), 3.89 (3H, s, OMe), 4.22 (2H, 
quartet, J 7.2, CO2CH2CH3), 5.13 (1H, d, J 12.3, PhCHHO), 5.18 (1H, d, J 12.3, PhCHHO), 6.34 
(1H, s, ArH), 7.31-7.50 (7H, m, 6 x ArH +NH). 
 
δC (125MHz, CDCl3): 14.2 (CH3), 23.2 (CH2), 29.9 (CH2), 37.3 (CH2), 46.9 (CH2), 56.3 (CH3), 60.1 
(CH), 61.0 (CH2), 62.7 (CH), 70.9 (CH2), 108.1 (CH), 113.1 (CH), 120.0 (q), 127.4 (CH), 128.0 
(CH), 128.4 (CH), 136.5 (q), 137.8 (q), 145.0 (q), 150.9 (q), 168.3 (q), 171.9 (q). 
 max (thin film cm-1): 723 (m), 1025 (s), 1119 (s), 1178 (s), 1218 (s), 1260 (s), 1373 (m), 1432 (s), 
1453 (m), 1503 (m), 1602 (s), 1623 (m), 1726 (m), 2860 (m), 2924 (s), 2953 (m). 
 
LRMS (ESI+): Found 447.2 [M+Na]+. 
 
HRMS (ESI+): Found 447.1895 [M+Na]+ requires C24H28N2NaO5 requires 447.1890. 
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10 Experimental: Intramolecular Cycloadditon of Azides onto Alkenes: Triazolino-
, Aziridino- and Azetindinobenzodiazepines.  
10.1 Synthesis of the Azetidinobenzodiazepines. 
10.1.1 Synthesis of 4-methyl-4-vinylazetidin-2-one. 
 
287
276
277
Me
N
Me
OClO2S N
Me
OH
Na2SO3, KOHCSI, -78
oC
 
Scheme 10-1 
 
Isoprene (8.82 mL, 6.00 g, 88.2 mmol, 2 eq) in dry ether (20 mL) was cooled to -78C before 
dropwise addition of CSI (3.84 mL, 6.24 g, 44.1 mmol, 1 eq) in dry ether (20 mL) over 30 minutes. 
The whole was allowed to reach -10C and the temperature was maintained for a further 4 hours. A 
solution of 25% aqueous Na2SO3: ether; 2:1 (21 mL) was cooled to -10C and the initial solution 
was added keeping the whole slightly basic with 10% aqueous KOH. The organic layer was 
separated and the aqueous phase was extracted with ether (1 x 20 mL). The combined organics were 
dried (MgSO4), filtered and concentrated to give a colourless oil (2.15 g, 44%) which needed no 
further purification. 
 
δH (400 MHz, CDCl3): 1.50 (3H, s, Me), 2.79 (2H, s, CH2), 5.10 (1H, dd, J 10.6, 0.7, CH=CHH), 
5.22 (1H, dd, J 17.2, 0.7, CH=CHH), 6.02 (1H, dd, J 10.6, 17.2, CH=CH2), 6.83 (1H, br, NH). 
 
δC (100 MHz, CDCl3): 24.8 (CH2), 50.7 (CH3), 54.5 (q), 113.8 (CH), 141.1 (CH2), 167.6 (q). 
 max (thin film cm-1): 923 (m), 1153 (m), 1186 (m), 1226 (m), 1274 (w), 1304 (m), 1372 (m), 1412 
(m), 1643 (m), 1720 (s), 2970 (w), 3235 (m). 
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LRMS (ESI+): Found 134.1 [M+Na]+, 291.2 [2M+3Na]+. 
10.1.2 Synthesis of 4-methyl-4-vinylazetidin-2-thione. 
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Scheme 10-2 
 
To the azetidin-2-one (1.49 g, 13.4 mmol, 1.0 eq) in dry THF (18 mL) was added Lawesson’s 
reagent (3.26 g, 8.06 mmol, 0.6 eq) and the whole was stirred at room temperature for an hour before 
being heated to reflux for a further hour. The reaction was allowed to reach ambient temperature 
before being concentrated and purified by silica chromatography (200 g) (EtOAc:Hex; 1:4) to give 
the product as a pale red oil (1.32 g, 77%). 
 
δH (400 MHz, CDCl3): 1.60 (3H, s, Me), 2.98 (2H, s, CSCH2), 5.21 (1H, d, J 10.6, CH=CHH), 5.28 
(1H, d, J 17.2, CH=CHH), 6.05 (1H, dd, J 10.6, 17.2 CH=CH2), 8.78 (1H, bs, NH). 
 
δC (100 MHz, CDCl3): 23.8 (CH3), 54.6 (CH2), 63.7 (q), 115.1 (CH2), 139.0 (CH), 202.2 (q). 
 max (thin film cm-1): 924 (s), 989 (m), 1016 (m), 1081 (s), 1217 (m), 1288 (m), 1374 (m), 1404 (s), 
1466 (s), 1640 (w), 2971 (w), 3147 (m). 
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10.1.3 Synthesis of 1-(2’-azidobenzoyl)-4-methyl-4-vinylazetidin-2-one. 
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Scheme 10-3 
 
The azidobenzoic acid (508 mg, 3.02 mmol, 1.0 eq) was heated to reflux in SOCl2 (4 mL) for 3 
hours under nitrogen. The excess SOCl2 was removed in vacuo and the crude acid chloride was 
redissolved in DCM (3 x 5 mL) which was removed in vacuo to yield the crude benzoyl chloride. 
 
The -lactam (457 mg, 4.12 mmol, 1.36 eq) in DCM (25 mL) and DMAP (100 mg) were chilled to -
10C. The crude acid chloride in DCM (5 mL) was added dropwise to the solution over 10 mins. The 
whole was maintained at -10C for 30 mins before the addition of Et3N (0.89 mL, 646 mg, 6.40 
mmol, 2.12 eq) and the whole was allowed to reach room temperature overnight. The reaction was 
concentrated and purified by silica chromatography (70 g) (EtOAc:Hex;1:4) to give the coupled 
product in rotermeric form as a dark yellow oil (498 mg, 65%).  
 
δH (400 MHz, CDCl3) rotamer 1: 1.87 (3H, s, Me), 2.98 (1H, d, J 16.2, COCHH), 3.08 (1H, d, J  
16.2, COCHH), 5.35 (1H, d, J 10.7, CHH=CH), 5.45 (1H, d, J 17.3, CHH=CH), 6.24 (1H, dd, J 
10.7, 17.3, CH=CH2), 7.22 (1H, t, J 7.6, ArH), 7.23 (1H, d, J  8.3, ArH), 7.42 (1H, dd, J 7.6, 1.3, 
ArH), 7.52 (1H, dt, J 8.3, 1.4, ArH).  
 
δH (400 MHz, CDCl3) rotamer 2: 1.51 (3H, s, Me), 2.68 (1H, d, J 15.8, COCHH), 2.82 (1H, d, J  
15.8, COCHH), 5.20 (1H, d, J 10.6, CHHCH), 5.32 (1H, d, J 17.2, CHHCH), 5.91 (1H, dd, J 10.6, 
17.2, CHCH2), 7.21 (1H, dt, J 7.6, 0.9, ArH), 7.24 (1H, d, J 7.6, ArH), 7.51 (1H, dt, J 7.8, 1.5, ArH), 
7.67 (1H, dd, J 7.8, 1.5, ArH).  
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δC (100 MHz, CDCl3) rotamer 1: 21.7 (CH3), 49.2 (CH2), 58.9 (q), 114.9 (CH2), 117.5 (CH), 123.7 
(CH), 125.8 (q), 128.1 (CH), 131.2 (CH), 137.1 (q), 137.2 (CH), 162.4 (q), 162.5 (q). 
 
δC (100 MHz, CDCl3) rotamer 2: 27.6 (CH3), 39.5 (CH2), 58.6 (q), 114.3 (CH2), 119.9 (CH), 123.5 
(q), 124.7 (CH), 130.8 (CH), 132.1 (CH), 138.9 (q), 139.9 (CH), 151.5 (q), 165.3 (q). 
 max (thin film cm-1): 1084 (m), 1216 (s), 1329 (s), 1391 (s), 1451 (m), 1478 (m), 1519 (s), 1604 (m), 
1656 (m), 1682 (m), 1721 (w), 1801 (s), 2131 (s), 2853 (m), 2925 (m). 
 
LRMS (ESI+): 279.1 [M+Na]+, 535.2 [2M+Na]+. C13H12N4NaO2 requires 279.1. 
 
HRMS (ESI+): 279.0862 [M+Na]+, C13H12N4NaO2 requires 279.0852. 
10.1.4 Synthesis of 8,9-dimethylazetidino [2,1-a] [1,4] benzodiazepin-2,11-dione. 
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Scheme 10-4 
 
The azetidinone (372 mg, 1.45 mmol) was heated to reflux in CHCl3 (10 mL) nitrogen and 
monitored by NMR every 24 hours. After 72 hours, the reaction was concentrated and purified by 
silica chromatography (22 g) using graduated elutation (EtOAc:Hex; 1:4-3:1) to give the imine as a 
yellow solid (74 mg, 22%). 
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δH (500 MHz, CDCl3): 2.00 (3H, s, Me), 2.49 (1H, s, Me), 3.42 (1H, d, J  16.0, COCHH), 3.77 (1H, 
d, J 16.0, COCHH), 7.52 (1H, dt, J 7.7, 1.0, ArH), 7.70 (1H, dd, J 8.0, 1.0, ArH), 7.78 (1H, dt, J 7.7, 
1.6, ArH), 8.32 (1H, dd, J 8.0, 1.6, ArH). 
 
δC (125MHz, CDCl3): 20.1 (CH3), 26.2 (CH3), 43.6 (CH2), 73.3 (q), 123.7 (q), 126.5 (CH), 126.7 
(CH), 127.4 (CH), 134.3 (CH), 149.7 (q), 155.2 (q), 158.1(q), 204.2 (q) 
 max (thin film cm-1): 702 (s), 730 (s), 1264 (s), 1421 (m), 1463 (m), 1609 (m), 1657 (m), 1686 (m), 
1721 (s), 1799 (w), 2928 (w). 
 
LRMS (ESI+): Found 229.1 [M+H]+, 251.1 [M+Na]+, 479.2 [2M+Na]+. 
 
HRMS (ESI+): Found 229.0978 [M+H]+, 479.1703 [2M+Na], C13H12N2NaO2 requires 229.0972 and 
C23H24N4NaO4 requires 479.1690.  
10.1.5 Synthesis of 1-(2’-azidobenzoyl)-4-methyl-4-vinyl-1-azetidin-2-thione. 
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Scheme 10-5 
 
The azidobenzoic acid (214 mg, 1.3 mmol, 1.0 eq) was heated to reflux under nitrogen in SOCl2 (4 
mL) for 4 hours. The excess thionyl chloride was removed in vacuo and the product dissolved in 
DCM (3 x 5 mL) and concentrated in vacuo to give the crude acid chloride. 
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The methylthiolactam (250 mg, 1.97 mmol, 1.5 eq) in DCM (25 mL) and DMAP (100 mg) was 
chilled to -10C. The crude acid chloride in DCM (5 mL) was added dropwise over 10mins and the 
whole was maintained at -10C for 30mins before dropwise addition of Et3N (0.41 mL, 299 mg, 2.95 
mmol, 2.25 eq). The whole was allowed to reach room temperature overnight and the reaction was 
concentrated and purified by silica chromatography (22 g) (EtOAc:Hex;1:4) to give the product as 
an orange oil (296 mg, 84%). 
 
δH (400 MHz, CDCl3): 1.92 (3H, s, Me), 2.93 (1H, d, J 16.9, CSCHH), 3.04 (1H, d, J 16.9, 
CSCHH), 5.38 (1H, d, J  10.8, CHHCH), 5.45 (1H, d, J 17.3, CHHCH), 6.31 (1H, dd, J 17.3, 10.8 
CHHCH), 7.20 (1H, dd, J 8.2, 0.8, ArH), 7.24 (1H, dt, J 7.6, 0.8, ArH), 7.36 (1H, dd, J 7.6, 1.5, 
ArH), 7.54 (1H, dt, J 8.2, 1.5, ArH). 
 
δC (100 MHz, CDCl3): 22.3 (CH3), 54.5 (CH2), 67.5 (q), 116.4 (CH2), 118.5 (CH), 125.1 (CH), 126.6 
(q), 128.9 (CH), 132.1 (CH), 137.7 (CH), 138.3 (q), 164.2 (q), 201.7 (q). 
 max (thin film cm-1): 909 (s), 931 (m), 1215 (s), 1322 (s), 1358 (m), 1448 (w), 1478 (m), 1674 (s), 
2131 (s). 
 
LRMS (ESI+): Found 295.1 [M+Na]+, 567.1 [2M+Na]+. 
 
HRMS (ESI+): Found 295.0623 [M+Na]+, C13H12N4NaOS requires 295.0624. 
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10.1.6 Synthesis of 12-methyl-1,2,3-triazolino[1,5-a]azetidino[1,4-c][1,4]benzodiazepin-2-on-14-
thione. 
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Scheme 10-6 
The N-(2’-azidobenzoyl)-azetidine (295 mg, 1.08 mmol) was heated at reflux in CHCl3 (10 mL) 
under nitrogen for 36 hours before being concentrated and purified by silica chromatography (22 g) 
(EtOAc:Hex;1:1) to give the triazolino product as a yellow solid (180 mg, 61%). 
 
δH (500 MHz, CDCl3): 1.22 (3H, s, Me), 2.89 (1H, d, J 16.8, SCCHH), 2.94 (1H, d, J 16.8, 
SCCHH), 4.27 (1H, dd, J 6.1, 12.2, CH3CHN), 4.37 (1H, dd, J 6.1, 17.7, N3CHH), 4.71 (1H, dd, J  
12.2, 17.7, N3CHH), 7.14 (1H, dt, J 7.1, 1.0, ArH), 7.52 (1H, dt, J 7.2, 1.6, ArH), 8.04 (1H, dd, J 8.4, 
0.9, ArH), 8.2 (1H, d, J 8.3, 1.5, ArH). 
 
δC (125MHz, CDCl3): 16.8 (CH3), 50.5 (CH2), 59.6 (CH), 65.0 (q), 70.4 (CH2), 115.9 (q), 118.6 
(CH), 123.4 (CH), 134.2 (CH), 134.5 (CH), 138.3 (q), 161.8 (q), 198.1 (q). 
 max (thin film cm-1): 745 (s), 1103 (m), 1162 (m), 1211 (m), 1251 (m), 1322 (s), 1461 (s), 1483 (s), 
1607 (s), 1651 (s), 1678 (s), 1720 (m), 2921 (w), 3000 (w). 
 
LRMS (ESI+): Found 295.1 [M+Na]+, 567.1 [2M+Na]+. 
 
HRMS (ESI+): Found 295.0622 [M+Na]+, C13H12N4NaOS requires 295.0624. 
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10.1.7 Synthesis of 11-thioxo-8,9-dimethyl-azetidino[2,1-c][1,4]benzodiazepin-2-one. 
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Scheme 10-7 
 
A sample of the triazolo compound from above (87 mg, 0.319 mmol) was heated at reflux in CHCl3 
(10 mL) under nitrogen for a week before being concentrated and purified by silica chromatography 
(15 g) (EtOAc:Hex;3:2) to give the methyl imine product as a yellow solid (25 mg, 32%). 
 
δH (400 MHz, CDCl3): 1.98 (3H, s, Me), 2.47 (3H, s, Me), 3.40 (1H, d, J  16.0, CSCHH), 3.77 (1H, 
d, J 16.0, CSCHH), 7.50 (1H dt, J  7.7, 1.0, ArH), 7.68 (1H, d, J 8.1, ArH), 7.77 (1H, dt, J 7.7, 1.5, 
ArH), 8.30 (1H, dd, J 8.1, 1.3, ArH). 
 
δC (100 MHz, CDCl3): 20.1 (CH3), 26.3 (CH3), 43.6 (CH2), 73.3 (q), 123.6 (q), 126.6 (CH), 126.7 
(CH), 127.3 (CH), 134.3 (CH), 149.6 (q), 155.2 (q), 158.0 (q), 204.4 (q). 
 max (thin film cm-1): 647 (s), 770 (s), 1103 (m), 1115 (m), 1132 (m), 1300 (m), 1323 (s), 1346 (s), 
1460 (s), 1606 (s), 1651 (s), 1676 (s), 1719 (m), 2928 (w), 2975 (w). 
 
LRMS (ESI+): Found 267.1 [M+Na]+. 
 
HRMS (ESI+): Found 267.0551 [M+Na]+, C13H12N2NaOS requires 267.0563. 
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10.2  Intramolecular Cycloadditon of Azides onto Alkenes: Aziridinopyrrolo-
benzodiazepines 
10.2.1 Synthesis of (S)-N-(ethoxycarbonyl)-prolinol. 
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Scheme 10-8 
 
To a stirring solution of S-prolinol (1.0 g, 9.89 mmol, 1.0 eq) in 4M NaOH (7 mL) was added ethyl 
chloroformate (1.13 mL, 1.287 g, 11.9 mmol, 1.2 eq) over 10mins at 0C. The reaction was 
maintained at 0C for 30mins followed by 30mins at ambient temperature. The reaction solution was 
neutralised with 2M HCl, the aqueous phase was separated and extracted with DCM (3 x 10 mL). 
The combined organic layers were dried (MgSO4), filtered and concentrated to give the crude 
product (1.64 g, 96%) as a yellow oil which was used as crude in the following reaction. 
 
δH (400 MHz, CDCl3): 1.27 (3H, t, J  7.1, COCH2CH3), 1.57 (1H, m, CHH), 1.74-1.91 (2H, m, CHH 
+ CHH), 1.99-2.08 (1H, m, CHH), 3.31-3.78 (1H, m, NCHH), 3.49-3.54 (1H, m, NCHH), 3.59-3.69 
(2H, m, CH2OH), 3.97-4.03 (1H, m, CH2OH), 4.14 (2H, quartet, J 7.1, COCH2CH3), 4.61 (1H, dd, J  
7.6, 2.6, NCHCH2). 
 
δC (100 MHz, CDCl3): 14.7 (CH3), 24.1 (CH2), 28.6 (CH2), 47.3 (CH2), 60.6 (CH), 61.6 (CH2), 67.3 
(CH2), 157.6 (q). 
 max (thin film cm-1): 770 (s), 906 (m), 1046 (s), 1106 (s), 1333 (s), 1379 (s), 1414 (s), 1667 (s), 2876 
(w), 2975 (w), 3400-3500 (br). 
 
LRMS (ESI+): Found 196.1 [M+Na]+, C8H15N4NaO3 requires 196.1. 
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10.2.2 Synthesis of (S)-N-(ethoxycarbonyl)-prolinal. 
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Scheme 10-9 
 
2M (COCl)2 in DCM (4.72 mL, 9.43 mmol, 1.2 eq) was diluted with dry DCM (12 mL) and cooled 
to -78C under N2. DMSO (1.34 mL, 1.474 g, 18.9 mmol, 2.4 eq) in DCM (5 mL) followed by the 
alcohol (1.36 g, 7.86 mmol, 1 eq) in DCM (5 mL) were added respectively, over 15mins. The whole 
was maintained at -78C for 30mins before dropwise addition of Et3N (5.48 mL, 3.98 g, 39.3 mmol, 
5 eq) over 10mins. The whole was allowed to reach room temperature over an hour before being 
quenched with a mixture of Et2O (12.5 mL) and H2O (12.5 mL). The organic layer was separated 
and the aqueous phase was extracted with DCM (3 x 10 mL). The combined organics were dried 
(MgSO4), filtered, concentrated and purified by silica chromatography (20 g) (EtOAc:Hex;2:3) to 
yield the aldehyde in rotameric form as a yellow oil (1.19 g, 89%). 
 
δH (400 MHz, CDCl3): 1.17 & 1.24 (3H, 2 x t, J 7.1 & 7.1, COCH2CH3), 1.76-1.92 (2H, m, CH2), 
1.93-2.09 (2H, m, CH2), 3.40-3.57 (2H, m, NCH2), 4.02-4.14 & 4.17-4.22 (3H, m, CO2CH2CH3 & 
NCHCHO), 9.48 & 9.56 (1H, 2 x d, J 2.5, 1.7, CHO). 
 
δC (100 MHz, CDCl3): 14.5/14.7 (CH3), 23.8/24.5 (CH2), 26.6/27.8 (CH2), 46.6/47.1 (CH2), 61.5 (2 x 
CH2), 64.8/65.1 (CH), 154.7/155.6 (q), 200.2/200.3 (CHO). 
 max (thin film cm-1): 729 (s), 771 (s), 914 (m), 1021 (m), 1102 (s), 1172 (m), 1341 (s), 1380 (s), 
1416 (s), 1466 (s), 1687 (s), 1733 (s), 2872 (m), 2980 (m). 
 
LRMS (ESI+): Found 194.1 [M+Na]+, C8H13NNaO3 requires 194.1. 
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10.2.3 Synthesis of (S)-N-2-ethenyl-1-ethoxycarbonylpyrrolidine. 
 
267 268
N
O
CO2Et
Ph3P+CH3Br-, nBuLi
N
CO2Et
THF, -78oC
 
Scheme 10-10 
 
1.6M nBuLi in hexanes (10.5 mL, 16.8 mmol, 2.4 eq) was added dropwise over 30mins to a stirring 
suspension of methyltriphenylphosphonium bromide (5.52 g, 15.4 mmol, 2.2 eq) in anhydrous THF 
(30 mL) at -78C under an inert atmosphere of nitrogen. The whole was allowed to reach -10C and 
kept at that temperature for 30mins before being cooled back to -78C. The aldehyde (1.20 g, 7.02 
mmol, 1.0 eq) in anhydrous THF (5 mL) was added dropwise over 10 mins. The whole was allowed 
to warm to -10C, where the temperature was maintained for 2 hours and then the mixture was 
allowed to reach room temperature overnight. The mixture was quenched with saturated aqueous 
NH4Cl (20 mL) and the aqueous layer was separated and extracted with EtOAc (3 x 10 mL). The 
combined organics were dried (MgSO4), filtered, concentrated and purified by silica chromatography 
(50 g) (EtOAc:Hex;3:2) yielding an air sensitive product as a mixture of rotamers in the form of a 
pale orange oil (536 mg, 45%). 
 
δH (400 MHz, CDCl3): 1.22-1.27 (3H, br, m, CH3), 1.71 (1H, bs, CH2CHHCH2), 1.81 (2H, br, m, 
NCHCH2), 1.97 (1H, m, br, CH2CHHCH2), 3.43 (2H, s, br, NCH2), 4.13 (2H, br, m, OCH2), 4.33 
(1H, br, m, NCH), 5.04-5.12 (2H, br, m, CH=CH2), 5.72 (1H, br, m, CH=CH2). 
 
δC (100 MHz, CDCl3): 14.2/14.8 (CH3), 22.6/23.4 (CH2), 31.2/31.9 (CH2), 46.3/46.5 (CH2), 
58.9/59.3 (CH), 60.4/60.8 (CH2), 113.8/114.1(CH2), 138.2/138.5 (CH), 155.1/155.4 (q). 
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10.2.4 Synthesis of (S)-N-(2’-azidobenzoyl)-2-ethenyl-pyrrolidine. 
269 240a268
N
CO2Et
N
N3
Cl
N3
N
Et3N, Et2O, r.t.
Ethylene Glycol,
KOH, 
H
NH2NH2
246a
O
O
 
Scheme 10-11 
 
To a vigorously stirred suspension of finely ground KOH (2.31 g, 41.2 mmol, 26 eq) in ethylene 
glycol (7.2 mL) was added hydrazine hydrate (0.25 mL, 7.92 mmol, 5 eq) and (S)-(-)-2-ethenyl-1-
ethoxycarbonylpyrrolidine (268 mg, 1.58 mmol, 1.0 eq) and the whole was heated to reflux (195C) 
for 4hours. The reaction was allowed to reach ambient temperature before being diluted with a 
mixture of Et2O (4 mL) and H2O (4 mL). The thick syrup was extracted with Et2O (3 x 5 mL) and 
dried with finely ground NaOH. Et3N (0.331 mL, 2.37 mmol, 1.5 eq) was added to the ethereal 
solution containing the amine at 0C under an inert atmosphere and was stirred for 10 mins before 
freshly prepared acid chloride (480 mg, 1.5 eq) in Et2O (5 mL) was added dropwise over 10mins 
and the whole was allowed to reach ambient temperature overnight. The reaction was diluted with 
water (20 mL), the ethereal layer was separated and the aqueous phase was extracted with ether (3 x 
10 mL). The combined organics were dried (MgSO4), filtered, concentrated and purified by silica 
chromatography (21 g) (EtOAc:Hex; 2:3) to yield the product as a mixture of rotamers (123 mg, 
32%) in the form of a yellow oil. 
 
δH (400 MHz, CDCl3): 1.73-2.15 (4H, m, 2 x CH2), 3.17-3.23 & 3.30- 3.36 (1H, m, CHHCH2), 3.64-
3.71 & 3.74-3.82 (1H, m, CHHCH2), 4.11-4.15 & 4.84-4.87 (1H, br, m, CHCH2), 4.70 & 5.35 (1H, 2 
x d, J 16.9, 17.1, CHHCH), 4.89 & 5.20 (1H, 2 x d, J 10.3 & 10.4, CHCHH), 4.89 & 5.20 (1H, 2 x d, 
J 10.3 & 10.4, CHCHH), 5.56 & 5.90 (1H, 2 x ddd, J 6.2, 10.4, 16.9 & 4.8, 10.4, 17.1, CHCH2) 
7.10-7.24 (3H, m, ArH), 7.32-7.45 (1H, m, ArH). 
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δC (100 MHz, CDCl3): 22.1/23.6 (CH2), 30.9/32.3 (CH2), 45.9/48.2 (CH2), 58.4/61.1 (CH), 
114.5/114.9 (CH2), 118.4/118.5 (CH), 124.6/125.2 (CH), 127.9/128.3 (CH), 129.6/130.1 (q), 
130.2/130.3 (CH), 136.1 (q), 136.9/137.6 (CH), 166.8/167.4 (q). 
 max (thin film cm-1): 750 (s), 932 (s), 1083 (m), 1149 (m), 1292 (s), 1415 (s), 1449 (s), 1479 (s), 
1598 (s), 1631 (s), 2128 (s), 2878 (m), 2973 (m), 3078 (w). 
 
LRMS (ESI+): Found 265.1 [M+Na]+, 507.2 [2M+Na]+. 
 
HRMS (ESI+): Found 265.1064 [M+Na]+, C13H14N4NaO requires 265.1060. 
 
10.2.5 Synthesis of pyrrolobenzodiazepine (270a) and aziridinopyrrolobenzodiazepine (271a). 
240a
243a
270a 271a
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N
N
N
N N
N
N
N
N
CHCl3, 
O O O O
X Y
 
Scheme 10-12 
 
The alkene (78 mg, 0.322 mmol) was dissolved in CHCl3 (10 mL) and heated at reflux under an inert 
atmosphere of nitrogen for 16 hours whilst being monitored by TLC (EtOAc:Hex;3:2). The reaction 
mixture was concentrated and purified by silica chromatography (20 g) (EtOAc:Hex; 3:2-4:1) to 
yield two spots on TLC which were purified by chromatography to give an inseparable mixture of 
the aziridine (271a) and the methyl imine (270a) products (271a:270a;X:Y;1:1) (43 mg, 55%). 
 
δH (400 MHz, CDCl3): 1.84-1.96 (2H, m, Y-CH2), 1.93 (1H, d, J 3.4, X-NCHHCH), 1.96-2.06 (3H, 
m, X-CH2 + Y-CHH), 2.09-2.22 (2H, m, X-CHH + Y-CHH), 2.27 (3H, s, X-NCCH3), 2.29-2.37 
(1H, m, X-CHH), 2.45 (1H, d, J 4.5, X-NCHHCH), 2.69-2.73 (1H, m, Y-CH), 3.24-3.30 (1H, m, Y-
Chapter 10  Experimental Part IV 
182 
 
CH), 3.45-3.52 (1H, m, Y-CHH), 3.56-3.63 (1H, m, Y-CHH), 3.64-3.72 (1H, m, X-CH), 3.74-3.84 
(2H, m, Y-CHH +Y-CHH), 6.94 (1H, dt, J 7.5, 1.1, Y-ArH), 7.04 (1H, dd, J 8.0, 0.9, Y-ArH), 7.14-
7.18 (2H, m, X-ArH+X-ArH), 7.25 (1H, dt, J 7.7, 1.6, Y-ArH), 7.40 (1H, dt, J 7.6, 1.6, X-ArH), 7.66 
(1H, dd, J 7.8, 1.5, Y-ArH), 7.93 (1H, dd, J 7.8, 1.5, X-ArH). 
 
δC (100 MHz, CDCl3): 22.4 (X-CH3), 23.2 (Y-CH2), 24.2 (X-CH2), 27.9 (X-CH2), 30.0 (Y-CH2), 
32.9 (X-CH2), 45.0 (Y-CH), 46.3 (Y-CH2), 46.4 (Y-CH2), 55.6 (X-CH), 58.3 (Y-CH), 122.2 (Y-CH), 
123.1 (Y-CH), 125.4 (Y-q), 125.5 (X-CH), 126.4 (X-CH), 127.0 (X-q), 129.8 (X-CH), 130.8 (Y-
CH), 131.4 (X-CH), 131.8 (Y-CH), 145.7 (X-q), 150.4 (Y-q), 165.5 (X-q), 166.9 (Y-q), 169.9 (X-q). 
 max (thin film cm-1): 907 (s), 1244 (m), 1320 (m), 1403 (m), 1454 (s), 1614 (s), 1681 (m), 1743 (m), 
2876 (w), 2924 (m), 2970 (w). 
 
LRMS (ESI+): Found 215.1 [M+H]+, 237.1 [M+Na]+, 451.2 [2M+Na]+, 665.3 [3M+Na]+. 
 
HRMS (ESI+): Found 215.1179 [M+H]+, C13H15N2O requires 215.1179. 
10.2.6 Synthesis of N-(2’-azidobenzenesulfonyl)-2-ethenyl-pyrrolidine. 
 
269 240b268
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CO2Et
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Scheme 10-13 
 
To a stirring suspension of KOH (4.28 g, 76.5 mmol, 26 eq) in ethylene glycol (15 mL), hydrazine 
hydrate (0.457 mL, 471 mg, 14.7 mmol, 5 eq) was added under nitrogen followed by the ester 
protected alkene (497 mg, 2.94 mmol, 1.0 eq), and the whole was heated at reflux (195
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hours. The reaction mixture was cooled to ambient temperature and was diluted with Et2O (9 mL) 
and water H2O (9 mL). The organic layer was separated and the aqueous layer was extracted with 
Et2O (3 x 5 mL) and dried over NaOH. Et3N (0.62 mL, 4.41 mmol, 1.5 eq) was added to the ethereal 
solution containing the amine at 0C and was stirred for 10 mins under an inert atmosphere of 
nitrogen before addition of the sulfonic acid chloride in Et2O, [which was prepared by heating at 
reflux 2-azidobenzenesulfonic acid (900 mg, 4.41 mmol, 1.5 eq) in 2M solution of oxalyl chloride in 
DCM (4.4 mL, 8.82 mmol, 3.0 eq) which was concentrated in vacuo and suspended in Et2O (3 x 
10ml)]. The whole was allowed to reach room temperature overnight. The reaction was diluted with 
water (30ml), the ethereal layer was separated and the aqueous layer was extracted with Et2O (3 x 
10ml). The combined organics were dried (MgSO4), filtered, concentrated in vacuo and purified by 
silica chromatography (20 g) (EtOAc:Hex;1:4) to yield the product as a yellow oil (163 mg, 20%). 
 
δH (400 MHz, CDCl3): 1.30-1.40 (1H, m, CHH), 1.83-1.92 (2H, m, CH2), 2.07-2.10 (1H, m, CHH), 
2.92-2.99 (1H, m, CHH), 3.54-3.57 (1H, m, CHH), 3.93-3.98 (1H, m, NCH), 4.37-4.40 (1H, m, 
CH=CHH), 4.54 (1H, dd, J 12.6, 17.8, CH=CHH), 5.30-5.37 (1H, m, CH=CH2), 7.16 (1H, t, J 8.0, 
ArH), 7.45 (1H, t, J  8.4, ArH), 7.83 (1H, d, J 8.4, ArH), 7.91 (1H, d, J 8.0, ArH). 
 max (thin film cm-1): 926 (m), 1026 (s), 1099 (m), 1157 (m), 1182 (s), 1296 (m), 1330 (m), 1445 
(m), 1471 (s), 1518 (m), 1592 (s), 1714 (m), 2137 (s), 2871 (m), 2977 (m). 
 
LRMS (ESI+): Found 301.1 [M+Na]+. 
 
HRMS (ESI+): Found 301.0722 [M+Na]+ requires 301.0730.
 
10.2.7 Synthesis of Aziridinopyrrolobenzothiadiazepine (271b). 
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Scheme 10-14 
 
The N-(2’-azidobenzenesulfonyl)-2-ethenyl-pyrrolidine (143 mg, 0.514 mmol) was heated at reflux 
under nitrogen in CHCl3 (10 mL) for 4 days. The crude product was concentrated and analysed by 
NMR to show little reaction. The crude product was dissolved in toluene (10 mL) and heated to 
reflux for 24 hours. The reaction was allowed to reach room temperature before the solvent was 
removed and the crude was purified by silica chromatography (20 g) (EtOAc:Hex;1:2) to yield the 
aziridine product (23 mg, 18%). 
 
δH (500 MHz, CDCl3): 1.81-2.07 (4H, m, 2 x CH2), 2.91-2.95 (1H, m, CHH), 3.32 (1H, dd, J 9.9, 
11.7, CHCHCHH), 3.50 (1H, apparent t, J 7.7, CHH), 3.57 (1H, dd, J 3.9, 11.7, CHCHCHH), 3.89 
(1H, apparent dt, J 2.9, 7.9, SO2NCH), 4.84-4.87 (1H, NCH2CH), 6.70 (1H, d, J 8.1, ArH), 6.84 (1H, 
t, J 7.8, ArH), 7.20 (1H, dt, J 7.8, 1.3, ArH), 7.70 (1H, dd, J 8.1, 1.2, ArH). 
 
δC (125MHz, CDCl3): 24.5 (CH2), 25.8 (CH2), 43.4 (CH2), 49.2 (CH2), 59.3 (CH), 62.9 (CH), 118.6 
(CH), 119.9 (CH), 125.7 (q), 129.2 (CH), 132.7 (CH), 144.6 (q). 
 max (thin film cm-1): 759 (s), 1009 (m), 1037 (m), 1081 (s), 1127 (s), 1274 (m), 1333 (s), 1482 (s), 
1520 (m), 1591 (s), 2926 (m), 2970 (w), 3066 (m), 3362 (w). 
 
LRMS (ESI+): Found 273.1 [M+Na]+, 523.1 [2M+Na]+, C12H14N2NaO2S requires 273.1 . 
10.2.8 Synthesis of (S)-N-(2'-azidobenzoyl)-2-(carbethoxy-1''-ethenyl)-pyrrolidine. 
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Scheme 10-15 
 
The aldehyde (273 mg, 1.12 mmol, 1.0 eq) was dissolved in toluene (10 mL). 
(Carbethoxymethylene) triphenylphosphorane (390 mg, 1.12 mmol, 1.0 eq) was added in one portion 
and the whole was stirred at room temperature in an inert atmosphere of nitrogen for 12 hours before 
being concentrated and purified by silica chromatography (40 g) (EtOAc:Hex; 3:2) to yield the 
product as a yellow oil as a mixture of rotamers (a:b;2:3;178 mg, 51%). 
 
δH (400 MHz, CDCl3): 1.29 & 1.31 (3H, t, J 7.1, 2 x COCH2CH3), 1.80-1.99 & 2.01-2.43 (4H, m, 
CH2), 3.21-3.28 & 3.78-3.86 (1H, m, CHH), 3.34-3.40 & 3.69-3.75 (1H, m, CHH), 4.13 & 4.21 (2H, 
quartet, J 7.1 & 7.1, COCH2CH3), 4.24-4.30 & 4.96-5.00 (1H, m, NCHCH2), 5.46 & 6.15 (1H, dd & 
d, J 15.6, 1.1 & 15.6, CHCHCO2Et), 6.59 & 6.94 (1H, dd & dd, J 15.6, 6.4 & 15.6, 4.9, 
CHCHCO2Et), 7.12 (1H, t, J 7.5, ArH), 7.14 (1H, d, J  7.3, ArH), 7.19-7.25 (1H, m, ArH), 7.40 & 
7.45 (2H, 2 x dt, J 7.8, 1.6, & 7.8, 1.6, ArH). 
 
δC (100 MHz, CDCl3): 14.2/14.3 (CH3), 22.3/23.8 (CH2), 30.5/32.1 (CH2), 46.1/48.2 (CH2), 57.2 
(CH), 60.4/60.6 (CH2), 118.5 (CH), 121.2/121.3 (CH), 124.9/125.2 (CH), 127.9 (CH), 129.1/129.5 
(q), 130.6 (CH), 133.7/136.2 (q), 146.5 (CH), 165.8/166.5 (q), 167.1/167.4 (q). 
 max (thin film cm-1): 753 (s), 1043 (m), 1093 (m), 1180 (s), 1301 (s), 1369 (m), 1414 (s), 1451 (s), 
1475 (m), 1633 (s), 1716 (s), 2130 (s), 2238 (w), 2880 (m), 2979 (m). 
 
LRMS (ESI+): Found 315.1 [M+H]+, 337.1 [M+Na]+, 651.3 [2M+Na]+. 
 
HRMS (ESI+): Found 315.1451 [M+H]+, C16H19N4O3 requires 315.1452. 
Chapter 10  Experimental Part IV 
186 
 
10.2.9 Synthesis of Aziridinopyrrolobenzodiazepine (274). 
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Scheme 10-16 
 
The substituted alkene (178 mg, 0.567 mmol) was heated at reflux under nitrogen in CHCl3 (10 mL) 
for 48 hours before being concentrated and purified by silica chromatography (20 g) (EtOAc:Hex 
;3:2) to yield the product as a mixture of diastereoisomers (a:b;1:1) in the form of a yellow oil (47 
mg, 30%). 
 
δH (400 MHz, CDCl3)[mixture of isomers]: 1.23 (3H, t, J 7.1, COCH2CH3, isomer “a”), 1.29 (3H, t, 
J 7.1, COCH2CH3, isomer “b”), 1.74-1.80 (2H, m, CH2),1.81-2.27 (4H, m, 2 x CH2), 2.77 (1H, d, J 
2.6, CHCO2Et), 3.08 (1H, dd, J 9.6, 2.6, NCH), 3.37 (1H, dt, J 8.7, 2.7, NCH),3.57 (1H, dt, J 7.3, 
12.0, CHH), 3.66-3.73 (4H, m, 2 x CH2), 3.74-3.79 (1H, m, CH), 3.78-3.87 (1H, m, CHH), 4.20 (2H, 
quartet, J 7.1, COCH2CH3, isomer “a”), 4.23 (2H, quartet, J 7.1, COCH2CH3, isomer “b”), 4.38 (1H, 
d, J 10.8, CH), 6.69 (1H, d, J 7.4, ArH), 6.94 (1H, dt, J 7.5, 0.9, ArH), 7.01 (1H, dt, J 7.5, 1.0, ArH),  
7.07 (1H, d, J 8.0, ArH), 7.19 (1H, dt, J 7.6, 1.6, ArH), 7.28 (1H, dt, J 7.7, 1.6, ArH), 7.70 (2H, dd, J 
7.8, 1.8, ArH). 
 
δC (100 MHz, CDCl3): 14.2 (CH3), 14.5 (CH3), 23.1 (CH2), 25.6 (CH2), 29.5 (2 x CH2), 42.6 (CH), 
46.4 (CH2), 47.0 (CH), 50.4 (CH), 56.6 (CH), 57.2 (CH), 60.1 (CH), 61.4 (CH2), 62.0 (CH2), 68.0 
(CH2), 121.3 (CH), 122.0 (CH), 123.1 (CH), 123.3 (CH), 125.3 (q), 126.6 (q), 130.7 (CH), 131.0 
(CH), 132.0 (CH), 132.2 (CH), 142.9 (q), 148.1 (q), 166.0 (q), 166.3 (q), 167.9 (q), 168.8 (q). 
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max (thin film cm-1): 752 (m), 1024 (s), 1178 (s), 1217 (s), 1260 (s), 1372 (m), 1454 (m), 1503 (m), 
1602 (s), 1622 (s), 1725 (s), 2871 (m), 2926 (m), 2977 (m). 
 
LRMS (ESI+): Found. 309.1 [M+Na]+. 
 
HRMS (ESI+): Found 309.1206 [M+Na]+, C16H18N2NaO3 requires 309.1210. 
10.2.10 Synthesis of N-(2’-azidobenzenesulfonyl)prolinol. 
 
232b 235b
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O O O O
 
Scheme 10-17 
 
2-Azido-benzenesulfonic acid (2.95 g, 14.83 mmol, 2.5 eq) was heated at reflux in a 2M solution of 
(COCl)2 in DCM (14.8 mL, 29.6 mmol, 5 eq) with a drop of DMF under an inert atmosphere of 
nitrogen for 5 hours. The reaction was allowed to reach room temperature before the crude acid 
chloride was concentrated in vacuo and redissolved in DCM (3 x 10 mL) to yield the crude sulfonyl 
chloride. 
 
K2CO3 (3.3 g, 23.7 mmol, 4 eq) in water (10 mL) was added in one portion to a stirring solution of 
S-prolinol (600 mg, 5.93 mmol, 1 eq) in DCM (15 mL). The crude acid chloride suspended in DCM 
(10 mL) was added slowly and the whole was stirred for 18 hours. The organic layer was separated 
and the aqueous layer was extracted with DCM (3 x 10 mL). The combined organics were dried 
(MgSO4), filtered, concentrated to give the product as a pure orange oil (1.61 g, 96%). 
 
δH (400 MHz, CDCl3): 1.67-1.78 (1H, m, CHH), 1.79-1.99 (3H, m, CHH + CH2), 2.79 (1H, bs, 
CH2OH), 3.38 (1H, dt, J  6.3, 10.2, NCHH), 3.49-3.56 (1H, m, NCHH), 3.62 (1H, dd, J 5.6, 11.5, 
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CHHOH), 3.70 (1H, dd, J 4.2, 11.5, CHHOH), 4.02-4.08 (1H, m, CHCH2OH), 7.27 (1H, dt, J  1.0, 
7.8, ArH), 7.32 (1H, dd, J 0.9, 8.0, ArH), 7.62 (1H, dt, J  1.5, 7.8, ArH), 8.02 (1H, dd, J 1.4, 8.0, 
ArH).  
 
δC (100 MHz, CDCl3): 24.7 (CH2), 29.0 (CH2), 49.5 (CH2), 61.8 (CH), 65.5 (CH2), 119.9 (CH), 
124.8 (CH), 129.0 (q), 132.6 (CH), 134.2 (CH), 138.2 (q). 
 max (thin film cm-1): 759 (s), 819 (m), 1043 (s), 1069 (s), 1146 (s), 1199 (m), 1264 (m), 1287 (s), 
1323 (s), 1439 (m), 1471 (s), 1583 (m), 2120 (s), 2876 (w), 2953 (w), 3172-3593 (mbr). 
 
LRMS (ESI+): Found 305.1 [M+Na]+, 587.1 [2M+Na]+. 
 
HRMS (ESI+): Found 305.0676 [M+Na]+, C11H14N4NaO3S requires 305.0679. 
10.2.11 Synthesis of N-(2’-azidobenzenesulfonyl)prolinal. 
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Scheme 10-18 
 
A 2M solution of oxalyl chloride in DCM (1.88 mL, 3.75 mmol, 1.2 eq) was diluted with DCM (10 
mL) and cooled to -78C under nitrogen. DMSO (0.532 mL, 586 mg, 7.5 mmol, 2.4 eq) in DCM (10 
mL) and the alcohol (800 mg, 3.125 mmol, 1 eq) in DCM (5 mL) were added respectively over 
10mins. The whole was maintained at -78C for 30 mins before dropwise addition of Et3N (2.18 mL, 
1.581 g, 15.6 mmol, 5 eq) and the whole was allowed to reach room temp. The reaction was 
quenched with a mixture of Et2O (10 mL) and H2O (10 mL). The organic layer was separated and 
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the aqueous phase was extracted with DCM (3 x 10 mL). The combined organics were dried 
(MgSO4), filtered, concentrated and purified by silica chromatography (20 g) (EtOAc:Hex; 2:3) to 
yield the product as a white solid (572 mg, 72%), which degraded rapidly and needed to be used 
quickly in subsequent reaction. 
 
δH (400 MHz, CDCl3): 1.83-1.95 (2H, m, CH2), 1.98-2.09 (1H, m, CHH), 2.15-2.23 (1H, m, CHH), 
3.40 (1H, dt, J 9.7, 7.2, NCHH), 3.57 (1H, ddd, J 5.5, 6.8, 9.7, CHH), 4.47 (1H, ddd, J 1.9, 4.5, 8.5, 
CHCHO), 7.28 (1H, dt, J 7.8, 1.0, ArH), 7.34 (1H, dd, J 8.0, 0.9, ArH), 7.64 (1H, dt, J  7.8, 1.6, 
ArH), 8.03 (1H, dd, J 8.0, 1.5, ArH), 9.72 (1H, d, J 1.9, CHO). 
 
δC (100 MHz, CDCl3): 25.0 (CH2), 27.7 (CH2), 48.8 (CH2), 67.1 (CH), 119.9 (CH), 124.9 (CH), 
128.9 (q), 132.5 (CH), 134.4 (CH), 138.2 (q), 200.5 (CH). 
 max (thin film cm-1): 820 (m), 999 (m), 1080 (s), 1122 (s), 1156 (s), 1265 (m), 1287 (s), 1332 (s), 
1439 (m), 1471 (s), 1603 (m), 1730 (s), 2122 (s), 2953 (w). 
 
MS: Product decomposed before analysis was possible. 
10.2.12 Synthesis of aziridinopyrrolobenzothiadiazepine (274b). 
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(Ph3P)=CHCO2Et,
 
Scheme 10-19 
 
The aldehyde (572 mg, 2.25 mmol, 1.0 eq) was dissolved in toluene (12 mL) and 
(carbethoxymethylene) triphenylphosphorane (785 mg, 2.25 mmol, 1 eq) was added in one portion 
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and the whole was stirred at room temperature for 18 hours. The reaction was concentrated and 
purified by silica chromatography (40 g) (EtOAc:Hex; 3:2) to yield, as a single isomer, the aziridine 
as a yellow oil (123 mg, 17%). 
 
δH (500 MHz, CDCl3): 1.41 (3H, t, J 7.1, COCH2CH3), 1.75-1.80 (1H, m, CHH), 1.87-2.01 (1H, m, 
CHH), 2.09-2.16 (1H, m, CHH), 2.27-2.35 (1H, m, CHH), 3.19 (1H, ddd, J 5.0, 9.6, 9.6, CHH), 
3.67-3.73 (2H, m, CHH + CHCHCH), 4.08 (1H, ddd, J 2.1, 7.4, 9.8, SO2NCH), 4.33-4.40 (2H, m, 
COCH2CH3), 4.94 (1H, d, J 10.7, CHCO2Et), 7.43 (1H, dt, J 7.7, 1.1, ArH), 7.55 (1H, dd, J 8.0, 1.1, 
ArH), 7.60 (1H, dt, J 7.7, 1.5, ArH), 8.04 (1H, dd, J 8.0, 1.5, ArH). 
 
δC (125MHz, CDCl3): 14.1 (CH3), 22.7 (CH2), 28.9 (CH2), 46.4 (CH2), 60.7 (CH), 61.8 (CH), 63.0 
(CH2), 85.4 (CH), 123.8 (CH), 126.6 (CH), 128.5 (CH), 131.6 (q), 133.6 (CH), 138.4 (q), 167.3 (q). 
 max (thin film cm-1): 1035 (m), 1066 (m), 1092 (s), 1135 (m), 1167 (s), 1205 (m), 1247 (m), 1271 
(m), 1344 (s), 1469 (s), 1503 (m), 1589 (m), 1738 (s), 2981 (m). 
 
LRMS (ESI+): Found 345.1 [M+Na]+, 723.2 [2M+Na]+. 
 
HRMS (ESI+): Found 345.0875 [M+Na]+, C15H18N2NaO4S requires 345.0879. 
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11 Experimental: Synthesis of other BDs via the cycloaddition of DPP. 
11.1.1 Synthesis of 2-(Carbamoylmethylamino)benzoic acid. 
 
1) 2-chloroacetamide, 
NaOH, Na2CO3, OH
O
NH2 NH
OH
O
NH2
O
312231
2.) 2M HCl
 
Scheme 11-1 
 
Anthranilic acid (2.74 g, 20.0 mmol, 1 eq) was dissolved in water (20 mL) and NaOH (800 mg, 20.0 
mmol, 1 eq) was added. A solution of Na2CO3 (2.12 g, 20.0 mmol, 1 eq) in water (20 mL) was added 
in one portion followed by dropwise addition of 2-chloroacetamide (3.80 g, 40.6 mmol, 2.03 eq) and 
the whole was heated at reflux for 18 hours. The reaction was allowed to reach ambient temperature 
before being acidified with 2M HCl until a white precipitate persisted at around pH4. The reaction 
was stored in the fridge overnight and the solid was collected by vacuum filtration to give the 
product as a pale pink solid (2.05 g, 53%). 
 
δH (400 MHz, d6-DMSO): 3.78 (2H, s, CH2CONH2), 6.50 (1H, d, J 8.3, ArH), 6.57 (1H, t, J 7.2, 
ArH), 7.19 (1H, bs, CONHH), 7.36 (1H, dt, J 7.2, 1.6, ArH), 7.53 (1H, bs, CONHH), 7.79 (1H, dd, J  
7.9, 1.6, ArH), 8.15 (1H, bs, NHCH2), 12.60 (1H, bs, CO2H). 
 
δC (100 MHz, d6-DMSO): 45.9 (CH2), 111.1 (q), 111.8 (CH), 115.0 (CH), 132.1 (CH), 134.9 (CH), 
150.5 (q), 170.1 (q), 171.4 (q). 
 max (thin film cm-1): 1114 (m), 1152 (s), 1167 (m), 1220 (s), 1271 (m), 1505 (m), 1557 (m), 1581 
(m), 1604 (s), 1661 (s), 3400-3450 (bw). 
 
Chapter 11  Experimental Part V 
192 
 
LRMS (ESI+): Found 217.1 [M+Na]+. 
 
HRMS (ESI+): Found 217.0582 [M+Na]+, C9H10N2NaO3 requires 217.0584. 
11.1.2 Synthesis of 1-Ethoxycarbonyl-1H-1,4-benzodiazepin-3,5-dione. 
 
 2) 5% citric acid  r.t.
N
H
OH
O
NH2
O
N
N
O H
O
EtO2C
312 313
1) Ethylchloroformate, 
Et3N, 
 
Scheme 11-2 
 
 2-(Carbamoylmethylamino)-benzoic acid (2.0 g, 10.3 mmol, 1 eq) was heated at reflux in MeCN 
(20 mL) with Et3N (5.0 mL, 36 mmol, 3.53 eq) for 15mins. The reaction was allowed to reach 
ambient temperature before ethylchloroformate (2.0 mL, 21 mmol, 2.04 eq) was added dropwise and 
the whole was brought back to reflux for 75 mins. The reaction was allowed to reach ambient 
temperature before being poured directly into 5% citric acid (2.5g in 50 mL of water) and diluted 
with ice to a total volume of 100 mL (i.e. 30g of ice) and the whole was stirred for 1 hour. The 
precipitate was collected via vacuum filtration and washed with water to give the product as a pale 
brown solid (1.22 g, 48%). 
 
δH (500 MHz, CDCl3): 1.18 (3H, bm, COCH2CH3), 3.83 (1H, bs, COCHH), 4.17 (2H, bm, 
COCH2CH3), 5.08 (1H, bs, COCHH), 7.23-7.36 (1H, m, ArH), 7.38 (1H, t, J 7.9, ArH), 7.55 (1H, t, 
J 7.4, ArH), 8.07 (1H, d, J 7.5, ArH), 8.47 (1H, bs, NH). 
 
δC (125MHz, CDCl3): 14.4 (CH3), 53.0 (CH2), 63.1 (CH2), 127.4 (q), 127.6 (CH), 127.8 (CH), 133.0 
(CH), 134.0 (CH), 140.5 (q), 153.9 (q), 164.2 (q), 171.0 (q). 
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max (thin film cm-1): 1037 (m), 1098 (m), 1134 (m), 1212 (s), 1240 (m), 1348 (s), 1380 (m), 1456 
(m), 1487 (m), 1653 (m), 1707 (s), 2895 (w), 3064 (w), 3139 (w). 
  
LRMS (ESI+): Found 271.1 [M+Na]+, 519.2 [2M+Na]+. 
 
HRMS (ESI+): Found 271.0687 [M+Na]+, C12H12N2NaO4 requires 271.0689. 
11.1.3 Synthesis of 1-Ethoxycarbonyl-1H-1,4-benzodiazepin-5-on-3-thione. 
 
Lawesson's
 reagent,
N
N
O H
O
EtO2C
N
N
O H
S
EtO2C313 314
THF, 
 
Scheme 11-3 
 
The diketone (610 mg, 2.46 mmol, 1 eq) was dissolved in dry THF (10 mL), Lawesson's reagent 
(497 mg, 1.23 mmol, 0.5 eq) was added in one portion and the whole was stirred at room 
temperature for 1 hour before being heated at reflux for 2 hours. The reaction mixture was 
concentrated and purified by silica chromatography (70 g) (EtOAc:Hex; 1:3) to yield the product as 
a yellow solid (162 mg, 25%). 
 
δH (500 MHz, CDCl3): 1.27 (3H, bs, COCH2CH3), 4.11-4.30 (3H, bm, COCH2CH3 + COCHH), 5.56 
(1H, bs, COCHH), 7.43 (1H, t, J  7.8, ArH), 7.44 (1H, d, J 7.8, ArH), 7.63 (1H, t, J 8.0, ArH), 8.18 
(1H, d, J 8.0, ArH), 10.08 (1H, bs, NH). 
 
δC (125MHz, CDCl3): 14.3 (CH3), 59.8 (CH2), 63.0 (CH2), 126.5 (q), 127.1 (CH), 127.4 (CH), 133.4 
(CH), 134.2 (CH), 141.3 (q), 153.5 (q), 162.7 (q), 204.6 (q). 
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max (thin film cm-1): 885 (m), 1049 (s), 1154 (s), 1223 (s), 1272 (s), 1313 (s), 1353 (s), 1379 (s), 
1421 (m), 1453 (m), 1498 (m), 1597 (m), 1648 (s), 1716 (s), 2964 (w), 3105 (m), 3173 (m). 
 
LRMS (ESI+): Found 265.1 [M+H]+, 287.0 [M+Na]+, 551.1 [2M+Na]+, C12H13N2O3S requires 
265.1. 
 
Structure confirmed by X-Ray crystallographic analysis (see discussion). 
11.1.4 Attempted S-Methylation of the 1,4-benzodiazepin-5-on-3-thione. 
N
N
O H
S
EtO2C
N
N
O
SMe
EtO2C
316
315
Me2S
 
Scheme 11-4 
 
The thione (572 mg, 2.16 mmol, 1 eq) was suspended in dimethyl sulfate (0.822 mL, 1.093 g, 8.67 
mmol, 4 eq) and stirred overnight. The suspension was dissolved ih DCM (4 mL) and heated in an 
oil bath at 40C for 6 hours. More dimethyl sulfate (0.45 mL) was added and the whole was stirred 
overnight at 40C. The reaction was concentrated and suspended in ether (10 mL). The reaction was 
quenched with 10% K2CO3 (20 mL) and the ether layer was separated. The aqueous phase was 
extracted with DCM (3 x 10 mL). The combined organics were dried, filtered and concentrated. 
Purification by silica chromatography (30 g) (EtOAc:Hex;2:3) gave no identifiable product.  
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To conclude this thesis, this page will give a brief personal overview of the project. It has been a 
great project and the main success was the cyclisations of the alkynes and the azides using the 
Bestmann-Ohira reagent (discussed in section 3.1). This could be expanded to include other amino 
acids derivatives (for example cystine, methionine etc..). The chemistry of the nitrile systems 
(discussed in section 3.2) could be further explored to establish if the amino-1,4-benzodiazepines or 
the tetrazolo-1,4-benzodiazepines are synthesised.  
 
The synthesis of the PBDs via a cyclopropenone addition (Chapter 6), could be further explored by 
the successful S-alkylation of the thioamide and then the addition of DPP. 
 
The chirality of the products are assumed throughout and have not been established during the 
synthesis of the compounds. Further work could be to establish the stereochemistry of the major 
products in this thesis.  
 
Further work could be carried out to establish the problem that I had in the nitro reduction to the 
amine discussed in Chapter 5. This would then lead onto a variety of avenues, firstly the work with 
the alkene and azides could be further explored. Also the chemistry that is established could be used 
to synthesis dimers via linking though the the OH on the benzene ring. The chemistry of section 3.1 
and then 3.2 could also be applied to afford a vast array of compounds.  
 
Other further work could include a variety of different substituted alkenes discussed in Chapter 4 
could be synthesied i.e. starting from a variety of 1,3 dienes for an example 1,3-butidiene and the 
compounds could be tested for their biological activity  
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